[
  {
    "nctId": "NCT03811548",
    "statement": "All patients must have a diagnosis of T2DM (meet the diagnostic criteria for diabetes issued by the World Health Organization in 1999)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03811548",
    "statement": "Patients must have a hemoglobin A1c (HbA1c) level ≥7.5% and ≤11% at screening, and ≥7.0% and ≤10.5% at baseline.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03811548",
    "statement": "Drug -naïve (never received anti-diabetic medication or did not receive anti-diabetic medication within 8 weeks before screening).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03811548",
    "statement": "Body Mass Index: 18.0~35.0 kg/m2 (both inclusive)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03811548",
    "statement": "History of type 1 diabetes mellitus (T1DM), diabetes caused by pancreatic injury, or secondary diabetes (e.g., diabetes caused by Cushing's syndrome or acromegaly)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03811548",
    "statement": "More than 10% change in body weight within the 3 months before screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03811548",
    "statement": "Any laboratory test indicators meet the following standards:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03811548",
    "statement": "fasting plasma glucose ≥ 15 mmol/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03811548",
    "statement": "aspartate aminotransferase, alanine aminotransferase levels > 3 times the upper limit of normal (ULN); total bilirubin > 1.5 times ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03811548",
    "statement": "hemoglobin < 100 g/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03811548",
    "statement": "eGFR < 60 mL/min/1.73m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03811548",
    "statement": "fasting triglycerides > 5.64 mmol/L (500 mg/dL)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Diagnosed with type 2 diabetes mellitus, and on a stable dose of an oral antidiabetic monotherapy before Screening A.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Female patients of childbearing potential who were sexually active agreed to use adequate contraception, and could neither pregnant nor lactating from Screening throughout the duration of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had a glycosylated hemoglobin level greater than or equal to 8.0% and less than or equal to 10.0% at Screening B.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had a fasting plasma glucose greater than or equal to 126 mg/dL (7.0 mmol/L) at Screening B.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Taking a stable dose of at least 1000 mg of metformin for at least 30 days before Screening B.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had a stable or worsening self-monitoring blood glucose level while taking metformin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had a low-density lipoprotein less than 160 mg/dL (4.1 mmol/L) at Screening A.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had a body mass index was less than or equal to 45 kg/m2 at Screening A.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Was willing to be counseled by the investigator or designee to follow an individualized, weight-maintaining diet during the study period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had evidence of insulin secretory capacity as demonstrated by a C-peptide concentration of greater than or equal to 1.5 ng/mL (0.50 nmol/L) at Screening A, and if necessary, after a repeat at Screening B.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Was able to perform daily self-monitoring blood glucose tests throughout the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had a normal thyroid-stimulating hormone level of less than 5.5 μIU/mL (5.5 mIU/L) and greater than or equal to 0.35 μIU/mL (0.35 mIU/L) at Screening A.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Was in good health as determined by a physician (ie, via medical history and physical examination), other than a diagnosis of type 2 diabetes mellitus.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had fasting clinical laboratory results within the normal ranges for the testing laboratory, or if not, the results were deemed not clinically significant by the investigator before Randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Diagnosed with type 1 diabetes mellitus, hemochromatosis, or had a history of ketoacidosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had any condition known to invalidate glycosylated hemoglobin results (eg, hemolytic states or hemoglobinopathies).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Took any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may have interfered with evaluation of the study medication, including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Insulin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Oral antidiabetics including sulfonylureas and alpha-glucosidase inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Systemic corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Warfarin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Rifampin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "St. John's Wort.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Thiazolidinediones",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Peroxisome proliferator-activated receptor agonists",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Nicotinic Acid",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Fibrates",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had a history of myocardial infarction, coronary angioplasty or bypass graft, unstable angina pectoris, transient ischemic attacks, clinically significant abnormal electrocardiogram, or documented cerebrovascular accident within 6 months before Screening A.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had abdominal, thoracic, or vascular surgery within 6 months before Screening A that in the investigator's opinion warranted exclusion from the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had a creatine phosphokinase value greater than 3 times the upper limit of normal at Screening A.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had persistent unexplained microscopic or macroscopic hematuria or a history of bladder cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had a triglyceride level greater than 500 mg/dL (5.6 mmol/L) at Screening A.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Received any alteration in allowed lipid lowering medication (dose or drug) within 2 months of Randomization, if applicable. The patient remained on a stable dose throughout the study. If deemed necessary, the dose could have been lowered with prior approval from the Sponsor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Donated and/or received any blood or blood products within 3 months before Randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had a history of drug abuse or a history of alcohol abuse within 2 years before Randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had a systolic blood pressure greater than 140 mm Hg or a diastolic blood pressure of greater than 95 mm Hg at Screening B.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had significant cardiovascular disease including but not limited to, New York Heart Association Functional (Cardiac) Classification III or IV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had a history of cancer other than basal cell or stage 1 squamous cell carcinoma of the skin that had not been in remission within 5 years before Randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had an alanine aminotransferase or aspartate aminotransferase level greater than 3 times the upper limit of normal, active liver disease, or jaundice at Screening A.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had a positive anti-hepatitis B surface antigen, or anti-hepatitis B e antigen test results at Screening A.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Was currently taking another investigational study medication or had taken an investigational study medication within 30 days before Screening A.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762957",
    "statement": "Had any other serious disease or condition at Screening A or at Randomization that might have affected life expectancy or made it difficult to successfully manage and follow the patient according to the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Histologically or cytologically confirmed ACC (advanced unresectable and/or metastatic)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Measurable disease based upon RECIST v1.1 as determined by the Investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Documented GC excess (too much cortisol).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "For patients who have received mitotane within 3 months prior to screening, mitotane levels must be <4 mg/L at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status ≤2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Adequate organ and bone marrow function (determined through blood and urine tests)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Negative pregnancy test for patients of childbearing potential at the Screening and every 6 weeks (+ or - 7 days) in female patients of childbearing potential.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Major surgery within 4 weeks prior to enrollment. If the participant underwent major surgery, they must have recovered adequately prior to starting study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Have received and responded (complete response [CR] or partial response [PR]) to prior treatment with any prior checkpoint inhibitor or any other agents targeting T-cell stimulation pathways",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Taking a concomitant medication that is a strong Cytochrome P450 3A (CYP3A) inducer, or that is a substrate of CYP3A with a narrow therapeutic index",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Known untreated parenchymal brain metastasis or have uncontrolled central nervous system (CNS) metastases. Patients must not require steroids and must be neurologically stable without corticosteroids for a minimum of 3 weeks prior to the commencement of the study. Patients with neurologic symptoms must undergo a CT/MRI to rule out occult CNS metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Requirement for chronic systemic GC treatment, such as active autoimmune disease requiring systemic treatment (corticosteroids or other immunosuppressive medication)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Patients requiring inhaled glucocorticoids but have no other alternative treatment option if their condition deteriorates during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Clinically relevant toxicity from prior systemic cytotoxic therapies or radiotherapy that in the opinion of the Investigator has not resolved to NCI-CTCAE v5.0 Grade 1 or less prior to the first dose of relacorilant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Treated with the following prior to the first dose of relacorilant:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Any investigational product, systemic anticancer therapy, or radiation therapy within 21 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Antibodies or anticancer vaccines within 60 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Mifepristone or other GR antagonists within 5 half-lives of these medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Adrenostatic medications within 5 half-lives of these medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "History of severe hypersensitivity to another monoclonal antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Other concurrent cancer or a history of another invasive malignancy within the last 3 years that has a likelihood of recurrence of >30% within the next 5 years. Adequately treated basal and squamous skin cancers, ductal carcinoma in situ, cervical cancer, prostate cancer, non-muscle invasive urothelial cancer or other tumors curatively treated with no evidence of disease are permissible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Human immunodeficiency virus (HIV) or current chronic/active infection with hepatitis C virus or hepatitis B virus including: Chronic or active hepatitis B as diagnosed by serologic tests. In equivocal cases, hepatitis B or C polymerase chain reaction may be performed and must be negative for enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Clinically significant uncontrolled condition(s) or a condition which, in the opinion of the Investigator, may confound the results of the trial or interfere with the patient's participation, including but not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction 3 months before study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Active infection that requires parenteral antibiotics.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04373265",
    "statement": "Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Diagnosis of Type 2 Diabetes Mellitus.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Has glycosylated hemoglobin levels between 6.0% and 8.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Treatment with metformin (2,000 to 3,000 mg daily) for at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Has reduced high-density lipoprotein cholesterol levels less than 40 mg/dl in males and less than 50 mg/dl in females, irrespective of treatment with statins.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Has central obesity defined as a waist circumference greater than or equal to 94 cm for men and greater than or equal to 80 cm for females.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Has a diagnosis of Type 1 Diabetes Mellitus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "other oral antidiabetic drugs than metformin or with insulin in the 3 months preceding study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Fibrates",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Rifampicin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Has any disease with malabsorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Has acute or chronic pancreatitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Has familial polyposis coli.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Has a medical history of myocardial infarction, transient ischemic attacks or stroke in the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Has heart failure as defined by the New York Heart Association classification I-IV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Has significant liver impairment, with an alanine aminotransferase level greater than 2.5 the upper limit of normal range.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Has significant renal impairment, with a serum creatinine level greater than 1.5 mg/dl for men and greater than 1.2 mg/dl for women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Has anemia of any etiology (defined as hemoglobin levels less than 10.5 g/dL) or any other hematologic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Has a diagnosis or suspicion of neoplastic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "History of chronic alcohol or drug abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Known allergy, sensitivity or intolerance to the study drugs and their formulation ingredients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00772174",
    "statement": "Participation in another trial in the 3 months preceding study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "pre-prandial short-acting or rapid-acting insulin alone or as part of a basal/bolus insulin regimen",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "coma, or loss of consciousness, - or - has had recurrent (≥3 times per week) episodes of hypoglycemia over the past 8 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "therapy and has not been on a stable dose for at least 6 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "steatosis)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "congestive heart failure within the past 3 months, or has any of the following",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "disorders within the past 3 months:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has type 2 diabetes mellitus",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has one of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "diagnosed with diabetes after age 40 years and insulin therapy was initiated at least 3 years following diagnosis",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "if diagnosed with diabetes under age 40 years or insulin started earlier than 3 years after diagnosis, has a fasting C-peptide greater than 0.7 ng/mL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "must be at least 18 years of age and less than or equal to 80 years of age (for participants in India: must be at least 18 years of age and less than or equal to 65 years of age)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "on a stable regimen of insulin for at least 10 weeks with or without metformin (at least 1500 mg/day) and/or sulfonylurea for at least 10 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "is highly unlikely to become pregnant (not of reproductive potential or agrees to remain abstinent or use (or have their partner use) an acceptable method of birth control during the study and for 14 days after the last dose of study medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has been treated with a dipeptidyl peptidase IV (DPP-4) inhibitor, a thiazolidinedione (TZD), or a glucagon-like peptide-1 (GLP-1) mimetic or analogue, within the past 12 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "currently on treatment with daily use (one or more injections per day) of a",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has symptomatic hyperglycemia that requires immediate initiation, adjustment, or addition of antihyperglycemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has a history of 2 or more episodes of hypoglycemia resulting in seizure,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has a history of ketoacidosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "is not appropriate for or does not agree to target a fasting glucose of 72-100 mg/dL [4.0-5.6 mmol/L]",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "is on or likely to require treatment with corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has undergone a surgical procedure within 4 weeks or has planned major surgery during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "is currently being treated for hyperthyroidism or is on thyroid hormone",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has a history of active liver disease (other than non-alcoholic hepatic",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has had new or worsening signs or symptoms of coronary heart disease or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "acute coronary syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "coronary artery intervention",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "stroke or transient ischemic neurological disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has a systolic blood pressure greater than 160 mm Hg or a diastolic blood pressure greater than 90 mm Hg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has severe peripheral vascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has a clinically important hematological disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has a history of malignancy that is less than 5 years from study start, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "has a positive urine pregnancy test",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "is pregnant or breast-feeding, or is expecting to conceive or donate eggs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01462266",
    "statement": "a user of recreational or illicit drugs or has had a recent history of drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Male or female aged 35 to 60 years (both inclusive)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Type 2 diabetes mellitus diagnosed < 2 years prior to enrolment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Glycated haemoglobin level ≥ 7% and ≤ 9.5%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "On stable oral monotherapy with metformin hydrochloride (1000 mg to 2500 mg/day) and regular diet and exercise regimen at least 12 weeks prior to enrolment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Body mass index between 18 to 30 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Ability to perform capillary blood glucose measurements",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Willing to provide informed and written consent for the clinical trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Able to comply with all requirements of clinical trial protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Subject with history or evidence of hypersensitivity to insulin or metformin hydrochloride or its excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Suffering from type 1 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Received treatment with sulphonylureas or alpha-glucosidase inhibitors, Glucagonlike peptide-1 (GLP-1) receptor agonists or Sodium-glucose co-transporter 2 (SGLT2) inhibitors or meglitinides or pramlintide or thiazolidinediones within 3 months prior to enrolment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Previously treated with insulin within 3 months prior to enrolment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "History of episodes of hypoglycaemia during 3 months prior to enrolment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Reduced awareness of hypoglycaemia or inability to identify and tackle hypoglycaemic episodes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "History of substantial weight loss defined as 5% decrease in body weight within the last 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Medical history of unstable angina within 1 year prior to enrolment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "History of tobacco or nicotine more than two packs/day within 3 months prior to enrolment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within 1 year prior to enrolment) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by >3 drinks per day or >14 drinks per week, or binge drinking).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "History of gastrointestinal disorders which may potentially interfere with absorption of the investigational product",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Treatment with systemic corticosteroids or with inhalational corticosteroids (Beclomethasone or budesonide) within the 3 months prior to enrolment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Likelihood of requiring treatment during the study period with prohibited medications mentioned (as defined in this clinical trial protocol)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Female subject who is pregnant, lactating or planning pregnancy during the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Female subject of childbearing age who is not willing to use adequate method of contraception during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Life expectancy of less than 6 months from screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Elective surgery or any other surgical procedure/s requiring general anaesthesia during the clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Has participated in another research trial within 12 weeks prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "History of diabetic ketoacidosis requiring hospitalization within 6 months prior to enrolment, case of proliferative retinopathy or advanced neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Subject having any of the following laboratory results at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) >3 times of upper limit normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Blood urea nitrogen (BUN) > 30 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Subject who has a positive serology for hepatitis B virus (HBV) or hepatitis C (HCV) or human immunodeficiency virus (HIV) infections at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Subject who has undergone pancreatectomy or pancreas islet transplant or renal transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Subject receiving or has received any immunomodulation medications within 1 year prior to enrolment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Subject with history or evidence of diabetic complications (e.g. diabetic retinopathy, diabetic neuropathy, or diabetic nephropathy, etc.), cardiac disorders, or any other systemic complication due to diabetes, which in the opinion of the Investigator signifies subjects' ineligibility for the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06473662",
    "statement": "Has any concurrent disease or medical/surgical condition, which required treatment of more than 3 months and which in the opinion of the Investigator does not allow participation of the subject in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Age ≥ 21 and ≤ 65 years at time of enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Diagnosed with T2DM with baseline:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Fasting plasma glucose ≥ 140 mg/dl (7.8 mmol/l) and ≤ 270 mg/dL (15 mmol/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "HbA1c levels ≥ 7.0% and ≤ 9.0% (53-75 mmol/mol)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Triglyceride level < 400 mg/dL (4.52 mmol/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "On oral anti-hyperglycemic drug regimen of metformin. Subjects may be on additional oral anti-hyperglycemic drug of a different drug class",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Years of T2DM ≤ 10 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Diagnosed hypertension with baseline:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Office blood pressure of SBP of ≥ 140 mmHg and ≤ 180 mmHg and DBP ≥ 90 mmHg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Mean 24-hour ambulatory SBP of ≥ 130 mmHg and ≤ 170 mmHg with ≥ 75% valid readings",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "On stable oral anti-hypertension drug regimen consisting of up to a maximum of three drugs",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "BMI between 27.5 and 40 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "C-peptide testing: non-fasting random or stimulated C-peptide ≥ 2 ng/mL (660 pmol/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Vessel diameter of 3 mm to 6.5 mm inclusively with a minimum arterial treatable length of 20 mm in one or more of the following arteries:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Renal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Hepatic",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "T1DM or poorly controlled T2DM (defined as HbA1c > 9.0% or use insulin as medication to control glucose level).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Office diastolic blood pressure < 90 mmHg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Current use of > 3 hypertension medications.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Currently on beta blockers or alpha blockers.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "One or more documented hyperglycemia episodes requiring hospitalization in the 180-day prior to screening date.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Prior evidence of hypoglycemia unawareness or serious hypoglycemia with loss of consciousness or confusion sufficient to prevent self-treatment in last 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "BMI > 40 kg/m2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Diagnosed proliferative retinopathy or evidence of peripheral neuropathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Lack of appropriate treatment site or anatomy precluding the intervention of the target arteries (renal and hepatic artery).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History of prior renal or hepatic artery intervention including balloon angioplasty, stenting, etc.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Arterial stenosis >50% of the normal diameter segment (diameter stenosis, compared to the angiographically normal proximal or distal segment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Any abnormality or disease in one or more of the target arteries that, per the physician assessment, precludes the safe insertion of the guiding catheter (including, but not limited to, artery aneurysm, excessive tortuosity, calcification).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Occlusive peripheral vascular disease that would preclude percutaneous femoral access for the procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Known or suspected secondary hypertension, such as Cushing's disease or Cushing's Syndrome, hyperaldosteronism, pheochromocytoma, thyroid and parathyroid abnormalities, history of pre-eclampsia, onset of hypertension prior to the age of 18.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Use of nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Severe or unstable cardiovascular comorbidities, such as AMI or ACS, cardiac valve stenosis, pulmonary embolism, heart failure with NYHA Class III or IV, chronic atrial fibrillation, primary pulmonary hypertension, COPD.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Renal transplant, history of nephrectomy or single kidney, renal tumor/cancer, known non-functioning kidney, unequal renal size (>2 cm difference in renal length between kidneys associated with a chronic kidney disease or a deterioration of the kidney function), chronic renal deficiency with eGFR ≤ 60ml/min/1.73m2, or on chronic renal replacement therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Prior liver transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Any organ transplantation procedures are planned in the 365 days following Index Procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Gastrointestinal permanent anatomic alteration surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Any surgical procedure within 30 days prior to Index Procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Currently taking the following medications within 90 days prior to screening and/or there is a need or anticipated need for these medications during the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Systemic Corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Anticonvulsants",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Centrally acting sympatholytics",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Bleeding disorders, such as bleeding diathesis, thrombocytopenia, and severe anemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Use of anticoagulation therapy which cannot be discontinued from 7 days before or 14 days after the Index Procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Any other condition(s) that would compromise the safety of the Subject or compromise study quality as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Significant alcohol consumption, defined as more than 2 drink units per day (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men, or inability to reliably quantify alcohol intake.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Active substance abuse, based on Investigator judgement, including inhaled or injected drugs, within 1 year prior to the initial screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Significant weight loss within the last 6 months (e.g., > 10% total body weight loss).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Hepatic decompensation defined as the presence of any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Serum albumin less than 3.5 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History of esophageal varices, ascites, or hepatic encephalopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "ALT or AST greater than 200 U/L.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Diagnosis of liver cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Chronic liver or biliary disease of the following etiology:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of Hepatitis B",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of Hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of current active autoimmune hepatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of primary biliary cholangitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of primary sclerosing cholangitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of Wilson's disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of alpha-1-antitrypsin deficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of hemochromatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of drug-induced liver disease, as defined on the basis of typical exposure and history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Known bile duct obstruction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Suspected or proven liver cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History of acute or chronic pancreatitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Human immunodeficiency virus (HIV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Subjects with a history of adverse reaction to heparin or heparin induced thrombocytopenia (HIT).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Systemic infection that the investigator judges would pose unacceptable procedural risks to the subject.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Known hypersensitivity to contrast media, nickel and ethanol that cannot be adequately pre-medicated.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Subject is depressed or on antidepressants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Pregnancy or breastfeeding or plan to get pregnant in next 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Life expectancy of less than 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Unwilling or unable to comply with the follow-up study requirements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Lacking capacity to provide informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Currently participation in another pre-market drug or medical device clinical study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Subjects meeting the following criteria at the Screening Visit will be eligible to participate in the trial:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Subjects are excluded from participation in the study if any of the following criteria apply:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Have given written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Male or Female",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Females of childbearing potential who are on approved birth control method: oral, injectable, or implantable hormonal contraceptives; intrauterine device; diaphragm plus spermicide or female condom plus spermicide",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Females of non-childbearing potential: hysterectomy, tubal ligation 6 months prior screening or post-menopausal for at least 1 year",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Previously diagnosed or newly diagnosed with T2DM",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Age 30 to 70 years, inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "BMI ≥ 18.5 kg/m2 and ≤ 40 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "HbA1C 7-10%, inclusive (exceptions between 6.7-7% may be enrolled with prior approval of SPONSOR)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Fasting plasma glucose < 300 mg/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Diet controlled or on stable dose of a sulfonylurea and/or meglitinides and/or metformin for ≥ 90 days before screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "No history of liver, biliary or intestinal disease (AST/ALT < 2X upper limit of normal value)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Normal TSH",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Agrees to maintain their regular diet and exercise routine",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Agrees to refrain from consumption of alcohol 48 hours prior to start of infusions (week 0 and week 12)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Type 1 diabetes mellitus or history of diabetic ketoacidosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Treatment with lipid lowering medication other than statins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Treatment with statins that have not been stable for 3 months before screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Treatment with colesevelam HCl, cholestyramine or colestipol for hyperlipidemia within the last 3 months of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Treatment with a thiazolidinedione (TZD) at any time",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Treatment with acarbose at any time",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Treatment with insulin in the past 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Treatment with antibiotics within the last 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Treatment with any medication affecting liver or intestinal function within the last 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Pregnant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Has had unstable weight within the last 3 months of screening (± 5 kg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "History of an allergic or toxic reaction to colesevelam HCl",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "History of dysphagia, swallowing disorders, or intestinal motility disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Serum triglycerides ≥ 350 mg/dL at screening visit (exceptions up to 500 mg/dl may be enrolled with prior approval of SPONSOR)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Serum LDL-C <60 mg/dL at screening visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Any condition or therapy which, in the opinion of the investigator, poses a risk to the subject or makes participation not in the subject's best interest",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Use of any investigational drug within 3 months of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Chronic treatment with oral corticosteroids at any time or acute treatment within the last 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "History of drug or alcohol abuse, is currently a user (including \"recreational use\") of any illicit drugs, or has a positive urine drug screen at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00596427",
    "statement": "Donated a unit of blood within 30 days before screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Females must be non-pregnant, non-lactating and post-menopausal.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "A glycosylated hemoglobin level greater than 7.5% and less than 10%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has an age of onset of Type 2 Diabetes greater than 35 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Is on metformin monotherapy up to the maximum tolerated daily dose.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has a normal or only slightly impaired renal function (a modification of diet in renal disease estimated glomerular filtration rate greater than 60 ml/min/1.73m2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Antihypertensives, statins and any other hypolipidemic medications have been initiated at least three months prior to enrollment; no dose modifications are allowed during the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has one or more cardiovascular comorbidities as follows:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "stable angina pectoris",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "previous (greater than three months) transient ischemic attack, cerebrovascular accident or carotid atherosclerosis as assessed by bilateral carotid artery ultrasonography",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "peripheral vascular complications documented by a history of claudication or rest pain, ultrasonography or angiography.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "and/or two or more of the following major cardiovascular risk factors:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "hypertension (blood pressure >130/80 mmHg or treatment)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "dyslipidemia (low-density lipoprotein-cholesterol >100 mg/dl or treatment and/or high-density lipoprotein-cholesterol <40 mg/dl in men and <45 mg/dl in women or treatment)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "smoking (>10 cigarettes/day)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has Type 1 Diabetes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Is on insulin therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Is severely obese defined as a body mass index greater than or equal to 40mg/m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has diabetic retinopathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has evidence of hepatic dysfunction including liver transaminase greater than three times the upper limit of normal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Is unable to remain on a stable dose of the following class of medications 30 days prior to randomization and throughout the six months of the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "antihypertensives",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "statins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "other hypolipidemic and antiplatelet drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has a history of alcohol or other drug abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has had a new diagnosis of cancer or recurrent cancer within five years of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has a need for chronic (greater than two weeks) immunosuppressive therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has had heart failure based on the New York Heart Association Functional Class I through IV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Other antidiabetic drugs (except metformin)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Fibrates",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Rifampicin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Glibenclamide interacting drugs, including nonsteroidal anti-inflammatory agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Other drugs that are highly protein bound, including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "sulphonamides",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "chloramphenicol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "probenecid",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "monoamine oxidase inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "fluoroquinolones antibiotics",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "oral miconazole",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has participated in another clinical study within the past three months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act (HIPAA) or other privacy authorization prior to any participation in study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Subject has self-reported type 2 diabetes.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Subject has HbA1c ≥ 7.5% and ≤ 12.5% measured within 30 days of screening visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Subject is on a stable diabetes therapeutic regimen of two or more diabetic medications (e.g., metformin plus one other antihyperglycemic agent) and/or insulin therapy for at least 2 months before screening visit. Dose changes or adjustments made within 2 months is acceptable as long as the patient has been on the medication regimen for 2 months or longer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Subject is ≥ 18 and ≤ 75 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Subject is a male or non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit. A urine pregnancy test is required for all female subjects unless she is not of childbearing potential, defined as postmenopausal for at least one year prior to screening visit or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "If female is of childbearing potential, is practicing one of the following methods of birth control (and will continue through the duration of the study):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Condoms, sponge, diaphragm, or intrauterine device;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Oral or parenteral contraceptives for 3 months prior to screening visit;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Vasectomized partner;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Total abstinence from sexual intercourse",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Subject is able to speak, read and write in English",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Subject has a Glooko compatible smartphone/device with an active data plan or access to Wi-Fi and downloaded at least one mobile application on their phone on their own.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Subject has performed self-monitoring of blood glucose at least five (5) times within two (2) weeks prior to screening visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Subject has type 1 diabetes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Subject has advanced disease (physical or psychological) that would prevent them from being able to comply with study tasks and considered exclusionary by the study physicians.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Subject has been on medication or therapy within the last 2 months that severely affects blood glucose levels (e.g. corticosteroids).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Subject has visual impairment which severely limits his/her ability to see or use the mobile application.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02974816",
    "statement": "Subject is a participant in another clinical study that has not been approved as a concomitant study by Glooko.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "- Patients meeting at least one of the following criteria will be excluded from the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Male and female patients meeting all the following criteria will be enrolled in the study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Aged between 20 and 75 years old.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Diagnosis of T2DM according to the criteria of the American Diabetes Association (ADA).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Not having received treatment with oral hypoglycemic agents or insulin within 12 weeks prior to the screening visit;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Glycated hemoglobin (HbA1c) levels at the screening visit of 7.5% ≤ HbA1c ≤ 10.5%, after appropriate treatment with diet and physical exercise for ≥ 12 weeks;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Body mass index (BMI) of 20 kg/m2 ≤ BMI ≤ 40 kg/m2 at the screening visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Signing the Informed Consent Form (ICF) before the performance of any study procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Fasting blood glucose values > 300 mg/dL with severe clinical manifestations present (significant loss weight, severe symptoms and/or ketonuria).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Current participation in weight loss programs, with or without anti-obesity drugs use.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Presence of heart failure functional class III or IV according to the New York Heart Association (NYHA).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Presence of symptomatic liver or gall bladder disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "History of myocardial infarction, transient ischemic attack or coronary angioplasty within 6 months prior to the screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "History of gastrointestinal resection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Estimated creatinine clearance (Cockroft and Gault formula) < 60 mL/min.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Serum ALT and/or AST level ≥ 2.5 x upper normal limit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Serum CPK level ≥ 3 x upper normal limit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Fasting triglycerides > 400 mg/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "History of major skin allergy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Use of corticosteroids within 3 months prior to the screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Concomitant treatment with warfarin, dicoumarinic agents or digoxin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Concomitant use of drugs or foods that interfere with the CYP3A4 pathway of liver metabolism including, but not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Inhibitors: antibacterial agents (erythromycin), antifungals (itraconazole, ketoconazole), antivirals (ritonavir, saquinavir, amprenavir, indinavir, nelfinavir), H2 receptor antagonists (cimetidine) and grapefruit juice;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Inducers: dexamethasone, rifampin and anticonvulsants (phenytoin, phenobarbital, carbamazepine)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "History of untreated or uncontrolled thyroid disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "History of drugs of abuse or moderate/heavy alcohol consumption within 2 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Presence of severe or uncontrolled diseases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Presence of pregnancy or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Women of childbearing potential who do not agree to use a proven effective contraceptive method, unless they are surgically sterile or declare being expressly exempt of pregnancy risk for not engaging in sexual practices or for engaging in them in a non-reproductive manner.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Participation in a clinical trial protocol within the previous 12 months unless, at the investigator's discretion, his or her participation may imply a direct benefit for the participant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02689362",
    "statement": "Presence of any condition which, at the investigator's discretion, may render the patient inadequate for study participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient able to understand the study information and providing written consents for his/her participation to the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Male or female",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient undergoing medical examination during the selection visit",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient aged between 18 and 75 years old (bounds included)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "T2D volunteer with:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "HbA1c between 6,5% and 8,5%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Bi-therapy associating metformin and sitagliptin at stable dose for at least 1 month",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "T2D volunteer without insulin therapy or GLP-1 analogues",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient with BMI ranging between 22 and 37 kg/m2 (bounds included)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient with stable body weight over the past three months (+/- 5 % of body weight)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient accepting to change its diet for two weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient not suffering from intolerance or allergy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient regularly consuming products proposed in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient regularly consuming 3 main meals per day",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Sedentary behavior or stable regular physical activity during the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient not presenting any disease during the medical examination / interview which could interfere with the results of the study according to the investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient covered by health assurance",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "General criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient under legal protection measure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient deprived of liberty by a court or an administrative decision",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient currently participating in another study or being in the exclusion period of another study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Volunteer that exceed the financial compensation allowed per year for participating in research programs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Biological criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Gamma-GT > 2.5 times above the norm (>160 UI/L)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "ASAT > 2.5 times above the norm (>85 UI/L)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "ALAT > 2.5 times above the norm (>137.5 UI/L)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Triglycerides > 4 g/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "LDL-cholesterol > 1.90 g/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "CRP > 15 mg/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Hemoglobin < 120 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Other biological abnormality with clinical significant relevance according to the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Therapeutic and medical criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient with type 1 diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "T2D treatment other than metformin and sitagliptin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient with past bariatric surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient with medical history of endocrine diseases who may interfere with glucose metabolism according to the investigator (such as thyroid dysfunction, acromegaly, hypercorticism…)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Uncontrolled high blood pressure defined by Systolic blood pressure > 150 mmHg or Diastolic blood pressure > 100 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Evidence of any other unstable or untreated clinically significant immunological, neoplasic, endocrine, haematological, gastrointestinal, hepatic, neurological or psychiatric abnormalities or medical disease according to the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Pregnant women or willing to become pregnant or lactating women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Women of childbearing age without an efficient contraceptive method according to the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient under a restrictive diet or willing to lose weight",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient with eating disorders (e.g. anorexia nervosa and bulimia) according to the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient without stable dietary habits or with specific diet (vegetarian, vegan,…) according to the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient who smokes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient regularly consuming more than 20 g/day of alcohol. Consumption of more than 3 alcoholic beverages per day is recognized as excessive. An alcoholic beverage is: 30 mL of spirituous, 120 mL of wine or 330 mL of beer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient regularly consuming recreational drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Patient consuming in the two previous months regularly corticoids, anorectics, adrenergic drugs, beta-blocking drugs, antiplatelet agent (like aspirin) or other drugs or supplement that should impact glucose metabolism (other than metformin or DPP4 inhibitor) in the investigator's opinion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03289494",
    "statement": "Adhesive plaster skin allergy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject has the ability to sign an informed consent form. Prior to randomization patients has signed the informed consent, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject 18 and older who has documented type 2 diabetes diagnosis at least 3 months before the screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject has HbA1c >/= 7.5% and </=12.5 % measured using a NGSP certified method",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject is initiating basal insulin therapy with insulin degludec or switching to insulin degludec from any basal insulin. The subject may also be on concomitant anti-hyperglycemic agents, including oral hypoglycemic (OAs), non-insulin injectables (e.g. GLP-1) which has been at a stable dose for approx. 3 months, or as determined by the Investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject is a male or non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit. A urine pregnancy test is required for all female subjects unless she is not of childbearing potential, defined as postmenopausal for at least one year prior to screening visit or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "If female is of childbearing potential, is practicing one of the following methods of birth control (and will continue through the duration of the study):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Condoms, sponge, diaphragm, or intrauterine device;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Oral or parenteral contraceptives for 3 months prior to screening visit;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Vasectomized partner;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Total abstinence from sexual intercourse",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject has a Glooko compatible smart device (smartphone/tablet) with an active data plan or access to Wi-Fi and downloaded at least one mobile application on their phone on their own. If subject does not have a Glooko compatible smart device, a loaner smart device can be provided for the study period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject is currently performing self-monitoring of blood glucose(SMBG)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject has had a severe hypoglycemia episode in the last 90 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject has type 1 diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject does not have access to a Glooko compatible smart device (smartphone or tablet)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject must not be using Glooko or any other electronic application for insulin titration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject is unable to read and understand English",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject is using short acting or pre-mixed insulin for more than 10 days in the last 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject is going to initiate short acting insulin prior to the study start",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Pregnant or breastfeeding women, or the intention of becoming pregnant or not using adequate contraceptive measures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Visual impairment resulting in inability to see application.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Use of systemic steroids for one week or more in the last 90 days from screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Unable to meet protocol requirements (performing SMBG, administering insulin)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Known hypersensitivity / intolerance to insulin degludec or any of its excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Participant in another clinical study?",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "In the opinion of the PI, if the subject is already on insulin and cannot be properly managed with only long acting insulin (e.g., the introduction of meal time insulin is necessary)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03091712",
    "statement": "Subject has any other condition or event considered exclusionary by the PI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Diagnosed type II diabetes mellitus (according to WHO criteria, 1999 - 2006).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Patient's age from 18 to 65 years inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Level of glycosylated hemoglobin 7.0- 10.0 %.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Dose of basal insulin ≥10 units/day combined with metformin or with metformin and sulfonylurea derivatives during not less than 3 months prior to inclusion in the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Body mass index ≥25.0 and ≤40.0kg/m^2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Constant body weight (without fluctuations > 10% during not less than 3 months prior to inclusion in the trial).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Glomerular filtration rate ≥ 60 ml/ min/1.73m^2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Stable dose of basal insulin for the last 3 months.(Permissible fluctuations are ±10%.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Usage of contraceptive methods by both gender patients of reproductive age during the trial and within 30 days after ending the participation in the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Availability of signed patient information sheet (Informed Consent form) for participation in the clinical trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Acute diabetes mellitus complications for 3 months prior to inclusion in the trial (diabetic ketoacidosis, hyperosmolar hyperglycemic state, lacticemia, severe hypoglycemia and hypoglycemic coma).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Diabetic retinopathy, preproliferative, proliferative or terminal stages (based on the results of oculist examination during screening period or 6 months prior to the trial).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Diabetic nephropathy, proteinuria stage, chronic kidney disease on 3, 4 or 5 stage.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Diabetic microangiopathy:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "ishemic heart disease (medical history of a sudden coronary death with successful reanimation, medical history of myocardial infarction, stable exertional angina III or IV FC; unstable angina; postinfarction cardiosclerosis; chronic heart failure III or IV FC);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "cerebrovascular diseases (medical history of acute cerebrovascular accident; progressive vascular leukoencephalopathy; vascular dementia);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "chronic obliterative peripheral vascular diseases (clinically significant);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "diabetic neuroosteoarthropathy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "diabetic foot (clinically significant).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Heart rhythm disorder:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "II-III atrioventricular block;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "sick sinus syndrome;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "long QT interval syndrome;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "complete left bundle branch block;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "block of 2/3 bundle branches;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "WPW syndrome;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "ventricular arrhythmia of III grade according Laun-Wolf;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "paroxysmal supraventricular tachycardia;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "paroxysmal/recurrent ventricular tachycardia;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "atrial flutter and fibrillation;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "ventricular flutter and fibrillation;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "heart pacemaker implant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Uncontrolled arterial hypertension characterized by the following blood tension values: systolic blood pressure over 160 mm Hg and/or diastolic blood pressure over 100 mm Hg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Severe concomitant pathology including clinically significant cardio- vascular diseases of III - IV functional class (according to New York Heart Association classification, 1964), nervous and endocrine system diseases, including morbid obesity (body mass index≥40.0 kg/m^2), renal insufficiency, liver failure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Medical history of pancreatectomy or transplantation of pancreatic/islet cells.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Medical history of renal transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Malignant neoplasms/suspected malignant neoplasms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Exacerbations or decompensation of chronic diseases affecting a patient's ability to participate in the clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "The results of analysis of liver enzymes (alanine aminotransferase, aspartate aminotransferase) more than threefold exceeding of upper limit of normal values.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Level of fasting triglycerides >5.64 mmol/L.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Medical history of bariatric surgical operations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Medical history of polyvalent allergy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Allergy/ intolerance to any of the components of medications used in the treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Intake of medicines listed in the section \"Prohibited concomitant treatment\" for 3 months prior to the inclusion in the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Pregnancy, breast-feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Drug addiction, alcohol usage in the amount exceeding 2 units of alcohol per day.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Mental disorders of a patient.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Night work.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Participation in other clinical trials in the course of 3 months prior to the inclusion in the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Patients, who from the investigator's point of view, will fail to comply with the observation requirements of the trial or with the intake regimen of the investigated medicines.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Other factors impeding patient's participation in the trial (for example, planned business trips or journeys).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Patient is related to the research personnel of the investigative site, who are directly involved in the trial or are the immediate relative of the researcher. The immediate relative includes husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868646",
    "statement": "Patient works for OOO \"NPF \"Materia Medica Holding\" (i.e. is the company's employee, temporary contract worker or appointed official responsible for the carrying out the research) or the immediate relative.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "Clinical diagnosis of type 1 diabetes for one year or more",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "Age 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "Body mass index (BMI) less than or equal to 35 kilograms per square meter (kg/m2)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "Have a hemoglobin A1c (HbA1c) 1.2 to 2.0 times the upper limit of the normal (ULN) reference range within 30 days prior to Visit 1 or collected and analyzed at a local laboratory at Visit 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "As determined by the investigator, are capable and willing to do the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "perform self monitoring of blood glucose (SMBG),",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "complete patient diaries as required for this protocol,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "use the insulin injection device(s) according to the instructions provided,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "are receptive to diabetes education,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "comply with the required study visits.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "Have taken any oral antihyperglycemic medications (OAMs) within 3 months prior to Visit 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "Have had more than one episode of severe hypoglycemia, as defined in the Abbreviations and Definitions section of the protocol, within 6 months prior to entry into the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "Are pregnant or intend to become pregnant during the course of the study or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable or women who are breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "Are receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy (excluding topical, intra-articular, intraocular, and inhaled preparations) or have received such therapy within the 4 weeks immediately preceding Visit 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487240",
    "statement": "Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Able and willing to provide written informed consent to participate in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Ambulatory male and female subjects (of any race) with T2D within the age range of 18-65 years (inclusive) at the time of screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "All female subjects must be of non-childbearing potential. All male subjects must agree with their partners to use double-barrier birth control or abstinence while participating in the study and for 12 weeks following the last dose of investigational product. For the purposes of this study, non-childbearing is defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Amenorrheic for at least 12 consecutive months; menopausal status in amenorrheic females will be confirmed by demonstrating levels of follicle stimulating hormone (FSH) >40-138 mIU/mL and estradiol < 30 pg/mL at entry. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH and/or estradiol levels are not consistent with a post-menopausal condition, determination of subject eligibility will be at the discretion of the principal investigator with agreement of the independent medical monitor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "At least 6 weeks post-surgical bilateral oophorectomy (with or without hysterectomy) or post tubal ligation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "The subject must be on stable metformin monotherapy for a minimum of 3 months prior to the Screening visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "HbA1c of 6.5%-9.5% (inclusive)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Body Mass Index (BMI) of 22-38 kg/m^2 (inclusive)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Resting supine blood pressure (BP) < 160/90 mmHg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Have a normal 12-lead electrocardiogram (ECG) or one with changes considered to be clinically insignificant on medical review and QTc intervals as defined below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "QTcB must be <450 msec for males and <470 msec for females (based on single or average QTc value of triplicate ECGs obtained over a brief period)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "QTcB must be <480 msec in subjects with Bundle Branch Block",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Comprehension of the nature and purpose of the study and able to comply with the protocol requirements",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Able to communicate in person and by telephone in a manner that allows all protocol procedures to be carried out safely and reliably in the opinion of the investigative site staff",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Any major illness in the 3 months prior to study entry or any significant ongoing chronic medical illness not related to diabetes (e.g., recent myocardial infarction, unstable angina, stroke, or transient ischemic attack) which in the opinion of the principal investigator or medical monitor could risk subject safety or interpretation of the results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Renal or liver impairment, defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Serum creatinine level of ≥ 1.4 mg/dL for females and ≥ 1.5 mg/dL for males",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "AST and ALT ≥ 2xULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "alkaline phosphatase and bilirubin > 1.5xULN (an isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "A positive test for HIV antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "History of or current gastrointestinal diseases influencing drug absorption as judged by the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Significant history of alcoholism or drug/chemical abuse, or a positive result of the urine drug/alcohol screen at the Screening Visit, or consuming more than 28 units of alcohol per week (one unit of alcohol equals about 250 mL of beer or lager, one glass of wine, or 20 mL spirits)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Participation in any clinical trial within 3 months prior to the first dose of investigational product in the current study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "History of difficulty in donating blood or accessibility of veins in left or right arm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Donation or loss of blood (more than 500 mL) within 3 months prior to receiving the first dose of investigational product",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Use of any prescription drug therapy, with the exception of any prescription medication administered at a stable dose for at least 6 weeks prior to Screening, provided the medication is not contraindicated by the metformin label (see Appendix A for Glucophage® Summary of Product Characteristics)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Use of any anti-diabetic therapy other than metformin, within 3 months of the first dose of investigational product",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Use of any dietary or herbal supplements within 3 weeks prior to the first dose of investigational product",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Active neoplastic disease or history of neoplastic disease within 5 years of study entry (except for basal cell carcinoma of the skin or carcinoma in situ)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01018017",
    "statement": "Increased risk of thrombosis, e.g., subjects with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05834868",
    "statement": "Body mass index: 18.0 kg/m^2~35.0 kg/m^2 (both inclusive) at the time of screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05834868",
    "statement": "HbA1c: 7.0%~10.0% (both inclusive) at the time of screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05834868",
    "statement": "Diagnosed with T2DM for 6 months or longer at the time of screening based on the World Health Organization (WHO) classification.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05834868",
    "statement": "Treated with stable insulin regimen as follow for at least 3 months with or without oral antidiabetic drug:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05834868",
    "statement": "Basal insulin (neutral protamine Hagedorn [NPH] insulin, insulin glargine, insulin degludec, insulin detemir) in combination with at least 1 prandial injection of bolus insulin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05834868",
    "statement": "Premixed insulin at least twice daily.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05834868",
    "statement": "Have other types of diabetes other than T2DM.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05834868",
    "statement": "Have used Glucagon-Like Peptide 1 (GLP-1) receptor agonist within 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05834868",
    "statement": "Have had 1 or more episodes of severe hypoglycemia within the 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05834868",
    "statement": "Have had 1 or more episodes of acute diabetic complications (diabetic ketoacidosis, hyperglycemic hyperosmolar state, diabetic lactic acidosis, etc.) within the 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05834868",
    "statement": "With concomitant conditions at screening that may affect the evaluation of the study, including cardiovascular and cerebrovascular diseases, respiratory diseases, gastrointestinal diseases, liver diseases, kidney diseases, nervous system diseases, psychiatric diseases, hematological diseases, immune system diseases, endocrine system diseases, pancreatic diseases, and/or malignant tumors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Males or females, age ≥18 and ≤70 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Diagnosed with stage 3 T1D within the following timeframes:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Part 1 Cohort 1: Participants diagnosed within 3 years prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Part 1 Cohort 2: Participants diagnosed between 3 to 15 years prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Part 2 : Participants diagnosed within 15 years prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Treated with insulin only for at least 2 months prior to screening and proficient in the following in the opinion of the investigator:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Counting carbohydrates",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Adjusting meal and correction boluses based on glucose readings with a stable insulin/carbohydrate ratio as well as correction factors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Adjusting insulin and dietary therapy during special situations (eg, exercise, stress, intermittent diseases)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "HbA1c ≥6.5 and ≤10.0% at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Fasting or stimulated C-peptide Concentration at Screening as follows:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "C-peptide concentration ≥0.2 nmol/L if diagnosed within 3 years prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "C-peptide concentration ≥0.08 nmol/L if diagnosed between 3 and 15 years prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Documented history of at least 1 T1D1-related autoantibody.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "If treated with lipid-lowering therapy, the dose must be stable for at least 30 days prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Men and women of childbearing potential must use adequate birth control measures for the duration of the trial and at least 90 days after discontinuing study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Women who are not pregnant or lactating.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Diagnosis of MODY, T2D or any other subtype of diabetes mellitus other than T1D.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Have had recurrence (≥2 episodes) of severe hypoglycemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Known self or family history (first-degree relative) of multiple endocrine neoplasia Type 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Use of diabetes medications except insulin within 2 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Any significant cardiovascular disease or QTcF prolongation within the last 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Participants with fasting triglyceride ≥500 mg/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Have an eGFR <60 mL/min/1.73 m2 by the CKDEPI Creatinine Equation at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Impaired liver function, defined as screening AST or ALT >1.5 × ULN, Total bilirubin >1.5 × ULN with the exception of Gilbert's Syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "History of acute or chronic pancreatitis, complete pancreatectomy or pancreas transplants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Serum lipase and/or amylase above 1.5 x ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Known positive test for HIV, HBV surface antigen and COVID-19.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Diagnosis of, or treatment for, any cancer within the last 2 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ, melanoma in situ) treated with potentially curative therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Active (symptomatic) celiac disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "History of stomach or intestinal surgery that would potentially alter absorption and/or excretion of orally administered drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "History of cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Currently participating in a formal weight loss program and/or are currently using any drugs for weight management within 2 months of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Use of Proton pump inhibitors (PPIs) is prohibited.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Treatment with a moderate or strong CYP3A4 inhibitor, inducer, or substrate within a week prior to dosing on Day 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Male or female subjects, age 20 to 75 years, inclusive with type 2 diabetes mellitus.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "At Visit 2/Period 1/Day 1, subjects will have been treated for their diabetes by metformin (≥1000 mg/day; any type and regimen), metformin and a DPP-4 inhibitor ( Dipeptidyl-Peptidase)-4), metformin and an SGLT-2 (Sodium-glucose co-transporter 2) inhibitor, metformin and TZD (Thiazolidinediones), or metformin and sulfonylurea. Subjects will have been on a stable regimen of metformin (defined as the same metformin dose and type) and other treatments for at least 8 weeks prior to Visit 2/Period 1/Day 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Body Mass Index (BMI) between 25 and 40 kg/m2, inclusive, at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Hemoglobin A1c (HbA1c) between ≥7.5 and ≤10.5% at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Fasting serum glucose greater than or equal to 126 mg/dL at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Females of childbearing potential must have a negative serum pregnancy test result at Screening and a negative urine pregnancy test at Visit 2/Day 1 for all study Periods.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Females who are not of childbearing potential are defined as: i. Postmenopausal (defined as at least 12 months with no menses in women ≥45 years of age) ii. Has had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; OR iii. Has a congenital or acquired condition that prevents childbearing.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Females of childbearing potential agree to avoid becoming pregnant while receiving study treatment and for 14 days after the last dose of study treatment by complying with one of the following: i. practice abstinence† from heterosexual activity OR ii. Use (or have her partner use) acceptable contraception during heterosexual activity.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Usage of anti-diabetic agents other than metformin, sulfonylurea, SGLT-2 inhibitors, TZD, or DPP-4 inhibitors within 6 weeks prior to Visit 2/Period 1/Day 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Presence of any clinically significant endocrine disease according to the Investigator (euthyroid subjects on replacement therapy will be included if the dosage of thyroxine is stable for at least six weeks prior to Screening).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Clinical diagnosis of type 1 diabetes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Fasting serum glucose >300 mg/dL at Screening; a single repeat test is allowable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Evidence of unawareness of hypoglycemia, a documented plasma glucose ≤50 mg/dL in the absence of symptoms of hypoglycemia at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Presence of any clinically significant condition (in the opinion of the Investigator) that might interfere with the evaluation of study medication, such as significant renal, hepatic, gastrointestinal (GI), cardiovascular (CV), immune disease, blood dyscrasias or any disorders causing hemolysis or unstable red blood cells, or clinically important hematological disorders (i.e. aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia) at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Presence or history of cancer within the past 5 years of Screening, with the exception of adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "A subject with a history of malignancy >5 years prior to Screening should have no evidence of residual or recurrent disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "A subject with a history of melanoma, leukemia, lymphoma, or renal carcinoma is excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Laboratory abnormalities at Screening including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "C-peptide < 1.0 ng/mL;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Positive pregnancy test in females of childbearing potential (at Screening and Visit 2/Periods 1-3/Day 1);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Abnormal serum thyrotropin (TSH) levels below the lower limit of normal or >1.5X (1.5 times) the upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Elevated liver enzymes (alanine transaminase (ALT), alanine aminotransferase (AST), alkaline phosphatase) >2X the upper limit of normal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Very high triglyceride levels (>600 mg/dL); a single repeat test is allowable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Any relevant abnormality that would interfere with the efficacy or the safety assessments during study treatment administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Positive history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic hepatitis B or C, primary biliary cirrhosis, or active symptomatic gallbladder disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Positive history of HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Use of the following medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "History of use of insulin for more than 1 week within 6 months prior to and none within 6 weeks prior to Visit 2/Period 1/Day 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "History of use of aprotinin at any time prior to Screening (e.g., Trasylol, any type or dose).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Administration of thyroid preparations or thyroxine (except in subjects on stable replacement therapy) within 6 weeks prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Administration of systemic long-acting corticosteroids within two months or prolonged use (more than one week) of other systemic corticosteroids or inhaled corticosteroids (if daily dosage is > 1,000 μg equivalent beclomethasone) within 30 days prior to Screening. Intra-articular and/or topical corticosteroids are not considered systemic.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, and inhaled steroids (as discussed above), and immunosuppressive or immunomodulating agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Subject is on a weight loss program and is not in the maintenance phase, or subject has started weight loss medication (e.g., orlistat or liraglutide), within 8 weeks prior to Screening. Subjects who have had bariatric surgery are also excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Subject is pregnant or breast-feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Subject has a Screening systolic blood pressure ≥165 mmHg or diastolic blood pressure ≥100 mmHg. Subjects will be allowed to take a BP rescue medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Subject is a user of recreational or illicit drugs or has had a recent history (within 1 year of Screening) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by >3 drinks per day or >14 drinks per week, or binge drinking) at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "Any clinically significant ECG abnormality at Screening or cardiovascular disease. Clinically significant cardiovascular disease will include:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to Screening,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "History of or currently have New York Heart Associate Class II-IV heart failure prior to Screening, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "One or more contraindications to metformin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954601",
    "statement": "At the Principal Investigator's discretion, any condition or other factor that is deemed unsuitable for subject enrollment into the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Estimated glomerular filtration rate ≥ 20 to < 90 mL/min/1.73 m2 determined at the screening visit or a documented occurrence in medical history at least 3 months prior to randomisation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Receiving background standard of care treatment for renal disease and/or T2DM and being treated according to locally recognised guidelines, as appropriate.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Receiving optimised and stable treatment with an angiotensin-converting-enzyme (ACE) inhibitor or an angiotensin II receptor antagonist for ≥ 3 months at screening at the maximum tolerated dose (MTD) unless contraindicated, not tolerated, or in the opinion of the investigator, not practically available or suitable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Micro- or macroalbuminuria as defined by UACR > 50 mg/g or 5.7 mg/mmol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Diagnosed with T2DM with glucose control managed with any insulin and/or any oral therapy combination including metformin, SGLT2 inhibitor, thiazolidinedione, or acarbose where no major dose changes (eg, > 50% increase in dose) have occurred within the 4 weeks prior to the start of the run-in period. Participants taking sulfonylureas or glitinides may be randomised following a 4-week washout period of the sulfonylurea/glitinide.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Haemoglobin A1c range of 6.5 % to 12.5% (inclusive) at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Body mass index > 25 kg/m2 at screening or > 23 kg/m2 for participants enrolled in Japan",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "History or presence of significant medical or psychological conditions, including significant abnormalities in laboratory parameters or vital signs including ECG, which in the opinion of the investigator, would compromise the participant's safety or successful participation in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Receiving renal replacement therapy or expected to require it within 6 months of being randomised",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Renal transplant or on the waiting list for renal transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Received a GLP-1 analogue-containing preparation within the last 30 days or 5 half-lives of the drug, if known (whichever is longer), at the time of Visit 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Received any of the following medications within the specified time frame prior to the start of the study (Visit 2):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Aspirin (acetylsalicylic acid) at a dose greater than 150 mg once daily and within the last 3 days prior to the start of the run-in period (Visit 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Paracetamol (acetaminophen) or paracetamol-containing preparations at a total daily dose of greater than 3000 mg and within the last 3 days prior to the start of the run-in period (Visit 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Ascorbic acid (vitamin C) supplements at a total daily dose of greater than 1000 mg and within the last 3 days prior to the start of the run-in period (Visit 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Participation in another clinical study with an investigational product administered in the last 30 days or 5 half-lives of the drug, if known (whichever is longer)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Participants with a known severe allergy/hypersensitivity to any of the proposed study interventions or excipients of the product",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight loss) or recent episodes of severe hypoglycaemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Type 1 diabetes mellitus (T1DM), history of diabetic ketoacidosis, or clinical suspicion of T1DM",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Participants with recent acute or subacute renal function deterioration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Significant inflammatory bowel disease, gastroparesis, or other severe disease or surgery affecting the upper gastrointestinal tract (including weight-reducing surgery and procedures) which may affect gastric emptying or could affect the interpretation of safety and tolerability data",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "History of acute or chronic pancreatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Alanine transaminase (ALT) ≥ 3 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Total bilirubin ≥ 2 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Poorly controlled hypertension defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Systolic BP > 180 mm Hg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Diastolic BP ≥ 90 mm Hg after 10 minutes of seated rest and confirmed by repeated measurement at screening. Participants who fail BP screening criteria may be considered for 24-hour ambulatory BP monitoring at the discretion of the investigator. Participants who maintain a mean 24-hour systolic BP ≤ 180 or diastolic BP < 90 mm Hg with a preserved nocturnal dip of > 15% will be considered eligible",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Unstable angina pectoris, myocardial infarction, transient ischemic attack or stroke within 3 months prior to screening, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Decompensated heart failure or hospitalisation for heart failure in the 3 months prior to screening or symptoms consistent with New York Heart Association heart failure Class III/IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "Basal calcitonin level > 50 ng/L at screening or history/family history of medullary thyroid carcinoma or multiple endocrine neoplasia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04515849",
    "statement": "History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Diagnosed within the past 12 months with T2DM according to 1999 World Health Organization(WHO) criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Men and women aged at least 18 years at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Either not received oral anti-diabetic drugs or had been on short-term (1 month) treatment that had been discontinued 3 months before enrolment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "HbA1c ≥ 7.5% and ≤ 10.5% at screening and HbA1c ≥ 7.0% and ≤ 10.5% at pre-randomization visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "FPG ≤ 13.3 mmol/L (≤ 240 mg/dL) .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "BMI≥18.5 kg/m2 and ≤ 45.0 kg/m2 .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "C-peptide ≥0.33nmol/L(≥1.0 ng/mL).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Able and willing to provide written informed consent and to comply with the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Women who are pregnant, intending to become pregnant during the study period, currently lactating females, or women of child-bearing potential not using highly effective, medically approved birth control methods.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Diagnosis or history of: a. Acute metabolic diabetic complications such as ketoacidosis or hyperglycemic hyperosmolar state b. Diabetes insipidus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Requirement for insulin therapy. Symptoms of poorly controlled diabetes, including but not limited to, marked polyuria and polydipsia with >10% weight loss during the 3 months before enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Triglycerides (fasting) > 9.3 mmol/L (> 800 mg/dL).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Patients with clinically apparent hepatobiliary disease, including but not limited to chronic active hepatitis and/or severe hepatic insufficiency. Alanine Aminotransferase(ALT) or Aspartate Aminotransferase(AST) > 3x upper limit of normal (ULN), or serum total bilirubin (TB) >34.2 μmol/L (>2 mg/dL).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Patients with following renal disease history or renal disease related features:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "History of unstable or rapidly progressing renal disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Patients with moderate /severe renal impairment or end-stage renal disease (eGFR< 60 mL/min/1.73 m2);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Urinary albumin: creatinine ratio >1800 mg/g;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Serum creatinine (Cr) ≥133 μmol/L (≥1.50 mg/dL) for male subjects; Serum Cr≥124 μmol/L (≥1.40 mg/dL) for female subjects;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Conditions of congenital renal glycosuria.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Severe uncontrolled hypertension defined as SBP ≥180 mmHg and/or BP ≥110 mmHg; Patients with SBP < 95mmHg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Any of the following cardiovascular diseases within 6 months of the enrollment visit:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Myocardial infarction;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Cardiac surgery or revascularization (coronary artery bypass graft/percutaneous transluminal coronary angioplasty);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Unstable angina;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Congestive heart failure New York Heart Association Class III or IV;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Transient ischemic attack or significant cerebrovascular disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "History of gastrointestinal disease or surgery including Roemheld Syndrome, severe hernia, intestinal obstruction, intestinal ulcer, gastroenterostomy, enterectomy, bariatric surgery or lap-band procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Malignancy within 5 years of the enrollment visit (with the exception of treated basal cell or treated squamous cell carcinoma).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Known immunocompromised status, including but not limited to, individuals who had undergone organ transplantation or acquired immunodeficiency syndrome (AIDS).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Any subject who, in the judgment of the investigator, was at risk for dehydration or volume depletion that might affect the interpretation of efficacy or safety data.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "History of bone fracture secondary to diagnosed severe osteoporosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases as judged by the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Replacement or chronic systemic corticosteroid therapy, defined as any dose of systemic corticosteroid taken for >4 weeks within 3 months before enrollment visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Administration of sibutramine, phentermine, orlistat, rimonabant, benzphetamine, diethylpropion, methamphetamine, or phendimetrazine within 30 days of enrollment visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Any subject who was currently abusing alcohol or other drugs or had done so within the last 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Donation of blood or blood products, blood transfusion, or participation in a clinical study requiring withdrawal of >400 mL of blood during the 6 weeks before the enrollment visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "History of hypersensitivity reaction to dapagliflozin or acarbose. Allergies or contraindication to the contents of dapagliflozin tablets or acarbose tablets.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Previous participation in a clinical trial with dapagliflozin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Administration of any other investigational drug within 30 days of planned enrollment to this study, or within 5 half-life periods of other investigational drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03344341",
    "statement": "Subject is, in the judgment of the Investigator, unlikely to comply with the protocol or has any severe concurrent medical or psychological condition that may affect the interpretation of efficacy or safety data.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Diagnosed (clinically) with type 1 diabetes (T1D) for at least 1 year or type 2 diabetes (T2D) for at least 6 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Using insulin injection regimen of basal/bolus or basal only for 3 months prior to screening, which includes:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "for bolus insulin (U-100) - a rapid-acting insulin analog (glulisine, lispro, or aspart).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "for basal insulin - degludec (U-100 or U-200), detemir (U-100), or glargine (U- 100 or U-300).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Participants with T2D may be on ≤ 3 anti-hyperglycemic medications in addition to insulin, including alpha-glucosidase inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 receptor agonist (GLP-1 RA; oral or injectable), meglitinides, metformin, sodium-glucose cotransporter-2 inhibitors (SGLTi-2), sulfonylureas, or thiazolidinediones consistent with product labeling.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Participants with T1D must be on insulin only.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Have point-of-care hemoglobin A1c (HbA1c) value of ≤11% at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Must be able to self-inject insulin dose (basal or basal/bolus) without assistance.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "If using Continuous Glucose Monitoring or Flash Glucose Monitoring device, must agree to stop use throughout duration of trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Must be able to read and speak English.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Able and willing to use only study-provided insulin Basaglar and/or Humalog for duration of trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Able and willing to follow insulin regimen specified by investigator throughout duration of trial, insulin dose may be titrated at investigator's discretion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Have no physical or cognitive disabilities that would, in the opinion of the investigator, preclude participant from using sponsor-provided iOS device for study activities and comply with study requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Agree not to post any personal medical data, pictures of the IIM system or information related to the study on any website or social media site (for example, Facebook, Twitter, LinkedIn, etc.).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Have refrigeration in home for storage of insulin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Women of childbearing potential participating:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Cannot be pregnant or intend to become pregnant during the trial period",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Cannot be breastfeeding (including the use of a breast pump)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Must remain abstinent or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Must use 1 highly effective method (less than 1% failure rate) of contraception or a combination of 2 effective methods of contraception for the entirety of the study and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Test negative for pregnancy based on a urine pregnancy test at the time of screening. Additional local urine pregnancy tests may be conducted for duration of trial at discretion of investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "If not able to take the basal insulin dose in 1 injection per day.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Have experienced an episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) within 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Have hypoglycemia unawareness as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Have had 1 or more emergency room visits or hospitalization due to poor glucose control (hyperglycemia or diabetic ketoacidosis [DKA]) within 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "History of renal transplantation, receiving renal dialysis, or diagnosed with stage IV chronic kidney disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Any of the following cardiovascular conditions within 6 months prior to screening: i. acute myocardial infarction (MI) ii. cerebrovascular accident (stroke) iii. unstable angina, or iv. hospitalization due to congestive heart failure (CHF)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Presence or history of severe congestive heart failure (New York Heart Association Class IV [CCNYHA 1994]).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Have history of or clinical signs of liver disease (for example, acute or chronic hepatitis, or cirrhosis).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Have active or untreated malignancy except basal cell or squamous cell skin cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Have any hypersensitivity or allergy to any of the insulins or excipients used in this trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Have vision loss or vision impairment that does not allow recognition of MMA screen features.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Have impaired dexterity which limits ability to use injection device or mobile MMA.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Have participated, within the last 30 days, in a clinical study involving an investigational product. If the previous investigational product has a long halflife, 5 half-lives or 30 days (whichever is longer) should have passed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Have previously completed or withdrawn from this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04484779",
    "statement": "Have previously used or are currently using an approved or investigational connected pen system.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Healthy male subjects at age between 20 and 45 at the screening test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects with a body weight of 55kg or more but less than 90kg and a Body Mass Index (BMI) of between 18.0 or more but less than 27.0",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "BMI (kg/m2) = Weight (kg) / {Height (m)}2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects who show the blood glucose level within the range of 70-125 mg/dL at the fasting plasma glucose (FPG) test conducted at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects who fully understand this clinical trial after hearing a detailed explanation about it, make a decision to participate in it by his/her own free will, and sign an informed consent form to comply with the precautions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects who have a present condition or past history of any disease involving liver, kidney, nervous system, immune system, respiratory system, or endocrine system, hematologic and oncologic disease, cardiovascular disease, or psychiatric disorder (mood disorder, obsessive-compulsive disorder, etc.) (including subjects carrying hepatitis virus in case of liver disease)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects with a past history of a gastrointestinal system disease (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or a gastrointestinal system surgery (however, subjects with a history of appendectomy or hernioplasty are not excluded)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects with a medical history of allergic reaction to drugs (aspirin, antibiotics, etc.) or clinically significant hypersensitivity reaction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects who show one of the following results at screening test:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Exceeds 1.5 times the upper limit of the normal range of blood AST (SGOT) and ALT (SGPT)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "The creatinine clearance calculated by Cockcroft-Gault equation is below 80 mL/min.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "QTc > 450 ms in ECG or clinically significant abnormal rhythm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "In the vital signs measured in sitting position after a rest for 3 minutes or longer, subjects who showed a systolic blood pressure of ≤ 100 mmHg or ≥ 150 mmHg, or a diastolic blood pressure of ≤ 60 mmHg or ≥ 95 mmHg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects who have a past history of drug abuse or have shown a positive reaction to drugs that are used in abusive manner or cotinine at a urine drug screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects who have taken any ethical drug or an herbal medication within 2 weeks before the date of first administration or have taken any over-the-counter (OTC) drug or vitamin preparation within 1 week (however, they can be included as subjects if considered appropriate at the investigator's discretion judgment)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subject who have already participated in other clinical trials within 2 months before the date of first drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subject who have had whole blood donation within 2 months or component blood donation within 1 month before the date of first drug administration, or transfusion in 1 month before the date of first drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects who have been drinking alcohol continuously (more than 21 units/week, 1 unit = 10 g of pure alcohol) or can't refrain from drinking alcohol during the clinical trial period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Smokers (however, if the subject stopped smoking more than 3 months before the date of the first drug administration, he/she can be selected as a subject)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "12) Subjects who have had grapefruit/ any food containing caffeine within 3 days before the date of the first drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Men or women with: a) newly detected type 2 diabetes based on a fasting plasma glucose greater than or equal to 7.0 mmol/l (126 mg/dL) or a 2 hour plasma glucose (FPG) greater than or equal to 11.1 mmol/l (200 mg/dL) on an oral glucose tolerance test, or b) a history of type 2 diabetes",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Hemoglobin A1c (A1C) 6.5-9.5% inclusive (for assays with upper limit of normal of 6%) within one month of screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Age ≥ 50 years and evidence of vascular disease defined as ≥1of:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "prior myocardial infarction",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "prior stroke",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "coronary, carotid or peripheral artery revascularization ≥ 4 years earlier",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "previous documented myocardial ischemia on either an exercise stress test or on any cardiac imaging, or previous unstable angina with ECG changes or cardiac enzyme elevation OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Age ≥ 55 years and evidence of subclinical vascular disease defined as ≥1 of:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "microalbuminuria or proteinuria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "history of treated or untreated hypertension with left ventricular hypertrophy by electrocardiogram (ECG) or echocardiogram",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "50% stenosis on any imaging of coronary, carotid or lower extremity arteries",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "ankle/brachial index <0.9 OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Age ≥ 60 years and at least 2 of the following cardiovascular disease risk factors:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "current tobacco use",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "LDL-c ≥3.4 mmol/L (130 mg/dL) or on a lipid lowering medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "HDL-c < 1.0 mmol/L (40 mg/dL) for men and < 1.3 mmol/L (50 mg/dL) for women or triglycerides ≥ 2.3 mmol/L (200 mg/dL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "BP lowering medication use or untreated SBP ≥ 140 mmHg or DBP ≥ 95 mmHg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Waist to hip ratio > 1.0 for men and > 0.8 for women",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "On no insulin and on less than or equal to 2 anti-diabetes drugs where at least one drug is at or below the half-maximal dose (as indicated in the MOP) with stable dosing for 10 weeks prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Type 1 diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Current need for insulin treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Symptomatic hyperglycemia requiring immediate therapy in the judgment of the physician",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "An acute cardiovascular event within 30 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Symptomatic heart failure (i.e. New York Heart Association class II or higher) or any episode of previous pulmonary edema or known ejection fraction < 0.4 or current use of loop diuretics",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Any fracture within the past 1 year",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Currently planned coronary, carotid or peripheral artery revascularization or cardiac valve surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Coronary, carotid or peripheral artery revascularization within the 4 years prior to screening in the absence of angina, MI, or stroke in the intervening period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "End stage renal disease requiring renal replacement therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Receiving drug therapy to treat liver disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "A diagnosis of cancer (other than superficial squamous, basal cell skin cancer, or adequately treated cervical carcinoma in situ) in the past 3 years or current treatment for the active cancer (other than prophylactic)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level > 2.5 times the upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "A prior heart transplant or awaiting a heart transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Previous or current hypercalcemia, hyperparathyroidism, osteomalacia or other contraindication for vitamin D therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Regular use of or indication for greater than 400IU of vitamin D daily",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Clinically or medically unstable with expected survival < 1 year",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Unwillingness to permit sites to contact their primary physicians to communicate information about the study and the participant's data",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Any other factor likely to limit protocol compliance or reporting of adverse events",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Inability to discontinue a TZD (if taking one) in the judgement of the physician/investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Contraindications to or history of hypersensitivity to the investigational products",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "History of renal stones within the past 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00879970",
    "statement": "Participation in another clinical trial of an investigational agent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patient is male or female aged above (or equal to) 19 years old at screening, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patient was diagnosed with type 2 diabetes mellitus at least 3 months prior to screening according to the diagnostic criteria of KDA for at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patient has FPG ≤ 270 mg/dl (15.0 mmol/L) at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patient who was treated with Metformin (≥1000 mg/day) for at least 8 weeks prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patient has HbA1c (6.5%≤HbA1c≤9.0%) at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patient has adequate renal and hepatic function at screening as defined by the following clinical chemistry results:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "(male) Serum creatinine <1.5 × upper limit of normal (ULN), (female) Serum creatinine <1.4 × upper limit of normal (ULN),",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Serum alanine aminotransferase <2.5 × ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Serum aspartate aminotransferase <2.5 × ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (eg, barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], and intrauterine devices) during the course of the study(excluding women who are not of childbearing potential and men who have been sterilized).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Male and female patients and their partners who have been surgically sterilized for less than 6 months prior to study entry must agree to use 2 medically accepted methods of contraception as per inclusion criterion 7.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Menopausal females must have experienced their last period more than 12 months prior to study entry to be classified as not of childbearing potential.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patient (or legal guardian, if applicable) is informed of the full nature and purpose of the study, including possible risks and side effects, and understand this information, voluntarily signed and dated the written informed consent in compliance with protocol before inclusion in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patients who have hypersensitivity/allergies to main ingredient of sitagliptin/teneligliptin or any of the excipients of Investigational products(eg. Mannitol).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patient with severe ketosis, diabetic coma or pre coma, Type 1 DM",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patient is suffering from any disease, including Type 2 diabetes or its complications that, in the opinion of the Investigator, is sufficiently severe to render the subject unfit, or affect the subject's ability, to participate in the study, for example:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Macroangiopathy with symptoms of coronary heart disease or peripheral arterial obstructive disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Microangiopathy with symptoms of (autonomous) neuropathy with any one or more of the following: gastroparesis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Symptoms of poor blood glucose control (polyuria, polydipsia or weight loss)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Severe infection, pre or post-operative, severe trauma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patient has a medical history of unstable angina, or heart failure(New York Heart Association class Ⅲ-IV) or any clinically significant ECG abnormalities such as ventricular tachycardia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "The subject has diastolic blood pressure >100 mmHg and/or systolic blood pressure >180 mmHg at the screening visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patient who has malignancy at screening or history of any malignancy (except history of no recurrence of malignancy more than 5 years)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Female patient whose pregnancy test is negative or who are pregnant, lactating, or are planning to become pregnant during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patient is expected to require additional diabetic treatment for his/her Type 2 diabetes or its complications during the study after the screening visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patient has a history of drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patient who is under malnutrition, weakness or, in the opinion of the Investigator, patient who drinks on average more than 28 units of alcohol per week (One unit of alcohol equals approximately 250 mL of beer, 125 mL of wine or 40 mL of spirits)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patients taking any of the following concomitant medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Oral anti-diabetic therapy excluding Metformin within 8 weeks of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Thiazolidinedione class of drugs within 12 weeks of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "GLP-1 analogues/DPP4 inhibitor class of drugs within 12 weeks of screening(but, following patients will be excluded from the study regardless of treatment duration of previous DPP4 inhibitors: patient who has experienced failure of glucose control with treatment of DPP4 inhibitors or patient who is not expected to have additional good effect of glucose control with administration of IP according to the investigator's opinion)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Anti-obesity agent within 12 weeks of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "All kinds of insulin administered within 12 weeks of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Systemic Corticosteroids or intermittent use of high-dose of steroids(inhaler)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Any other investigational drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "Patients who have participated in a study with an investigational drug within 12 weeks of Screening or who are currently receiving treatment with any other investigational drug in a study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02512523",
    "statement": "The presence of any other condition including clinical laboratory test results that leads the investigator to conclude that the patient is inappropriate for inclusion in the clinical study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Males or females aged 18 or older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects diagnosed with type 2 diabetes mellitus according to the American Diabetes Association (ADA) criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects treated with stable doses of insulin and/or other hypoglycemic agent(s) for type 2 diabetes mellitus for at least 2 months prior to randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects whose fasting blood glucose levels are reasonably stable for at least 2 months prior to randomization and during the 2-week screening period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have Hemoglobin A1c levels of 7.5 to 10.0 % at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects whose BMI is 30 or above.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who can give written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have any DM-related end-organ damages.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have any disease likely to limit life span and/or increase risks of interventions such as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Carotid B-mode ultrasound test results indicating clinically significant stenosis in the common carotid arteries requiring intervention by angioplasty or resection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Cancer treatment in the past 5 years, with the exception of cancers which have been cured, and carry a good prognosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Infectious disease: HIV positivity, active tuberculosis, or pneumonia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have any of the following conditions related to cardiovascular disease:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Hospitalization for the treatment of heart disease in the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "New York Heart Association Functional Class > 2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Left Bundle branch block on ECG at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Third degree atrioventricular block on ECG at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Uncontrolled hypertension with average systolic blood pressure of > 160 mmHg or diastolic blood pressure > 95 mmHg at Screening and Baseline.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Pulse rate > 95 beats per minute at Screening and Baseline.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Stroke or transient ischemic attack in the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have any of the following conditions related to gastrointestinal disease:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Chronic hepatitis or cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Episode of alcoholic hepatitis or alcoholic pancreatitis in the past 2 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Inflammatory bowel disease requiring treatment in the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Significant abdominal surgery (e.g., gastrectomy, gastric bypass) in the past 2 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have serum creatinine > 1.5 mg/dL for male or > 1.4 mg/dL for female.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have chronic obstructive airway disease or asthma requiring daily therapy or home use oxygen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have hematocrit < 36.0% for male or < 33.0% for female.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have any of the following conditions or behaviors likely to affect the conduct of the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Weight loss of > 10% in the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Unable to walk without assisted device.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Major psychiatric disorder which would impede conduct of the research.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Excessive alcohol intake (i.e., more than 2 drinks/day).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who take any of the following medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Psychoactive agents such as monoamine oxidase inhibitors and antidepressants (e.g., lithium, Prozac, Zoloft, Serzone, Paxil, Effexor).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Any other medications that may pose harm to the subject.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Female subjects who have a positive serum pregnancy test at Screening, plan a pregnancy during study period, or are breast feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Female subjects who don't meet any of the following criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Surgically sterile (i.e., have had bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) at least 6 months before randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Post-menopausal for at least 12 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "If sexually active, they should use oral contraceptives, double barrier contraception (e.g., condom with spermicide), intrauterine device, or other methods approved by the Sponsor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have been diagnosed with Type 2 diabetes according to the World Health Organization (WHO) criteria treated with basal insulin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Are receiving ≥10 units of basal insulin per day and ≤110 units per day at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have HbA1c value of 6.5% - 10% inclusive, at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have a Body mass index (BMI) less than or equal to 45 kilogram/square meter (kg/m²)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have been treated with one of the following stable insulin regimens at least 90 days prior to screening:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "once daily U100 or U200 of insulin degludec",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "once daily U100 or U300 of insulin glargine",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "once or twice daily U100 of insulin detemir, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "once or twice daily human insulin NPH",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "acceptable non insulin glucose lowering therapies may include 0 to up to 3 of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "dipeptidyl peptidase (DPP-4) IV inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "SGLT2 inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "metformin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "alphaglucosidase inhibitors or,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Glucagon-Like Peptide-1 (GLP-1) receptor agonists",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Participants must be willing to stay on stable dose throughout the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have Type 1 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have acute or chronic hepatitis, cirrhosis, or obvious clinical signs or symptoms of any other liver disease, except Nonalcoholic Fatty Liver Disease (NAFLD)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Estimated glomerular filtration rate (eGFR) <20 milliliters/minute/1.73 square meter (m²)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have active or untreated malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Are pregnant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have a significant weight gain or loss the past 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have received anytime in the past 6 months, any of the following insulin therapies:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "prandial insulin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "insulin mixtures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "inhaled insulin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "U-500 insulin, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "continuous subcutaneous insulin infusion therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have had any of New York Heart Association Class IV heart failure or any of the following CV conditions in the past 3 months:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "acute myocardial infarctions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "cerebrovascular accident (stroke), or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "coronary bypass surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Gastrointestinal: have undergone gastric bypass (bariatric) surgery, restrictive bariatric surgery (Lap-Band) or sleeve gastrectomy within 1 year prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Males or females aged 18 through 65 years (Parts A-D) or 75 years (Part E) at the time of screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Parts A, B, C only: Participants with or without T2DM. If participants have a diagnosis of T2DM, the glucose control managed with diabetes diet and in addition to metformin treatment no more than two treatment options (with a stable dose 3 months prior to screening). Part D only: Participants who are diagnosed with T2DM, have inadequate glycaemic control with diet and exercise. Participants who are prescribed an oral anti-diabetic agent such as metformin, a DPP IV inhibitor, sulphonylurea, glinides, alphaglucosidase inhibitors, and an SGLT2 inhibitor may be eligible to enter the study following a washout of 4-weeks or 5-half lives (whichever is longer) washout period. Part E only: Participants are eligible to be included in the Part E only if they meet all of the following criteria at screening:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Diagnosed with T2DM.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Are treated with diet and exercise only, or any combination of OAD with stable doses in the 3 months prior to dosing.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Participants prescribed a DPP IV inhibitor or a GLP-1RA-containing medicine, alone or in combination with other OADs, may be eligible to enter the study if they have not been treated with any of these drugs for at least 35 days or 5 drug half-lives (whichever is longer) prior to randomisation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Participants with a screening HbA1c value within the target range of • ≥ 42 to ≤ 86 mmol/mol (6% to 10%).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Body mass index from ≥27 (≥25 in Part D) to ≤39.9 kg/m2 (inclusive) (Part A-D) or ≥ 27 kg/m2 (Part E).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Written informed consent and any locally required authorization (eg, European Union Data Privacy Directive) obtained from the participant prior to performing any protocol-related procedures, including screening evaluations",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Ability to complete and meet all eligibility requirements for randomisation within 60 days after signing the ICF.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Venous access suitable for multiple cannulations.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Willing and able to self-administer weekly SC injections (Parts C, D and E only).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Participants with T2DM treated with insulin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Participants with T2DM treated with more than 3 anti-diabetic therapies (Parts A-D only).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Participants with or without T2DM treated with a GLP-1RA or GLP-1RA/GIPRA within 3 months of screening (Parts A to D only) or within 35 days of randomisation or five half-lives (whichever is shorter) of dosing (Part E only).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "History of any clinically important disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Serum calcitonin suggestive of thyroid C-cell hyperplasia (calcitonin level > 50 ng/L), medullary thyroid carcinoma, or history or family history of multiple endocrine neoplasia at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "History or presence of GI, renal, or hepatic disease (with the exception of Gilbert's syndrome), or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs, as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "History of cancer within the last 10 years, with the exception of non-melanoma skin cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Any clinically important illness (apart from T2DM), as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Any medical/surgical procedure, or trauma within 4 weeks prior to screening, at the discretion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Symptoms of insulinopenia or poor blood glucose control (eg, significant thirst, nocturia, polyuria, polydipsia, or weight loss).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Positive hepatitis B or hepatitis C virus serology at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Positive human immunodeficiency virus test at screening or participant taking antiretroviral medications as determined by medical history or participant's verbal report.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "At screening blood tests, any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "AST ≥ 1.5 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "ALT ≥ 1.5 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "TBL ≥ 1.5 × ULN (with the exception of Gilbert's syndrome)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Haemoglobin below the lower limit of the normal range or any other clinically significant haematological abnormality as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Total serum calcium, albumin-corrected calcium or ionised calcium < LLN at screening (Part E).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Impaired renal function defined as estimated glomerular filtration rate (eGFR) ≤ 60 mL/minute/1.73m2 as defined by Chronic Kidney Disease Epidemiology Collaboration (2021) (Part A to D); or ≤ 45 mL/minute/1.73 m2 (Part E).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Any clinically important abnormalities in clinical chemistry, haematology, coagulation, or urinalysis results other than those specifically described as exclusion criteria herein, as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Significant late diabetic complications (macroangiopathy with symptoms of congestive heart disease or peripheral arterial disease, microangiopathy with symptoms of neuropathy, gastroparesis, retinopathy requiring treatment, nephropathy) detected in laboratory results or in clinical history/documentation as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Abnormal vital signs, after 10 minutes of supine rest, defined as any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Systolic BP < 90 mmHg or ≥ 150 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Diastolic BP < 50 mmHg or ≥ 90 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "HR < 50 or > 85 bpm at resting state",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Participants may be re-tested for the vital signs criteria only once if, in the investigator's judgement, they are not representative of the participant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG and any abnormalities in the 12-lead ECG that, as considered by the investigator, may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology or left ventricular hypertrophy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Participants with implantable cardiac defibrillator or a permanent pacemaker, and participants with symptomatic tachy- or brady-arrhythmias.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Participants with unstable angina pectoris or stable angina pectoris classified higher than Canadian Cardiovascular Society class II or an acute coronary syndrome/acute myocardial infarction or coronary intervention with percutaneous coronary intervention or coronary artery bypass grafting or stroke within 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "In Parts A-D: History of hospitalisation caused by heart failure or a diagnosis of heart failure. In Part E, severe congestive heart failure (New York Heart Association Class III or IV) or recent (< 6 months) hospitalisation due to heart failure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Known or suspected history of drug abuse within the past 3 years as judged by the investigator (Parts A-E) and or a positive screen for drugs of abuse at screening (Parts A-D only).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Whole blood or red blood cell donation, or any blood loss > 500 mL (or > 400 mL in Part D) during the 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "History of psychosis or bipolar disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "History of major depressive disorder within the 2 years prior to screening or depression, where the participant is deemed to be clinically unstable as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Previous hospitalisation for any psychiatric reason.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "PHQ-9 score ≥ 15 within the 2 years prior to screening or at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Received another new chemical entity (defined as a compound that has not been approved for marketing), or has participated in any other clinical study that included drug treatment within at least 30 days or 5 half-lives prior to the first administration of study intervention in this study (whichever is longer). The period of exclusion to begin 30 days or 5 halflives of IMP after the final dose, or after the last visit, whichever is longest. Participants consented and screened, but not randomised into this study or a previous Phase 1 study, are not excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "History of lactic acidosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Use of any of the following medicinal products:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Use of systemic corticosteroids within 28 days prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Use of compounds known to prolong the QTc interval.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Use of any herbal preparations or medicinal products licensed for control of body weight or appetite within 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Received another new chemical entity (defined as a compound that has not been approved for marketing), or has participated in any other clinical study that included drug treatment within at least 30 days or 5 half-lives prior to the first administration of study intervention in this study (whichever is longer). The period of exclusion to begin 30 days or 5 half-lives of IMP after the final dose, or after the last visit, whichever is longest. Participants consented and screened, but not randomised into this study or previous AZD9550, AZD6234, or AZD9550/AZD6234 combination studies, are not excluded from Part E.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Previous enrolment or randomisation in the present study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Concurrent participation in another study of any kind is prohibited.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Ongoing weight loss diet (hypocaloric diet) or use of weight loss agents, unless the diet or treatment has been stopped at least 3 months prior to screening and the participant has had a stable body weight (± 5%) during the 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Participants who are vegans, ones with medical dietary restrictions, or participants who are willingly conducting any diet likely to increase ketone levels (Atkins or any similar diet based on increased protein consummation or low carbohydrate content) (Part A-D only).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Excessive intake of caffeine-containing drinks or food (eg, coffee, tea, Coca-Cola/Pepsi or similar drink type, chocolate) as judged by the investigator (Part A-D only).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the previous 3 months prior to screening (Part A-D only).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Participants who cannot communicate reliably with the investigator or vulnerable participants (eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "The participant is an employee, or close relative of an employee, of AstraZeneca, the CRO, or the study site, regardless of the employee's role.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Contra-indication to MRI: such as participants with pacemakers, metallic cardiac valves, magnetic material such as surgical clips, implanted electronic infusion pumps or other conditions that would preclude proximity to a strong magnetic field; participants with history of extreme claustrophobia or participant cannot fit inside the MRI scanner cavity (Parts B and C only).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "Serum triglyceride concentrations > 500 mg/dL (5.6 mmol/L) at screening or any other metabolic condition judged by the investigator as likely to precipitate acute pancreatitis (Part E only).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06151964",
    "statement": "History of use of marijuana or THC-containing products within 3 months prior to screening or unwillingness to abstain from marijuana or THC-containing products use during the study (Part E only).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "Male or female.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "Age above or equal to 18 years at the time of signing informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "Diagnosed with T2D (type 2 diabetes) greater than or equal to 180 days prior to the day of screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "HbA1c (glycated haemoglobin) below or equal to 9.0 percent (below or equal to 75 mmol/mol).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "Depending on biopsy/non-biopsy population:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "For subjects in the non-biopsy population: Serum creatinine-based eGFR greater than or equal to 30 and below or equal to 75 mL/min/1.73 m^2(CKD-EPI).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "For subjects in the biopsy sub-population: Serum creatinine-based eGFR greater than or equal to 40 and below or equal to 75 mL/min/1.73 m^2(CKD-EPI).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "UACR ( Urinary albumin-to-creatinine ratio ) greater than or equal to 20 and below 5000 mg/g.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "Treatment with maximum labelled or tolerated dose of a renin-angiotensin-aldosterone system (RAAS) blocking agent including an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB)) unless such treatment is contraindicated or not tolerated.Treatment dose must be stable for at least 28 days prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "Use of any glucagon-like peptide 1 receptor agonist (GLP-1 RA) within 30 days prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "A prior solid organ transplant or awaiting solid organ transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 180 days prior to the day of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "Presence or history of malignant neoplasms (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) within 5 years prior to the day of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "Congenital or hereditary kidney diseases including polycystic kidney disease, autoimmune kidney diseases including glomerulonephritis or congenital urinary tract malformations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and Visit 2. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "Treatment with systemic anti-inflammatory or immunosuppressant drugs within 90 days prior to screening. Stable treatment with acetylsalicylic acid for prevention of cardiovascular events and occasional use of propionic acid derivatives drugs (e.g. ibuprofen) is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "Any contraindication for MRI according to standard checklist used in clinical routine, including claustrophobia or metallic foreign bodies, metallic implants, internal electrical devices, or permanent makeup/tattoos that cannot be declared MR compatible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04865770",
    "statement": "Combination use of an ACE (angiotensin-converting enzyme) inhibitor and an ARB (angiotensin II receptor blockers).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Has Type 2 diabetes on insulin therapy for ≥ 6 months and on their current regimen for ≥3 months prior to study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Their insulin management must be one of the following;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "an injection regimen of prandial insulin at least once daily,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "or, prandial insulin at least once daily plus basal insulin at least once daily,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "or, continuous subcutaneous insulin infusion (CSII) with no plans to change during the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "HbA1c result ≥7.5% (58 mmol/mol) and ≤12.0% (108 mmol/mol) on entry to the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Reports self-testing of blood glucose levels on a regular basis equivalent to a minimum of 10 tests per week, for at least 2 months prior to study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "In the investigator's opinion the subject is considered technically capable of using the Abbott Sensor Based Glucose Monitoring System.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "In the Investigator's opinion the subject is proactive and therefore willing to modify their diabetes management",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Aged 18 years or over.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Insulin regimen consists entirely of basal or includes bi-phasic insulin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Subject is currently prescribed animal insulin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Subject is currently prescribed steroid therapy or is likely to require steroid therapy for any acute or chronic condition during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Has known allergy to medical grade adhesives.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Currently participating in another device or drug study that could affect glucose measurements or glucose management.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Currently using a Continuous Glucose Monitoring (CGM) device or has used one within the previous 4 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Is planning to use a CGM device at any time during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Total daily dose of insulin (TDD) is >1.75iu/kg at entry to the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "A female subject who is pregnant or planning to become pregnant within the study duration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Currently receiving dialysis treatment or planning to receive dialysis during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Has experienced an acute myocardial infarction within previous 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Has a concomitant disease or condition that may compromise patient safety, including unstable coronary heart disease, cystic fibrosis, serious psychiatric disorder, or any other uncontrolled medical condition.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Has a pacemaker or any other neuro stimulators.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Has experienced any episode of severe hypoglycaemia, requiring third party assistance and/or admission to hospital, in the previous 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "Has experienced any episode of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS) in the previous 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082184",
    "statement": "In the investigator's opinion, the subject is considered as unsuitable for inclusion in the study for any other reason.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Have been diagnosed with type 2 diabetes mellitus (T2DM)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Are at least 18 years of age or legal age of consent in the jurisdiction in which the study is taking place, whichever is older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Have HbA1c at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "≥7.0% and ≤10.5% if background diabetes medication does not include a sulfonylurea, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "≥7.5% and ≤10.5% if background diabetes medication includes a sulfonylurea.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Are on stable treatment of at least 1 and no more than 3 oral antihyperglycemic drugs for at least 90 days before screening. Antihyperglycemic drugs may include metformin, SGLT-2 inhibitors, and/or sulfonylureas",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Have increased risk for cardiovascular (CV) events due to:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Coronary heart disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Peripheral arterial disease, presumed to be of atherosclerotic origin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Cerebrovascular disease, presumed to be of atherosclerotic origin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Chronic kidney disease (CKD)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Congestive heart failure (CHF) New York Heart Association (NYHA) functional classification II to III",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Are of stable weight (± 5%) for at least 90 days prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Have a BMI ≥25 kilograms per meter squared (kg/m2) at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Have type 1 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Have had chronic or acute pancreatitis any time prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema (e.g. laster photocoagulation or intravitreal injections of anty-VEGF inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Have a known clinically significant gastric emptying abnormality",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood alanine transaminase (ALT) or aspartate aminotransferase (AST) enzyme level ≥5.0 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Have had any of the following within 60 days prior to screening: acute myocardial infarction, cerebrovascular accident (stroke), or hospitalization for congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Have an eGFR <15 mL/min/1.73 m2 as determined at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Have been taking any other diabetes medicines other than metformin, SGLT-2 inhibitors, and/or sulfonylureas during the last 90 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05803421",
    "statement": "Have used any weight loss drugs, including herbal or nutritional supplements, within 90 days of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Be able to give written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Have type 2 diabetes treated with diet and exercise alone or in combination with metformin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "If treated with metformin, must have been on a stable dose of the drug for a minimum of 3 months with a stable A1c value",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "If treated with diet and exercise alone, must have A1c value ≥6.5%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "If treated with diet and exercise + metformin, must have a stable A1c between 7.0% and 8.5% for at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "BMI >25 but <45",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "If female, must meet all the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Not pregnant or breastfeeding",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "If of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice and be willing to continue to practice appropriate birth control during the entire duration of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Must be able to communicate with the investigator, and understand and comply with protocol requirements",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects who have received an antibiotic, antifungal, antiparasitic, or antiviral treatment within 30 days prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects who plan to use antibiotic, antifungal, antiparasitic, or antiviral treatment during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects using a proton pump inhibitor must be on a consistent dose that will be maintained throughout the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Present use of probiotics/nutritional supplements. (Note: The use of replacement doses of Vitamin D, calcium supplements, and a single daily multi-vitamin tablet is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects who have participated in a structured weight-loss program within the past 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects who have changed body weight ≥3% within the past month",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Excess alcohol consumption; with an alcoholic drink defined as 284 ml of beer, lager, stout , 100 ml of wine or 35.5 ml spirits",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Women: More than 11 standard drinks/week",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Men: More than 17 standard drinks/week",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects who have received an experimental drug within 30 days prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Hospitalization for any reason within the 3 months prior to study entry (Same day surgery centre visits/procedures allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Active GI disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "History of any surgery on the gastrointestinal tract except appendectomy and cholecystectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Cystic fibrosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Significant renal Impairment defined as estimated Glomerular Filtration Rate <45 ml/min",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects receiving systemic corticosteroid therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects receiving Immunosuppression therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects with any condition that the investigator deems as a sound reason for disqualification from enrollment into the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Participants aged 18 to 74 years (inclusive) at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Provision of signed and dated written informed consent (with the exception of consent for genetic and non-genetic research) prior to any study specific procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Body mass index (BMI) between 27 and 35 kg/m^2 (inclusive) at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Hemoglobin A1c (HbA1c) range of 6.5% to 8.5% (inclusive) at screening (Note: Participants may be re-tested for the HbA1c entry criterion only once.).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Willing and able to self-inject study drug for the duration of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Diagnosed with type 2 diabetes mellitus with glucose control managed with metformin monotherapy where no significant dose change (increase or decrease >= 500 mg/day) has occurred in the three months prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Female participants must have a negative pregnancy test at screening and randomization, and must not be lactating.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Female participants of childbearing potential who are sexually active with a male partner must be using at least one highly effective method of contraception from screening and up to 4 weeks after the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "History of, or any existing condition that, in the opinion of the investigator, would interfere with evaluation of the study drug, put the participant at risk, influence the participant's ability to participate or affect the interpretation of the results of the study and/or any participant unable or unwilling to follow study procedures during the run-in period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Any participant who has received another study drug as part of a clinical study or a glucagon-like peptide-1 (GLP-1) analogue containing preparation within the last 30 days or 5 half-lives of the drug (whichever is longer) at the time of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Concurrent participation in another study of any kind and repeat randomization in this study is prohibited.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Any participant who has received any of the following medications prior to the start of the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Herbal preparations or drugs licensed for control of body weight or appetite",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Opiates, domperidone, metoclopramide, or other drugs known to alter gastric emptying",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Antimicrobials within the quinolone, macrolide or azole class",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Any change in antihypertensive medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Aspirin (acetylsalicylic acid)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Paracetamol (acetaminophen) or paracetamol-containing preparations",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Ascorbic acid (vitamin C) supplements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Severe allergy/hypersensitivity to any of the proposed study treatments, standardized meals, or excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight loss), a history of type 1 diabetes mellitus or diabetic ketoacidosis, or if the participant has been treated with daily SC insulin within 90 days prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Acute pancreatitis, pancreatic amylase, and/or pancreatic lipase > 3 × upper limit of normal range (ULN); history of chronic pancreatitis; or serum triglyceride levels > 11 mmol/L (1000 mg/dL) at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Significant inflammatory bowel disease, gastroparesis or other severe disease or surgery affecting the upper gastrointestinal tract (including weight-reducing surgery and procedures), which may affect gastric emptying or could affect the interpretation of safety and tolerability data.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Significant hepatic disease (except for nonalcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Aspartate transaminase (AST) >= 3 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Alanine transaminase (ALT) >= 3 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Total bilirubin (TBL) >= 2 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Impaired renal function defined as estimated glomerular filtration rate (GFR) < 60 mL/minute/1.73m^2 at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Poorly controlled hypertension defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Systolic blood pressure (BP) > 160 mm Hg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Diastolic BP or >= 90 mm Hg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead ECG or any abnormalities that may interfere with the interpretation of serial ECG changes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Prolonged QT intervals corrected for heart rate or family history of long QT-segment at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "PR (PQ) interval prolongation, intermittent second or third-degree atrioventricular (AV) block, or AV dissociation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Persistent or intermittent complete bundle branch block.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Unstable angina pectoris, myocardial infarction, transient ischemic attack, or stroke within 3 months prior to screening, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Severe congestive heart failure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Basal calcitonin level > 50 ng/L at screening or history/family history of medullary thyroid carcinoma or multiple endocrine neoplasia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Hemoglobinopathy, hemolytic anemia or chronic anemia or any other condition known to interfere with the interpretation of HbA1c measurement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell, squamous cell skin cancer, or in situ cervical cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Any positive results for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "History of substance dependence, alcohol abuse, or excessive alcohol intake. Participants who use benzodiazepines for chronic anxiety or sleep disorders may be permitted to enter the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Symptoms of depression or any other psychiatric disorder requiring treatment with medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "History of severe allergy/hypersensitivity, including to any component of the investigational product formulation or other biological agent, or ongoing clinically important allergy/hypersensitivity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03745937",
    "statement": "Blood/plasma donation within 1 month of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "3.1.\nBe of non-childbearing potential:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "For inclusion in the study subjects should fulfill the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Provision of signed and dated, written informed consent prior to any study specific procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Healthy male and/or female subjects aged 18 to 55 years with suitable veins for cannulation or repeated venipuncture.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Female subject must either:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) at Screening and negative urine pregnancy test within 24 hours prior to first IMP administration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation. 3.2. Or, if of childbearing potential:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) at Screening and within 24 hours prior to first IMP administration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Must not be nursing (breastfeeding).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "If heterosexually active, agree to consistently use a highly effective method of contraception to avoid pregnancy, from at least 4 weeks prior to dosing and throughout the study and for up to 90 days after the last dose of IMP. 4. Sexually active fertile male subjects must use effective birth control for the entire study and 90 days after the last dose of IMP if their partners are women of childbearing potential. 5. Have a body mass index (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Subjects will not enter the study if any of the following exclusion criteria are fulfilled:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "History of any clinically significant disease or disorder which, in the opinion of the PI, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Current or recent (within 3 months of first IMP dosing) gastrointestinal disease that may impact drug absorption and affect the PK of the study drugs. Additionally, any gastrointestinal surgery (e.g., partial gastrectomy, pyloroplasty) including cholecystectomy that may impact drug absorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Any major surgery, as determined by the investigator, within 4 weeks of first IMP dosing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Donation of > 400 mL of blood within 8 weeks or donation of plasma (except at the Screening Visit) within 4 weeks of first IMP dosing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Blood transfusion within 4 weeks of first IMP dosing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Inability to tolerate oral medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Inability to tolerate venipuncture or inadequate venous access as determined by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Recent (within 6 months of first IMP dosing) drug or alcohol abuse as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), Diagnostic Criteria for Drug and Alcohol Abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Subjects who drink more than 3 cups of coffee or other caffeinecontaining products a day, or 5 cups of tea a day.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Use of tobacco-containing or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to first check-in (Day -1, Treatment Period 1), or a positive nicotine test (i.e., cotinine) at Screening and/or check-in.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "History of diabetes mellitus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "History of heart failure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "History of chronic or recurrent urinary tract infection (defined as 3 occurrences per year)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Recent vulvovaginal mycotic infection (within 2 months prior to first IMP dosing).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Any other sound medical, psychiatric and/or social reason as determined by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest. Note: subjects consented and screened, but not randomized in this study or a previous Phase1 study, are not excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to saxagliptin, dapagliflozin and metformin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Positive screen for drugs of abuse or cotinine at Screening or on first admission to the study center or positive screen for alcohol on first admission to the study center",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Use of saxagliptin, dapagliflozin and/or metformin within 3 months prior to the first administration of IMP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Use of any prescription drugs or OTC acid controllers within 4 weeks prior to the first administration of IMP except medication cleared by the medical monitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Use of any prescribed or non-prescribed medication including analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life. Note: Hormonal replacement therapy is not allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03138356",
    "statement": "Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "iv. Vasectomy with one of the following: diaphragm with spermicide; cervical cap; contraceptive sponge; condom; IUD; or hormonal contraception (see above).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "†Abstinence can be used as the sole method of contraception if it is in line with the subject's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees.\nPeriodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Male and female subjects aged 18 and older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Body mass index (BMI) of 19-30 kg/m2 at Screening and stable weight, with no more than 5 kg gain or loss in the 3 months prior to Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "T1D subjects must have:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "A documented history of type 1 diabetes for at least 6 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Should be on an MDI regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "C peptide levels of ˂ 0.7 ng/mL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "HbA1C ≥ 6.5% to ≤10%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Females of childbearing potential must have a negative serum pregnancy test result at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Females who are not of childbearing potential are defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "post-menopausal (defined as at least 12 months with no menses in women ≥45 years of age) or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "has had a hysterectomy and/or bilateral oophorectomy, or had bilateral tubal ligation or occlusion at least 6 weeks prior to Screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Subjects who are of childbearing potential must: a. agree to remain abstinent from heterosexual activity† or agree to use (or have their partner use) acceptable contraception to prevent pregnancy within the projected duration of the trial and for 14 days after the last dose of blinded investigational product. Two methods of contraception will be used to avoid pregnancy. Acceptable combinations of methods include: i. Use of one of the following double-barrier methods: diaphragm with spermicide and a condom; cervical cap and a condom; or a contraceptive sponge and condom ii. Use of hormonal contraception (any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent [including oral, subcutaneous, intrauterine and intramuscular agents, and cutaneous patch]) with one of the following: diaphragm with spermicide; cervical cap; contraceptive sponge; condom; vasectomy; or IUD. iii. Use of an IUD with one of the following: condom; diaphragm with spermicide; contraceptive sponge; vasectomy; or hormonal contraception (see above).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Clinical diagnosis of type 2 diabetes;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Evidence of unawareness of hypoglycemia unawareness, a documented plasma glucose ≤50 mg/dL in the absence of symptoms of hypoglycemia at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "FPG >300 mg/dL at Screening; a single repeat test is allowable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Use of the following medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Administration of thyroid preparations or thyroxine (except in subjects on stable replacement therapy) within 6 weeks prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Administration of systemic long-acting corticosteroids within two months or prolonged use (more than one week) of other systemic corticosteroids or inhaled corticosteroids (if daily dosage is > 1,000 μg equivalent beclomethasone) within 30 days prior to Screening. Intra-articular and/or topical corticosteroids are not considered systemic.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Laboratory abnormalities at Screening including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Abnormal serum thyrotropin (TSH) levels below the lower limit of normal or >1.5X the upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Elevated liver enzymes (alanine transaminase (ALT), alanine aminotransferase (AST), alkaline phosphatase) >2X the upper limit of normal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Very high triglyceride levels (>600 mg/dL); a single repeat test is allowable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Any relevant abnormality that would interfere with the efficacy or the safety assessments during study treatment administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Subject has a Screening systolic blood pressure ≥165 mmHg or diastolic blood pressure ≥100 mmHg. Subjects will be allowed to take a BP rescue medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Any clinically significant ECG abnormality at Screening or cardiovascular disease. Clinically significant cardiovascular disease will include: a. History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to Screening,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "History of or currently have New York Heart Associate Class II-IV heart failure prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Presence of any clinically significant endocrine disease according to the Investigator (euthyroid subjects on replacement therapy will be included if the dosage of thyroxine is stable for at least six weeks prior to Screening).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Presence of any clinically significant condition (in the opinion of the Investigator) that might interfere with the evaluation of study medication, such as significant renal, hepatic, gastrointestinal (GI), cardiovascular (CV), immune disease, blood dyscrasias or any disorders causing hemolysis or unstable red blood cells, or clinically important hematological disorders (i.e. aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia) at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "History of gastrointestinal disorders (e.g. hypochlorhydria) with the potential to interfere with drug absorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Presence or history of cancer within the past 5 years of Screening, with the exception of adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "A subject with a history of malignancy >5 years prior to Screening should have no evidence of residual or recurrent disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "A subject with a history of melanoma, leukemia, lymphoma, or renal carcinoma is excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Positive history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic hepatitis B or C, primary biliary cirrhosis, or active symptomatic gallbladder disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Positive history of HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Known allergy to soy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Subject is on a weight loss program and is not in the maintenance phase, or subject has started weight loss medication (e.g., orlistat or liraglutide), within 8 weeks prior to Screening. Subjects who have had bariatric surgery are also excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "S ubject is pregnant or breast-feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Subject is a user of recreational or illicit drugs or has had a recent history (within 1 year of Screening) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by >3 drinks per day or >14 drinks per week, or binge drinking) at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "At the Principal Investigator's discretion, any condition or other factor that is deemed unsuitable for subject enrollment into the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Females or males ≥40 years up to 75 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Individuals with type 2 diabetes diagnosed for at least 6 months based on the American Diabetes Association standards (ADA, 2017) and on stable dose of metformin for at least 6 weeks prior to screening and HbA1c at screening visit of ≥42 mmol/mol (6.0%) and ≤75 mmol/mol (9.0%) measured at local hospital laboratory.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "No significant signs or symptoms of coronary artery disease or, if known coronary artery disease, currently free of symptoms and a) all major epicardial vessels with <50% stenosis within 12 months prior to screening, or b) if revascularized with all major epicardial vessels with <50% remaining stenosis after stenting or bypass surgery procedure determined between 3 and 12 months prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Normal left ventricular ejection fraction (≥50%) assessed within 1 year prior to informed consent, and if applicable, after most recent acute episode of coronary artery syndrome, or at screening visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Body mass index (BMI) ≥ 25 kg/m2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Blood pressure at screening that would require a change in blood pressure treatment over the study period or any of the following: systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "History of stroke or other clinically significant cerebrovascular disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Any of the following cardiovascular diseases known within 3 months prior to signing the consent at enrolment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Atrial fibrillation, or other unstable or severe arrhythmia affecting heart function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Unstable heart failure or any heart failure with NYHA class III and IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Significant valvular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Significant peripheral artery disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Planned cardiac surgery or angioplasty within 3 months from enrolment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Clinical diagnosis of type 1 diabetes, maturity onset diabetes of the young (MODY), secondary diabetes or diabetes insipidus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Verified body weight variability of >3 kg during the 3 proceeding months before screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Active malignancy requiring treatment at the time of visit 1 (with the exception of successfully treated basal cell or treated squamous cell carcinoma).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Patients with severe hepatic impairment (Child-Pugh class C).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Unstable or rapidly progressing renal disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Ongoing treatment with other antidiabetic drugs than metformin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Ongoing treatment with loop diuretics.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Contraindications to dapagliflozin therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Ongoing treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except for T2D.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 1 month prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Estimated Glomerular Filtration Rate (eGFR) <45 mL/min/1.73 m2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study treatment intake.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Any condition when MRI and CT-PET is contraindicated such as, but not limited to, having a metallic implant (such as pacemaker or cochlear implant), permanent make up, claustrophobia or BMI ≥40 kg/m2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Involvement in the planning and/or conduct of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Plasma donation within one month of screening or any blood donation/blood loss >450 mL during the 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03387683",
    "statement": "Women who has a positive pregnancy test at enrolment or randomization, or are breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Subjects must meet all of the following criteria to be eligible for participation in the study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Age ≥ 21 and ≤ 65 years at time of enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Disease diagnosed 2.1 Diagnosed with T2DM with baseline: And / Or 2.2 Diagnosed hypertension with baseline:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Fasting plasma glucose ≥ 140 mg/dl (7.8 mmol/l) and ≤ 270 mg/dL (15 mmol/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "HbA1c levels ≥ 7.0% and ≤ 9.0% (53-75 mmol/mol)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Triglyceride level < 400 mg/dL (4.52 mmol/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "On oral anti-hyperglycemic drug regimen of metformin. Subjects may be on additional oral anti-hyperglycemic drug of a different drug class",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Years of T2DM ≤ 10 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Office blood pressure of SBP of ≥ 140 mmHg and ≤ 180 mmHg and DBP ≥ 90 mmHg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Mean 24-hour ambulatory SBP of ≥ 130 mmHg and ≤ 170 mmHg with ≥ 75% valid readings",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "On stable oral anti-hypertension drug regimen consisting of up to a maximum of three drugs",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "BMI between 27.5 and 40 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "C-peptide testing: non-fasting random or stimulated C-peptide ≥ 2 ng/mL (660 pmol/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Vessel diameter of 3 mm to 7 mm with a minimum arterial treatable length of 20 mm in one or more of the following arteries:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Renal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Hepatic",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "T1DM or poorly controlled T2DM (defined as HbA1c > 9.0% or use insulin as medication to control glucose level).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Office diastolic blood pressure < 90 mmHg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Current use of > 3 hypertension medications.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Currently on beta blockers.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "One or more documented hyperglycemia episodes requiring hospitalization in the 180-day prior to screening date.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Prior evidence of hypoglycemia unawareness or serious hypoglycemia with loss of consciousness or confusion sufficient to prevent self-treatment in last 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "BMI > 40 kg/m2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Diagnosed proliferative retinopathy or evidence of peripheral neuropathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Lack of appropriate treatment site or anatomy precluding the intervention of the target arteries (renal and hepatic artery).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History of prior renal or hepatic artery intervention including balloon angioplasty, stenting, etc.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Arterial stenosis >50% of the normal diameter segment (diameter stenosis, compared to the angiographically normal proximal or distal segment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Any abnormality or disease in one or more of the target arteries that, per the physician assessment, precludes the safe insertion of the guiding catheter (including, but not limited to, artery aneurysm, excessive tortuosity, calcification).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Occlusive peripheral vascular disease that would preclude percutaneous femoral access for the procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Known or suspected secondary hypertension, such as Cushing's disease or Cushing's Syndrome, hyperaldosteronism, pheochromocytoma, thyroid and parathyroid abnormalities, history of pre-eclampsia, onset of hypertension prior to the age of 18.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Use of nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Severe or unstable cardiovascular comorbidities, such as AMI or ACS, cardiac valve stenosis, pulmonary embolism, heart failure with NYHA Class III or IV, chronic atrial fibrillation, primary pulmonary hypertension, COPD.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Renal transplant, history of nephrectomy or single kidney, renal tumor/cancer, known non-functioning kidney, unequal renal size (>2 cm difference in renal length between kidneys associated with a chronic kidney disease or a deterioration of the kidney function), chronic renal deficiency with eGFR ≤ 60ml/min/1.73m2, or on chronic renal replacement therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Prior liver transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Any organ transplantation procedures are planned in the 365 days following Index Procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Gastrointestinal permanent anatomic alteration surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Any surgical procedure within 30 days prior to Index Procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Currently taking the following medications within 90 days prior to screening and/or there is a need or anticipated need for these medications during the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Systemic Corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Anticonvulsants",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Centrally acting sympatholytics",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Bleeding disorders, such as bleeding diathesis, thrombocytopenia, and severe anemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Use of anticoagulation therapy which cannot be discontinued from 7 days before or 14 days after the Index Procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Any other condition(s) that would compromise the safety of the Subject or compromise study quality as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Significant alcohol consumption, defined as more than 2 drink units per day (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men, or inability to reliably quantify alcohol intake.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Active substance abuse, based on Investigator judgement, including inhaled or injected drugs, within 1 year prior to the initial screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Significant weight loss within the last 6 months (e.g., > 10% total body weight loss).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Hepatic decompensation defined as the presence of any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Serum albumin less than 3.5 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History of esophageal varices, ascites, or hepatic encephalopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "ALT or AST greater than 200 U/L.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Diagnosis of liver cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Chronic liver or biliary disease of the following etiology:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of Hepatitis B",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of Hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of current active autoimmune hepatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of primary biliary cholangitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of primary sclerosing cholangitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of Wilson's disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of alpha-1-antitrypsin deficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of hemochromatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of drug-induced liver disease, as defined on the basis of typical exposure and history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Known bile duct obstruction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Suspected or proven liver cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History of acute or chronic pancreatitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Human immunodeficiency virus (HIV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Subjects with a history of adverse reaction to heparin or heparin induced thrombocytopenia (HIT).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Systemic infection that the investigator judges would pose unacceptable procedural risks to the subject.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Known hypersensitivity to contrast media, nickel and ethanol that cannot be adequately pre-medicated.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Subject is depressed or on antidepressants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Pregnancy or breastfeeding or plan to get pregnant in next 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Life expectancy of less than 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Unwilling or unable to comply with the follow-up study requirements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Subjects or their legally authorized representatives unable to provide informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Currently participation in another pre-market drug or medical device clinical study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03851432",
    "statement": "T2DM Patients with inadequate glycemic control (HbA1c level≥7.0% and ≤10.5% at baseline) on metformin monotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03851432",
    "statement": "Body Mass Index: 18.0~35.0 kg/m2 (both inclusive)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03851432",
    "statement": "History of type 1 diabetes mellitus (T1DM), diabetes caused by pancreatic injury, or secondary diabetes (e.g., diabetes caused by Cushing's syndrome or acromegaly)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03851432",
    "statement": "More than 10% change in body weight within the 3 months before screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03851432",
    "statement": "Any laboratory test indicators meet the following standards:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03851432",
    "statement": "fasting plasma glucose ≥ 15 mmol/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03851432",
    "statement": "aspartate aminotransferase, alanine aminotransferase levels > 3 times the upper limit of normal (ULN); total bilirubin > 1.5 times ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03851432",
    "statement": "hemoglobin < 100 g/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03851432",
    "statement": "eGFR < 60 mL/min/1.73m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03851432",
    "statement": "fasting triglycerides > 5.64 mmol/L (500 mg/dL)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Age ≥ 18 and < 85 years at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Signed and dated written informed consent (with the exception of consent for genetic and nongenetic research) prior to performing any protocol-related procedures, including screening evaluations.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Diagnosed with type 2 diabetes mellitus (T2DM) with glucose control managed with any insulin and/or oral therapy combination where no significant dose changes of oral therapy of more than 50% have occurred in the 3 months prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Body mass index (BMI) between 25 and 45 kg/m^2 (inclusive) at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Haemoglobin A1c (HbA1c) range of 6.5 % to 10.5% (inclusive) at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Renal impairment with estimated glomerular filtration rate (eGFR) ≥ 30 and < 60 mL/min/1.73 m^2 at screening. Approximately 16 participants (40%) are required to have a screening eGFR ≥30 and < 45 mL/min/1.73 m^2 and at least 16 participants (40%) are required to have screening eGFR ≥45 and < 60 mL/min/1.73 m^2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Females of childbearing potential must have a negative pregnancy test at screening and randomisation, and must not be lactating. Women of childbearing potential who are sexually active with a non-sterilized male partner must be using at least one highly effective method of contraception from screening and up to 4 weeks after the last dose study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "History or presence of significant medical or psychological conditions, including substance dependence/abuse, or significant abnormalities in laboratory parameters or vital signs including electrocardiogram (ECG), which in the opinion of the investigator, would compromise the participant's safety or successful participation in the study. As an example, severe anaemia (haemoglobin < 7.0 g/dL) could be exclusionary due to blood sampling required by the protocol, at the discretion of investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Concurrent participation in another interventional study of any kind and repeat randomisation in this study is prohibited.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Any participant who has received another study drug as part of a clinical study or a glucagon-like peptide-1 (GLP-1) analogue-containing preparation within the last 30 days or 5 half-lives of the drug (if known; whichever is longer) at the time of Visit 2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Any participant who has received any of the following medications within the specified timeframe prior to the start of the study (Visit 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Herbal preparations within 1 week prior to the start of dosing (Visit 4) or drugs licensed for control of body weight or appetite (eg, orlistat, bupropion-naltrexone, phentermine-topiramate, phentermine, lorcaserin) within 30 days (or 5 half-lives of the drug) prior to the start of dosing (Visit 4)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Aspirin (acetylsalicylic acid) at a dose greater than 150 mg once daily and within the last 3 days prior to the start of the run-in period (Visit 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Paracetamol (acetaminophen) or paracetamol-containing preparations at a total daily dose of greater than 3000 mg and within the last 3 days prior to the start of the run-in period (Visit 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Ascorbic acid (vitamin C) supplements at a total daily dose of greater than 1000 mg and within the last 3 days prior to the start of the run-in period (Visit 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Opiates, domperidone, metoclopramide, or other drugs known to alter gastric emptying and within 2 weeks prior to the start of dosing (Visit 4)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Severe allergy/hypersensitivity to any of the proposed study treatments or excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight loss), a history of type 1 diabetes mellitus or diabetic ketoacidosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Participants who have undergone a renal transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Participants with suspicion of acute or subacute renal function deterioration (eg, participants with large fluctuations of creatinine values documented within the 6 months prior to screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Significant inflammatory bowel disease, gastroparesis, or other severe disease or surgery affecting the upper gastrointestinal (GI) tract including weight-reducing surgery and procedures) which may affect gastric emptying or could affect the interpretation of safety and tolerability data",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "History of acute or chronic pancreatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Alanine transaminase (ALT) ≥ 3 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Total bilirubin ≥ 2 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Poorly controlled hypertension defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Systolic blood pressure (BP) > 180 mm Hg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Diastolic BP ≥ 100 mm Hg Participants who fail BP screening criteria may be considered for 24-hour ambulatory blood pressure monitoring (ABPM) at the discretion of the investigator. Participants who maintain a mean 24-hour systolic BP ≤ 180 or diastolic BP < 100 mm Hg with a preserved nocturnal dip of > 15% will be considered eligible",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Unstable angina pectoris, myocardial infarction, transient ischemic attack or stroke within 3 months prior to screening, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Severe congestive heart failure (New York Heart Association Class III or IV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Basal calcitonin level > 50 ng/L at screening or history/family history of medullary thyroid carcinoma or multiple endocrine neoplasia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Any positive results for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody, and human immunodeficiency virus (HIV) antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "Nephrotic range proteinuria defined as spot urine albumin creatinine ratio (ACR) > 250 mg/mmol at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03550378",
    "statement": "History of substance dependence, alcohol abuse, or excessive alcohol intake (defined as an average weekly intake of > 21 alcoholic drinks for men or > 10 alcoholic drinks for women) within 3 years prior to screening, and/or a positive screen for drugs of abuse or alcohol at screening or on Day -5. Participants who use tricyclic antidepressants or benzodiazepines for an established clinical indication may be permitted to enter the study based upon the judgement of the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Diagnosed with type 2 diabetes mellitus (T2DM).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Current TDD >200 but ≤600 units of non U-500R insulin (MDI or CSII) and/or U-500R by MDI with syringe and vial for ≥3 months at entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "If TDD of U-500R and other insulins are combined, then insulin other than U-500R not to exceed 25% of TDD.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "HbA1c ≥7.5% and ≤12.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Body mass index ≥25 but ≤50 kilograms per meter squared.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have a history of stable body weight.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Concomitant antihyperglycemic agent (AHA) therapy may include metformin (MET), dipeptidyl peptidase-4 inhibitors and/or pioglitazone.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Approximately 64 to 96 subjects using glucagon-like peptide-1 (GLP-1) receptor agonists or sodium-glucose cotransporter 2 (SGLT2) inhibitors will be enrolled in Study Group B.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Diagnosed with type 1 diabetes mellitus (T1DM) or other types of diabetes apart from T2DM.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have obvious clinical or radiographic signs or symptoms of liver disease (except nonalcoholic fatty liver disease), cirrhosis, acute or chronic hepatitis, or alanine aminotransferase (ALT/SGPT) and/or aspartate aminotransferase (AST/SGOT) levels ≥2.5X upper limit of normal (ULN), alkaline phosphatase ≥2X ULN or total bilirubin ≥2X ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have chronic kidney disease Stage 4 and higher or history of renal transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have history of more than 1 episode of severe hypoglycemia within the 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have received U-500R insulin by CSII in the 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Are taking chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have an irregular sleep/wake cycle.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have used any weight loss drugs in the 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have a history of bariatric surgery including Roux-en-Y gastric bypass surgery, gastric banding, and/or gastric sleeve.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have a history of an active or untreated malignancy, or in remission from a clinically significant malignancy during the last 5 years before screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Significant hearing loss and/or vision impairment deemed by the investigator to interfere with the safe use of OmniPod U-500 system.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have cardiac disease with functional status that is New York Heart Association (NYHA) Class III or IV per New York Heart Association Cardiac Disease Functional Classification or have congestive heart failure requiring pharmacologic treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Are women breastfeeding or pregnant, or intend to become pregnant during the course of the study; are men who intend to impregnate their partners; or are sexually active of procreation potential not actively practicing birth control by a method determined by the investigator to be medically acceptable. Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Male or female participants with T2DM in accordance with American Diabetes Association (ADA) guidelines",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Meet one of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Be on stable Met-IR monotherapy 1000 mg/day for ≥8 weeks with a Screening A1C ≥7.5% and ≤11.0%. OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Be on stable Met-XR monotherapy 1000 mg/day for ≥8 weeks with a Screening A1C ≥7.5% and ≤11.0%. OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Not on any anti-hyperglycemic agent (AHA) for ≥8 weeks (≥12 weeks if previously taking thiazolidinediones) with a Screening A1C ≥8.5% and ≤12.0%. OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Be on stable monotherapy with a sulfonylurea, a glinide, or an α-glucosidase inhibitor for ≥8 weeks with a Screening A1C ≥7.5% and ≤11.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "A body mass index (BMI) ≥18.0 kg/m2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Is a male or a female not of reproductive potential (defined as one who is postmenopausal or has had a hysterectomy and/or bilateral oophorectomy, or had bilateral tubal ligation or occlusion at least 6 weeks prior to Screening visit). If participant is a female of reproductive potential, must agree to remain abstinent from heterosexual activity or agrees to use (or have her partner use) acceptable contraception to prevent pregnancy while receiving blinded study drug and for 14 days after the last dose of blinded study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Has a history of type 1 diabetes mellitus or a history of ketoacidosis or has a history of secondary causes of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "A known hypersensitivity or intolerance to any DPP-4 inhibitor. A known hypersensitivity or intolerance to metformin, including participants who were previously unable to tolerate metformin at a dose >1000 mg/day or who have evidence of intolerance to the dose of metformin they are currently taking.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Has been treated with any of the following agents within 8 weeks (12 weeks for thiazolidinediones) of study participation:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Insulin of any type (except for short-term use [i.e., ≤7 days] during concomitant illness or other stress)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "DPP-4 inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Pioglitazone or rosiglitazone (thiazolidinediones)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Glucagon-like peptide-1 receptor (GLP-1R) agonists",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Sodium glucose co-transporter 2 (SGLT2) inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Bromocriptine (Cycloset™)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Colesevelam (Welchol™)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Any other AHA with the exception of protocol-approved agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Intends to initiate weight loss medication during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Has undergone bariatric surgery within 12 months of Screening visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Has started a weight loss medication or a medication associated with weight changes within the prior 12 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "A history of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, NYHA functional class III-IV heart failure, or severe peripheral vascular disease (e.g., claudication with minimal activity, a nonhealing ischemic ulcer, or disease which is likely to require surgery or angioplasty) within 3 months of study participation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "A history of malignancy ≤5 years prior to study participation (i.e., the diagnosis occurred, or any evidence of residual or recurrent disease occurred, within the past 5 years), except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer. Note: A patient with any history of melanoma, leukemia, lymphoma, or renal cell carcinoma is excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Has human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "with AIDS related complications, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "has not been on a stable anti-retroviral regimen for >6 months, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "has progressive disease, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "using agents associated with glucose intolerance such as nucleoside reverse transcriptase inhibitors (NRTIs) such as azidothymidine (AZT), didanosine (ddI), and stavudine (d4T).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Is on or likely to require treatment for ≥14 consecutive days or repeated courses of pharmacologic doses of corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Has undergone a major surgical procedure within 12 weeks prior to signing the informed consent form (ICF) or has major surgery planned during the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Currently participating, or has participated, in a study in which the participant received an investigational compound or used an investigational device within the prior 12 weeks of signing informed consent or is not willing to refrain from participating in another study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "Is pregnant or breast-feeding, has a positive urine pregnancy test, or is planning to conceive or donate eggs during the study, including 14 days following the last dose of blinded investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02791490",
    "statement": "A recent history of alcohol or drug abuse (within 3 years) or is a user of recreational or illicit drugs at the time of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Screening eGFR ≥15.0 and ≤60.0 mL/min/1.73 m2;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "A history of type 2 diabetes; diagnosis should have been made at ≥ 30 years of age (if diabetes developed at a younger age, a fasting C-peptide level must be ≥ 0.1 ng/mL to confirm type 2 diabetes);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Male or female patients at least 18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Treatment with an angiotensin converting enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB) for at least 6 weeks prior to Study Day 1. The dosage of ACE inhibitor and/or ARB must be stable for 2 weeks prior to and/or during screening (i.e., no change in dosage or medication). Patients not taking an ACE inhibitor and/or ARB, or taking an ACE inhibitor and/or ARB at levels below the goal dose set by K/DOQI guidelines must have a documented medical contraindication (e.g., hyperkalemia, hypotension), which the investigator must provide and discuss with a medical monitor prior to Study Day 1. Patients not taking an ACE inhibitor and/or ARB because of a medical contraindication must have discontinued treatment at least 8 weeks prior to Study Day 1;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Mean systolic blood pressure (SBP) ≤160 mmHg and ≥105 mmHg and mean diastolic blood pressure (DBP) ≤90 mmHg during screening; both mean SBP and mean DBP (determined as the average of three readings) must be within the described range during the screening period;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Willing to practice methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) during screening, while taking study drug and for at least 30 days after the last dose of study drug is ingested;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Serum magnesium level must be ≥1.3 mEq/L (0.65 mmol/L) during the screening period;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Willing and able to cooperate with all aspects of the protocol;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Willing to and able to give written informed consent for study participation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Type 1 diabetes mellitus (juvenile onset). If a history of diabetic ketoacidosis exists, a fasting C-peptide level must confirm type 2 diabetes;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Known non-diabetic renal disease (e.g., known polycystic kidney disease, family history of a hereditary form of kidney disease, or congenital absence of one kidney) [nephrosclerosis superimposed on diabetic kidney disease is acceptable];",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Ongoing clinical investigation with evidence (e.g., unexplained hematuria or red blood cell or white blood cell casts) suggesting non-diabetic renal disease other than nephrosclerosis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "History of a renal donation, transplant or a planned transplant from a living donor during the study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Albumin/creatinine (ACR) during screening period greater than 3500 mg/g (395.5 mg/mmol);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Hemoglobin A1c level >11.0% (97 mmol/mol) during screening period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Acute dialysis or acute kidney injury within 12 weeks prior to screening or during screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Clinical signs and/or symptoms of uremia and expected need for renal replacement therapy within 6 weeks following Study Day 1, as assessed by the investigator;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Recently active cardiovascular disease defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Unstable angina pectoris within 12 weeks before Study Day 1;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before Study Day 1;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Cerebrovascular accident, including transient ischemic attack within 12 weeks before Study Day 1;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Clinical diagnosis of severe obstructive valvular heart disease or severe obstructive hypertrophic cardiomyopathy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Atrioventricular block, 2o or 3o;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Administration of a contrast agent that may induce nephropathy within 30 days prior to Study Day 1 or planned during the study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Systemic immunosuppression for more than 2 weeks, cumulatively, within the 12 weeks prior to Study Day 1 or anticipated need for immunosuppression during the study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Total bilirubin, aspartate transaminase (AST), or alanine transaminase (ALT) level greater than the upper limit of normal (ULN) or alkaline phosphatase level >2x ULN on ANY screening laboratory test result;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Female patients who are pregnant, intend to become pregnant during the study, or are nursing;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "BMI < 18.5 kg/m2;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Known hypersensitivity to any component of the study drug;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Current history of drug or alcohol abuse, as assessed by the investigator;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Clinically significant infection requiring intravenous administration of antibiotics or hospitalization within 6 weeks prior to or during the screening period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Hepatitis B surface antigen positive;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Diagnosis or treatment of a malignancy in the past 5 years, excluding non-melanoma skin cancer and carcinoma in situ of the cervix, or a condition highly likely to transform into a malignancy during the course of the study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "A clinical condition that, in the judgment of the investigator, could potentially pose a health risk to the patient while involved in the study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Participation in a clinical study involving any intervention within 30 days prior to Study Day 1, concurrent participation in such a study, or participation in a prior clinical study involving bardoxolone methyl in any form;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Unable to understand verbal or written information in English;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Mental incapacity to consent;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01551446",
    "statement": "Contraindications to MRI (implants, pace makers, claustrophobia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Patients must have ESRD and been on PD for longer than 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Patients must have had a diagnosis of T2DM prior to starting dialysis",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Patients must have RRF, as defined by the mean of urea and creatinine clearance on a 24 hour urine collection, ≥ 25 Liters/week/1.73 m2 documented in the four months prior to the Screen A visit",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Patients must have RRF, as defined by the mean of urea and creatinine clearances on a 24 hour urine collection, ≥ 25 Liters/week/1.73 m2 at both the Screen A and Screen B visits",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "The RRF value obtained at the Screen B visit, must not be less than 50% of the RRF value obtained at the Screen A visit",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Patients must be at least 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Patients must have a mean systolic blood pressure (SBP) on three readings at both Screen A and Screen B visits ≤ 160 mmHg and ≥ 90 mmHg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Patients must have a mean diastolic blood pressure (DBP) on three readings at both Screen A and Screen B visits < 100 mmHg and ≥ 40 mmHg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Patients must be willing to practice methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) during screening, while taking study drug and for at least 30 days after the last dose of study drug is ingested",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Patients must be willing and able to cooperate with all aspects of the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Patients must be willing and able to give written informed consent to participate in the study. They must provide consent for access to medical data according to appropriate local data protection legislation and allow authorization to access medical records that describe events captured in the endpoints",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of Autosomal Dominant Polycystic Kidney Disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Currently Active Systemic Lupus Erythematosus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of Hepatitis B Surface Antigen +",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of Hepatitis C Antibody + being treated with antiviral therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of an organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "A planned renal transplant from a living donor during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of hospitalization for congestive heart failure or pulmonary edema within 12 weeks before study randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of cirrhosis of the liver",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of amyloidosis or light chain nephropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of hemoglobin A1c level > 11.0% (97 mmol/mol) within 12 weeks before study randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of recently active cardiovascular disease defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Unstable angina pectoris within 12 weeks before study randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before study randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Cerebrovascular accident, including transient ischemic attack within 12 weeks before study randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of a diagnostic or interventional procedure that required intravenous administration of an iodinated contrast agent or gadolinium within 12 weeks before study randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of known severe obstructive valvular heart disease or severe obstructive hypertrophic cardiomyopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of known 2o or 3o atrioventricular block not successfully treated with a pacemaker",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History or resuscitated sudden cardiac death",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of an automatic implantable defibrillator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "QTc greater than 0.50 seconds on an ECG obtained during either Screen A or Screen B visits",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "A serum magnesium level less than 1.4 meq/L on either Screen A or Screen B visit laboratory test results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of systemic immunosuppression for more than 15 days, cumulatively, within the 12 weeks prior to study randomization or anticipated need for more than 15 days of immunosuppression during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Total bilirubin, aspartate transaminase (AST), or alanine transaminase (ALT) level greater than the upper limit of normal (ULN) or alkaline phosphatase level greater than two times the ULN on either the Screen A and Screen B visit laboratory test results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Known hypersensitivity to any component of the study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Current history of drug or alcohol abuse, as assessed by the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of clinically significant infection requiring intravenous administration of antibiotics or hospitalization within 12 weeks before study randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "In patients who have been on peritoneal dialysis for ≥ 6 months, two or more episodes of peritonitis in the 6 months before study randomization. In patients who have been on peritoneal dialysis for <6 months, one episode of peritonitis before study randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of a diagnosis or treatment of a malignancy in the past 5 years, excluding non-melanoma skin cancer and carcinoma in situ of the cervix",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "History of a clinical condition that, in the judgment of the investigator, could potentially pose a health risk to the patient while involved in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Patient is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Participation in a clinical study involving any intervention within 30 days prior to Screen A visit, concurrent participation in such a study, or participation in a prior clinical study involving bardoxolone methyl in any form",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01576887",
    "statement": "Female patients who are pregnant, intend to become pregnant during this study, or are nursing",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have had type 2 diabetes mellitus for at least 1 year",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have been receiving basal insulin (neutral protamine Hagedorn [NPH], detemir, or glargine) and a stable dose of 0 to 3 oral antihyperglycemic medications (OAMs) used as specified in the local prescribing information for at least 90 days prior to screening. At least 1 of the OAMs must be dosed at, or above, half the maximum daily dose allowed by local regulations or at the maximally tolerated dose",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have a hemoglobin A1c (HbA1c) less than or equal to 9.0% at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have a body mass index (BMI) less than or equal to 45.0 kilograms per square meter (kg/m^2)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Women of childbearing potential who are not breastfeeding, have a negative pregnancy test at screening and randomization, do not plan to become pregnant during the study, and have practiced reliable birth control for at least 6 weeks prior to screening and will continue to do so during the study and until 2 weeks after the last dose of study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have routinely used insulin glargine twice daily in the 90 days prior to the study or have used routine, mealtime insulin therapy (outside of pregnancy) anytime in the past 6 months, except for short-term treatment up to a maximum of 4 continuous weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have used rosiglitazone, pramlintide, glucagon-like peptide 1 (GLP-1) receptor agonist concurrently or within 90 days prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "For participants on OAMs: have any restrictions for cardiac, renal, and hepatic diseases in the local product regulations",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Are taking, or have taken within the 90 days preceding screening, prescription or over-the-counter medications to promote weight loss",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have had any episodes of severe hypoglycemia within 6 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have had 1 or more episodes of diabetic ketoacidosis or hyperosmolar state/coma in the 6 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have cardiac disease with functional status that is New York Heart Association Class III or IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have a history of renal transplantation, or are currently receiving renal dialysis or have serum creatinine greater than or equal to 2 milligrams per deciliter (mg/dL) (177 micromoles per liter [µmol/L])",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have obvious clinical signs or symptoms of liver disease (excluding non-alcoholic fatty liver disease [NAFLD]), acute or chronic hepatitis, non-alcoholic steatohepatitis (NASH), or elevated liver enzyme measurements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the measurement of HbA1c",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have active or untreated cancer, have been in remission from clinically significant cancer(other than basal cell or squamous cell skin cancer) for less than 5 years, or are at increased risk for developing cancer or a recurrence of cancer in the opinion of the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Are receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy (excluding topical, intranasal, intraocular, and inhaled preparations) or have received such therapy within the 8 weeks immediately preceding screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have fasting triglycerides greater than 400 mg/dL (4.5 millimoles per liter [mmol/L]) at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Have an irregular sleep/wake cycle (for example, participants who sleep during the day and work during the night) in the investigator's opinion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "Lipid-lowering medication: Are using or have used any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "niacin preparations as a lipid-lowering medication and/or bile acid sequestrants within 90 days prior to screening or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01582451",
    "statement": "lipid-lowering medication at a dose that has not been stable for at least 90 days prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Age ≥22 and ≤70 years old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Type 2 diabetes diagnosis meeting the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "HbA1c > 7.0% and ≤ 9.0% (53 mmol/mol - 75 mmol/mol), AND",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "On at least two anti-diabetic medications; one at the highest tolerated dose with no changes in medication dose in the 12 weeks prior to the first screening visit",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Waist circumference ≥102 cm (male) and ≥88cm (female)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Diagnosis of hypertension: SBP ≥140mmHg OR SBP ≥130mmHg on hypertension medication(s)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Documented status of stable lifestyle modifications",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Women of childbearing potential (WOCBP) must be using at least one acceptable method of contraception throughout the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "BMI >40 kg/m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Diagnosis of type 1 diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Use of insulin within 90 days of consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Two or more self-reported or documented severe hypoglycemia events (severe hypoglycemia event defined as: hypoglycemia associated with severe cognitive impairment requiring external assistance for recovery) in the 180 days prior to Index Procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "One or more documented hyperglycemia episodes requiring hospitalization in the 180-days prior to Index Procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "During medication run in period, uncontrolled hyperglycemia noted by a fasting glucose value of >270mg/dL or >360mg/dL at any point that is then confirmed by a second measurement (not on the same day)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "A history of bariatric surgery, renal denervation, baroreflex activation therapy, or liver transplant, or these procedures are planned in the 365 days following Index Procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Any surgical procedure within 30 days prior to Index Procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History of or current symptomatic gallstones (e.g., cholecystitis, bile duct dilatation) without a cholecystectomy being performed (Note: subjects who have had a cholecystectomy are not excluded)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Previous hepatobiliary surgery/intervention that in the opinion of the investigator could preclude the ability to perform denervation of the common hepatic artery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Currently taking the following medications within 90 days prior to screening and/or there is a need or anticipated need for these medications during the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Systemic corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Anticonvulsants",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Centrally acting sympatholytics",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Use of anticoagulation therapy which cannot be discontinued from 7 days before to 14 days after the Index Procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Any other condition(s) that would compromise the safety of the Subject or compromise study quality as judged by the Investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "eGFR <45 mL/min/1.73 m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of proliferative retinopathy or advanced autonomic neuropathy (e.g., orthostatic hypotension attributable to autonomic neuropathy, a diagnosis of gastroparesis, or a clinical history strongly suggestive of delayed gastric emptying)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Myocardial infarction, unstable angina within 1 year prior to consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Widespread atherosclerosis with documented intravascular thrombosis or unstable plaques",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Documented history or concurrent signs of significant thyroid disease NOTE: If a subject is on chronic thyroid drug treatment, and has a serum TSH test result in normal range at Screening they may enter study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count <100,000/microliter, or documented coagulopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Significant alcohol consumption, defined as more than 2 drink units per day (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men, or inability to reliably quantify alcohol intake",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Active substance abuse, based on Investigator judgment, including inhaled or injected drugs, within 1 year prior to the initial screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Significant weight loss within the last 6 months (e.g., >10% total body weight loss)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Hepatic decompensation defined as the presence of any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Serum albumin less than 3.5 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "International normalized ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History of esophageal varices, ascites, or hepatic encephalopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "ALT or AST greater than 200 U/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Diagnosis of liver cirrhosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Chronic liver or biliary disease of the following etiology:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of Hepatitis B",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of Hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of current active autoimmune hepatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of primary biliary cholangitis (PBC)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of primary sclerosing cholangitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of Wilson's disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of alpha-1-antitrypsin deficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of hemochromatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or evidence of drug-induced liver disease, as defined on the basis of typical exposure and history",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Known bile duct obstruction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Suspected or proven liver cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History of acute or chronic pancreatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Subjects unable to undergo CT for any reason",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Currently enrolled in any other investigational trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History of an acute neurologic event including epilepsy, seizures, stroke, and transient ischemic attack.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Iliac/femoral artery stenosis precluding insertion of the catheter",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Subjects with a history of adverse reaction to heparin or heparin induced thrombocytopenia (HIT)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Subjects with conditions that can affect RBC turnover, those who have received a blood transfusion in the past 90 days, or expect to have an elective procedure during the course of the study that may require blood transfusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Not a candidate for surgery or general anesthesia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Unwilling to comply with study requirements, including medication run-in, SMBG, patient diary and follow-up visits",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Subjects with implantable pacemakers, implantable cardiac defibrillators or implantable neurostimulators Anatomic Exclusions from CT Angiogram",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Replaced or accessory LHA or RHA determined on CT angiogram.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Vessel tortuosity or variant vascular anatomy that could preclude the access or maneuvering of the device from the femoral artery to the target location",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Evidence of CHA and/or portal vein intraluminal thrombus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "CHA vessel diameter <4.0mm or >7.0mm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "CHA diameter stenosis >30%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "CHA vessel length <20mm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "The participant was given the diagnosis of grade I or II essential hypertension and was judged by the principal investigator or investigator that they can be appropriately treated with azilsartan 20 mg and telmisartan 40 mg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Sitting systolic blood pressure of ≥ 130 mmHg and < 180 mmHg or sitting diastolic blood pressure of ≥ 80 mmHg and < 110 mmHg at the start of the treatment period (Week 0) Sitting blood pressure will be measured until 2 consecutive stable measurements are obtained (i.e., the difference between 2 measurements: diastolic blood pressure of <5 mmHg and systolic blood pressure of < 10 mmHg) after resting in a sitting position for at least 5 minutes. The average value of the last 2 measurements will be recorded (the first the decimal place is rounded off).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Type 2 diabetes mellitus",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "HbA1c (NGSP (National Glycohemoglobin Standardization Program) value) of < 8.4% during 3 months before informed consent, with a ≤ 0.3% change in HbA1c (peak minus nadir) during 3 months before informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "No change in diet/exercise therapy during the 3 months before the informed consent in a participant who has been on diet/exercise therapy and instructed to improve life style (e.g., diet and exercise)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Age ≥ 20 years at the time of consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Outpatients",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Capable of providing written consent before participation in this study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Grade III essential hypertension (i.e., sitting systolic blood pressure 180 mmHg or sitting diastolic blood pressure ≥ 110 mmHg), secondary hypertension, or malignant hypertension.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Grade II essential hypertension (i.e., sitting systolic blood pressure ≥ 160 mmHg or sitting diastolic blood pressure ≥ 100 mmHg) for which antihypertensive drug(s) are used",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Use of oral antihypertensive medication within 2 weeks before the start of the treatment period Participants who are on any antihypertensive agent at the time of informed consent can be enrolled in the study only after 2-week washout following informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Use of RAS inhibitors or thiazolidines within 3 months before the start of the treatment period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Type 1 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Fasting blood glucose of < 180 mg/dL and HOMA-R of ≤ 1.6 at the start of the treatment period (Week 0)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Receiving or requiring any of the following at the time of informed consent:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, or other parenteral hypoglycemic agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Combination therapy with 3 or more oral hypoglycemic agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Change of antidiabetic medication (including dosage change) within 3 months before the start of the treatment period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Having diagnosed/treated any of the following cardiovascular diseases within 3 months before the start of the treatment period:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Cardiac disease/condition: myocardial infarction, coronary revascularization procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Cerebrovascular disease: cerebral infarction, cerebral haemorrhage, transient ischaemic attack",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Advanced hypertensive retinopathy (retinal bleeding or oozing, papilloedema)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Having diagnosed/treated for any of the following cardiovascular diseases more than 3 months before the start of the treatment period, and is now still in unstable condition.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Cardiac disease/condition: myocardial infarction, coronary revascularization procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Cerebrovascular disease: cerebral infarction, cerebral haemorrhage, transient ischaemic attack",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Past or current history of any of the following cardiovascular diseases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Cardiac valve stenosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Angina pectoris requiring medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Congestive cardiac failure requiring medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Arrhythmia requiring medication (e.g., paroxysmal atrial fibrillation, severe bradycardia, torsade de pointes, and ventricular fibrillation)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Arteriosclerosis obliterans with intermittent claudication or other symptoms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Have severe ketosis, diabetic coma or precoma, severe infection, or serious trauma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Clinically evident renal disorder (e.g., eGFR <30 mL/min/1.73 m2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Markedly low bile secretion or severe hepatic disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "History of hypersensitivity or allergy to azilsartan or telmisartan or to both.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Presence of hyperkalemia (potassium level ≥ 5.5 mEq/L on laboratory testing)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Currently participating in any other clinical study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Pregnant women, women with possible pregnancy, or breast-feeding women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Other participants who are inappropriate for participation in this study in the opinion of the principal investigator or investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Histologically documented unresectable stage III NSCLC. Mediastinal (N2) involvement must be confirmed by biopsy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Stable disease or clinical response after primary therapy of chemo-radiation treatment for unresectable stage III disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Primary therapy should be a minimum of 2 cycles of Platinum-based first-line chemotherapy, given concurrent with thoracic radiation. The combined modality should consist of either:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "induction (2 cycles) chemotherapy followed by concurrent chemo-radiation therapy; or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "concurrent chemo-radiation therapy followed by 2 cycles of consolidation chemotherapy; or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "concurrent chemoradiation therapy alone",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "A minimum radiation dose of greater than or equal to (>=) 6,000 centigray (cGy) should be administered. Subjects must have completed the primary therapy at least 4 weeks and no later than 6 months prior to study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (<=) 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Ability to understand and willingness to sign a written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Other protocol defined inclusion criteria could apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Undergone lung cancer specific therapy (including surgery) prior to primary chemo-radiation therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Received immunotherapy/systemic immunosuppressive drugs/investigational systemic drugs within 4 weeks prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Subjects with brain metastases, pleural effusion, unless cytologically confirmed to be non-malignant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Autoimmune disease or immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Clinically significant hepatic, renal dysfunction or cardiac diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Clinically significant active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Pregnant or lactating, women of childbearing potential, unless using effective contraception as determined by the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "Other protocol defined inclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "Patients with:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "Patients who or with:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "Epidermal Growth Factor Receptor (EGFR) mutation-positive result per the institution's testing methodology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "Adequate organ function, defined as all of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "Absolute Neutrophil Count (ANC) > 1500/mm3. (ANC >1000/mm3 may be considered in special circumstances such as benign cyclical neutropenia as judged by the investigator and in discussion with the sponsor).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "Platelet count >75,000/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "Serum creatinine < 1.5 times of the upper limit of normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "Total Bilirubin < 1.5 times upper limit of (institutional) normal (Patients with Gilbert's syndrome total bilirubin must be <4 times institutional upper limit of normal).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) < three times the upper limit of (institutional) normal (ULN) (if related to liver metastases < five times ULN).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "Eastern Cooperative Oncology Group (ECOG) score between 0 - 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "written informed consent by patient or guardian prior to admission into the trial that is consistent with International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP) guidelines and local law.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "prior treatment with an EGFR tyrosine kinase inhibitor (TKI)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "anti-cancer treatment within 2 weeks prior to start of trial treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "radiotherapy within 14 days prior to drug administration, except as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "known pre-existing interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "meningeal carcinomatosis and symptomatic brain metastases (patients with asymptomatic brain metastases, who were previously treated, are eligible provided they have had Stable Disease (SD) for at least 4 weeks on stable doses of medication)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subjects must satisfy the following criteria to be enrolled in the study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "The presence of any of the following will exclude a subject from enrollment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject with histological or cytological confirmation of extensive stage Small Cell Lung Cancer (ES SCLC) or Stage IIIb or IV squamous Non-Small Cell Lung Cancer (sqNSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has received 1 or 2 prior lines of therapies, defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Cohort A (SCLC, Immune Checkpoint Inhibitor naïve):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "At least 1 prior treatment including a platinum-based chemotherapy doublet",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "A minimum of 3 cycles of platinum-based chemotherapy in first line treatment, unless stopped at 2 cycles due to treatment-related toxicity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Cohort B (SCLC, ICI progressors):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "At least 1 prior first or second line treatment includes an ICI",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "If treatment includes an ICI as maintenance therapy, at least 1 cycle of ICI in maintenance should have been completed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "At least 1 prior treatment including a platinum-based chemotherapy doublet",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "A minimum of 3 cycles of platinum-based chemotherapy, with or without ICI, in first line treatment, unless stopped at 2 cycles due to treatment-related toxicity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject must have progressed during ICI therapy, defined as unequivocal progression on or within 3 months of the last dose of ICI therapy (if no subsequent therapy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Cohort C (sqNSCLC, ICI progressors):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "At least 1 prior first or second line treatment includes an ICI",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "If treatment includes an ICI as maintenance therapy, at least 1 cycle of ICI in maintenance should have been completed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "At least 1 prior treatment including a platinum-based chemotherapy doublet",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "A minimum of 3 cycles of platinum-based chemotherapy, with or without an ICI, in first line treatment, unless stopped at 2 cycles due to treatment-related toxicity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject must have progressed during ICI therapy, defined as unequivocal progression on or within 3 months of the last dose of ICI therapy (if no subsequent therapy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has progressed at the last line of therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has a measurable disease defined by RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject agrees to provide a tumor biopsy from primary or metastatic site prior to first dose and at a pre-specified timepoint during treatment. Core biopsy is required however, in the event a core biopsy may not otherwise be feasible in the opinion of the treating physician, an endobronchial ultrasound-guided fine needle aspirate [EBUS-FNA]) biopsy, using the largest gauge needle, may be performed instead.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has ECOG Performance Status of 0 to 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject must have the following laboratory values:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Absolute neutrophil count (ANC) ≥ 1.5 x 109/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Hemoglobin (Hgb) ≥ 9 g/dL (one-time blood transfusion is allowed)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Platelet (Plt) Count ≥ 150 x 109/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "White blood cells (WBC) ≥ 2 x 109L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Serum AST/serum glutamic oxaloacetic transaminase (SGOT) or ALT/serum glutamic pyruvic transaminase (SGPT) ≤ 3 x upper limit of normal (ULN) or ≤ 5 x ULN if presence of liver metastases",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Total serum bilirubin ≤ 1.5 x ULN (≤ 3 x ULN, if Gilbert's syndrome or if indirect bilirubin concentrations are suggestive of extrahepatic source of the elevation)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Creatinine clearance (CrCl) ≥ 60 mL/minute based on Cockcroft-Gault or modification of diet in renal disease (MDRD) or ≥ 60 mL/min/1.73 m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has not recovered to Grade 2 or lower clinically significant toxicities related to the prior therapy (alopecia excluded).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has received prior LSD1 therapies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has a history of severe hypersensitivity reactions to other monoclonal antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject with symptomatic and untreated or unstable central nervous system (CNS) metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has recently been treated with whole brain radiation or stereotactic radiosurgery for CNS metastases must have completed therapy at least 2 weeks prior to Cycle 1 Day 1 and has a follow-up brain computed tomography (CT) or magnetic resonance imaging (MRI) demonstrating either stable or improving metastases 2 or more weeks after completion of radiotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject must be asymptomatic and off steroids or on stable dose of steroids for at least 2 weeks (≤ 10 mg daily prednisone or equivalent) prior to first dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has persistent diarrhea due to a malabsorptive syndrome (such as celiac sprue or inflammatory bowel disease) ≥ NCI CTCAE Grade 2, despite medical management), or any other significant gastrointestinal (GI) disorder that could affect the absorption of the study treatments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject with symptomatic or uncontrolled ulcers (gastric or duodenal), particularly those with a history of and/or risk of perforation and GI tract hemorrhages.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject with any hemorrhage/bleeding event > NCI CTCAE Grade 2 or haemoptysis > 1 teaspoon within 4 weeks prior to the first dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has any of the following cardiovascular criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Evidence of acute or ongoing cardiac ischemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Current symptomatic pulmonary embolism",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Unstable angina pectoris or myocardial infarction ≤ 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Heart failure of New York Heart Association Classification III or IV ≤ 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Persistent or clinically meaningful ventricular arrhythmias prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Cerebral vascular accident or transient ischemic attack ≤ 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "QT corrected based on Fridericia's equation (QTcF) ≥ 450 milliseconds (msec) on Screening ECG, a baseline prolongation of QTcF interval ≥ 450 msec (NCI CTCAE Grade ≥ 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "A history of additional risk factors for Torsades de pointes (TdP) (eg, heart failure, hypokalemia, family history of Long QT Syndrome)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Uncontrolled hypertension (blood pressure ≥ 160/95 mm Hg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has known human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has known chronic active hepatitis B or C virus (HBV, HCV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject who is seropositive due to HBV vaccination is eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject who has no active viral infection and is under adequate prophylaxis against HBV reactivation is eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has any other malignancy within 2 years prior to enrollment, with the exception of adequately treated in-situ bladder cancer, in-situ carcinoma of the cervix, uteri, nonmelanomatous skin cancer, ductal in situ breast carcinoma, thyroid cancer, or early stage prostate cancer (all treatment of which should have been completed 6 months prior to enrollment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has medical conditions requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "A brief (≤ 7 days) course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of nonautoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Adrenal replacement steroid doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption) are permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has active autoimmune diseases or history of autoimmune diseases that may relapse. Subjects with the following diseases are allowed to be enrolled after further screening: type I diabetes, hypothyroidism managed with hormone replacement therapy only, skin diseases not requiring systemic treatment (such as vitiligo, psoriasis, or alopecia), or diseases not expected to recur in the absence of external triggering factors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject is pregnant or nursing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has a history of persistent skin rash ≥ NCI CTCAE Grade 2 related to prior ICI therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has organ transplant history, including allogeneic stem cell transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has interstitial lung disease history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has received a live/attenuated vaccine within 30 days of first dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has previous SARS-CoV-2 infection either suspected or confirmed within 4 weeks prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Acute symptoms must have resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the subject at a higher risk of receiving investigational treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Key Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Key Exclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Note: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Part A: histologically or cytologically confirmed advanced malignant solid tumor that is refractory to or intolerant of standard therapy or for which no standard therapy is available",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Part B: Pancreatic Adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Presence of histologically confirmed inoperable locally advanced or metastatic pancreatic adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Part B: NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Stage IIIB with malignant pleural effusion/pleural seeding or stage IV histologically confirmed NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Absence of known epidermal growth factor receptor (EGFR) mutation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Absence of known translocation or inversion events involving the ALK gene locus (resulting in EML4-ALK fusion)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Part B: Esophagogastric Adenocarcinoma:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Histologically confirmed inoperable advanced gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction) or relapsed gastric adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Human epidermal growth factor receptor 2 (HER2)-negative tumor (primary tumor or metastatic lesion)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Part B: First-Line Colorectal Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Radiographically measureable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "No prior cytotoxic chemotherapy to treat their metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Part B: Second-Line Colorectal Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Radiographically measureable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Received first-line combination therapy containing oxaliplatin and fluoropyrimidine with or without bevacizumab for metastatic disease with documented evidence of disease progression during or after treatment completion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Part B: Breast Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Histologically or cytologically confirmed metastatic breast cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Radiographically measureable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Previous hormonal therapy for metastatic breast cancer or cytotoxic adjuvant chemotherapy is allowed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Treatment with weekly single-agent paclitaxel is appropriate in the opinion of the treating physician",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "HER-2 negative tumor (primary tumor or metastatic lesion)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Individuals with known central nervous system (CNS) metastases, unless metastases are treated and stable and the individual does not require systemic steroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Myocardial infarction, symptomatic congestive heart failure, unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Anti-tumor therapy within 28 days of study drug dosing; concurrent use of hormone therapy for breast or prostate cancer is permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Histologically or cytologically confirmed Stage IIIB or IV advanced or metastatic NSCLC with measurable neoplastic disease. Sputum cytology alone is not considered an acceptable method of diagnosis;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Prior therapy must meet all of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Subject has experienced disease progression or unacceptable toxicity/intolerance after receiving at least 1 systemic platinum-containing regimen;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Subject with a tumor of non-squamous histology must be tested for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangement. Subject with EGFR activating mutation or ALK rearrangement must have experienced disease progression or unacceptable toxicity/intolerance after receiving at least one EGFR tyrosine kinase inhibitor or ALK inhibitor;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Subject has received PD-1/PD-L1 blockade or has been informed of the results of relevant positive Phase 3 trials with these agents.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 at baseline;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Minimum life expectancy of 3 months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Agrees to use a medically effective method of contraception. Male subjects and women of child-bearing potential (WOCBP) must agree to use effective contraception, e.g., oral contraceptives, double barrier method (condom plus spermicide or diaphragm plus spermicide), or practice true abstinence from sexual intercourse during the study and for 3 months after the last dose. Women of child-bearing potential include female subjects who have experienced menarche and have not undergone surgical sterilization or are not postmenopausal (defined as amenorrhea ≥ 12 consecutive months without an alternative medical cause);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "WOCBP must have a negative serum pregnancy test within 7 days prior to receiving investigational product and a negative urine pregnancy test on Day 1 of each Cycle;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Recovered (i.e., Grade ≤ 1 or to a baseline level) from the effects of recent surgery, radiotherapy, chemotherapy, hormonal therapy, or other therapies for cancer (with the exception of alopecia for which no resolution is required and peripheral neuropathy which must have resolved to Grade ≤ 1 for subjects receiving prior taxane-based chemotherapy);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Adequate organ function defined as below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Total bilirubin ≤ upper limit of normal (ULN);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Hemoglobin (Hgb) ≥ 9.0 g/dL;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Serum creatinine (sCr) ≤ 1.5 x ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Absolute neutrophil count (ANC) ≥ 1500 cells/mm3;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Platelets ≥ 100 × 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Sufficient archived tumor samples (if taken within 6 months prior to treatment may be submitted) available for PD assessments, or willingness to undergo a pre-treatment core needle biopsy, preferably of the primary tumor, in order to obtain such tissue;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Willing and able to undergo a post-dose core needle biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Prior treatment with docetaxel or mogamulizumab;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Requires administration of a prohibited medication or treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Has a significant uncontrolled intercurrent illness including, but not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Ongoing or active infection requiring antibiotics;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Clinically significant cardiac disease (class III, or IV of the New York Heart Association classification; unstable angina pectoris, myocardial infarction within 6 months or is post angioplasty or stenting within 6 months; clinically significant cardiac arrhythmia, or uncontrolled hypertension (i.e., systolic blood pressure > 150 mm Hg, diastolic blood pressure > 90 mmHg) despite anti-hypertensive medication;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Uncontrolled diabetes, active liver disease, poorly controlled chronic obstructive pulmonary disease, serious or non-healing wound, ulcer, or fracture;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Known or tests positive for human immunodeficiency virus, hepatitis B, or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Active known auto-immune disease with the exception of autoimmune thyroiditis, vitiligo, and alopecia;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Pleural effusion requiring repetitive drainage, i.e., an indwelling catheter or 2 thoracenteses with 6 weeks of the first dose of mogamulizumab;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Received monoclonal antibodies (for any reason), chemotherapy, surgery, investigational therapy, or radiotherapy within 14 days of the first dose of mogamulizumab;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Received live, attenuated vaccine within 28 days prior to the first dose of mogamulizumab;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Use of immunosuppressive medication within 14 days before the first dose of mogamulizumab. Note: Inhaled, intranasal, intra-articular, or topical corticosteroids are allowed. Non-immunosuppresive doses of systemic steroids for adrenal replacement or for contrast allergy are allowed;;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Any history or signs of central nervous system metastases;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Any history or signs of pulmonary lymphangitic spread;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Experienced a Grade 3 or higher hypersensitivity reaction to monoclonal antibodies or other therapeutic proteins, and the reaction could not be controlled or prevented on subsequent infusion with standard therapies such as antihistamines, 5-hydroxytryptamine (5-HT3) receptor antagonists, or corticosteroids;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "The subject has a history of severe hypersensitivity reactions to drugs formulated with polysorbate 80;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "History of second primary cancer within the past 5 years, with the exception of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Curatively resected non-melanomatous skin cancer;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Curatively treated cervical intraepithelial neoplasia or prostate carcinoma with current prostate specific antigen (PSA) < 0.01 ng/mL; or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Curatively treated ductal carcinoma in situ of the breast;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "The subject is pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "The subject has aspartate aminotransferase and/or alanine aminotransferase > 1.5 × ULN, with concomitant alkaline phosphatase > 2.5 × ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Pathologically confirmed diagnosis of NSCLC considered to be of squamous histology, including mixed histology, in the opinion of the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Locally advanced (stage IIIb) or metastatic (stage IV) NSCLC not considered eligible for curative therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Documented disease progression or relapse (based on investigator's assessment) during or after completion of at least 2 cycles of platinum-based chemotherapy as first line treatment of Stage IIIB/IV SCC of the lung. This includes patients relapsing within 6 months of completing (neo)adjuvant/curative-intent chemotherapy or definitive chemoradiotherapy. Patients should be eligible to receive 2nd line therapy in the opinion of the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "At least one target lesion (outside the brain) that can be accurately measured per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. In patients who only have one target lesion and a biopsy of the lesion is required; the baseline imaging must be performed at least two weeks after the biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Availability and willingness to provide a fresh tumour tissue sample obtained after relapse or progression on or after prior therapy. In case a fresh biopsy cannot be obtained (e.g. inaccessible lesions or patient safety concern), an archived specimen may be submitted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Adequate organ function (all screening labs should be performed within 10 days prior to treatment initiation).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Recovery from major surgery or any previous anti-cancer or radiation therapy-related toxicity to ≤ CTCAE Grade 1 at C1_V1 (except for alopecia; stable sensory neuropathy must be ≤ CTCAE Grade 2).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "At least 18 years of age or over the legal age of consent in countries where that is greater than 18 years at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Male or female patients. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, starting with the screening visit and through 120 days after the last dose of pembrolizumab treatment and 2 weeks after last afatinib treatment, respectively, as listed in the protocol. A list of contraception methods meeting these criteria is provided in the patient information.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Note: Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to taking study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the patient to be eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Prior therapy with any immune checkpoint inhibitor; however, prior (neo) adjuvant checkpoint inhibitor therapy is allowed if completed at least 12 months before relapse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Prior therapy with EGFR inhibiting drugs; however, prior EGFR-targeted (neo) adjuvant therapy is allowed if completed at least 12 months before relapse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Treatment with prior chemotherapy, non-EGFR targeted therapy, or anti-cancer hormonal treatment within 2 weeks prior to the first dose of trial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Current or previous treatment with experimental therapy or use of an investigational device within 30 days prior to the first dose of trial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to the first dose of trial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Received a live vaccine within 30 days prior to the first dose of trial treatment. Seasonal flu vaccines that do not contain live virus are permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the trial or interfere with the evaluation of the efficacy and safety of the test drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Radiotherapy within 4 weeks prior to start of treatment except as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Palliative radiotherapy to regions other than the chest is allowed up to 2 weeks prior to start of treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Single dose palliative radiotherapy for symptomatic metastasis within 2 weeks prior to start of treatment may be allowed but must be agreed with the Sponsor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Major surgery (according to the investigator's assessment) performed within 4 weeks prior to start of treatment or planned during the projected course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Requirement or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Known history of hypersensitivity to afatinib or any of its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Known history of hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. -- Note: Patients with previously treated brain metastases may participate provided they are radiologically stable i.e. without evidence of progression for at least four weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable, and without requirement of steroids treatment for at least 14 days prior to first dose of study treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids or current ILD/pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Any history or presence of uncontrolled gastrointestinal disorders that could affect the intake and/or absorption of the study drug (e.g. nausea, vomiting, Crohn's disease, ulcerative colitis, chronic diarrhoea, malabsorption) in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Active infectious disease requiring systemic therapy or which puts the patient at increased risk in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Previous or concomitant malignancies at other sites than the lung, except:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Effectively treated non-melanoma skin cancers;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Effectively treated carcinoma in situ of the cervix;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Effectively treated ductal carcinoma in situ;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Other effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Known human immunodeficiency virus (HIV) (HIV 1/2 antibodies), hepatitis B (e.g. HBsAg reactive) or known active hepatitis C infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "History of active TB (Bacillus Tuberculosis).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of ≥3, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the investigator. Myocardial infarction within 6 months prior to start of treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Psychiatric, substance abuse disorders, or chronic alcohol abuse or any condition as per investigator's opinion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "Further criteria apply, some were shortened.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Epidermal Growth Factor Receptor (EGFR) mutation-positive results per the institution's testing methodology",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Male or female patients age >=18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Adequate organ function, defined as all of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Absolute neutrophil count (ANC) >1500/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Platelet count>75,000/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Serum creatinine<1.5 times of the upper limit of (institutional) normal and/or creatinine clearance (measured or calculated)>45ml/min",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Total bilirubin <1.5 times upper limit of (institutional) normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) < three times the upper limit of (institutional) normal (if related to liver metastases < five times ULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Eastern Cooperative Oncology Group (ECOG) score between 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Written informed consent by patient or guardian prior to admission into the trial that is consistent with International Conference on Harmonization (ICH)- Good Clinical Practice (GCP) guidelines and local law",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Recovery from any previous therapy related toxicity to <=CTCAE Grade 1 at study entry (except for stable sensory neuropathy <=CTCAE Grade 2 and alopecia)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Prior treatment with an EGFR tyrosine kinase inhibitor (TKI)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Hormonal anti-cancer treatment within 2 weeks prior to start of trial treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Radiotherapy within 28 days prior to drug administration, except as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Single dose palliative treatment for symptomatic metastases outside above allowance to be discussed with sponsor prior to enrolling",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Major surgery within 4 weeks before starting trial treatment or scheduled for surgery during the projected course of the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Known hypersensitivity to afatinib or any of its excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to starting trial treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Women of Child-Bearing Potential (WOCBP) and men who are able to father a child, unwilling to use adequate contraception prior to trial entry, for the duration of trial participation and for at least 2 weeks after treatment has ended",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Childbearing potential who:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "are nursing or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "are pregnant or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "are not using an acceptable method of birth control, or do not plan to continue using this method throughout the trial and/or do not agree to submit to pregnancy testing required by this protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patients ability to comply with the trial or interfere with the evaluation of safety for the trial drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Requiring treatment with any of the prohibited concomitant medications that cannot be stopped for the duration of trial participation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Known pre-existing interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Presence of poorly controlled gastrointestinal disorders that could affect the absorption of the trial drug (e.g. Crohn's disease, ulcerative colitis, malabsorption, or Common Terminology Criteria grade =2 diarrhea of any aetiology) based on investigator assessment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Active hepatitis B infection (defined as presence of Hepatitis B (HepB) sAg and/or HepB DNA), active Hepatitis C (HEP C) infection (defined as presence of Hep C RNA) and/or known Human Immunodeficiency Virus (HIV) carrier",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Meningeal carcinomatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "Symptomatic brain metastases (patients with asymptomatic brain metastases, who were previously treated, are eligible provided they have had Stable Disease (SD) for at least 4 weeks on stable doses of corticosteroid)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient has radically resected NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The NSCLC is of pathological stage IA-T1b, IB, II or IIIA NSCLC The surgical technique for resection of the patient's tumor is anatomical, involving at least a segmentectomy The patient's tumor shows expression of PRAME.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient is ≥ 18 years of age at the time of first consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "Written informed consent has been obtained from the patient prior to performance of any study-specific procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient is free of disease (no residual tumor, no loco-regional recurrence, no distant metastasis), as confirmed by a post- thoracic surgery contrast-enhanced computed tomography (CT scan) of the chest, upper abdomen and by a contrast-enhanced CT scan or Magnetic Resonance Imaging (MRI) of the brain. Other examinations should be performed as clinically indicated.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2 at the time of randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "Adequate bone-marrow reserve, adequate renal, hepatic and adrenal function as assessed by standard laboratory criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "If the patient is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to administration of study product, have a negative pregnancy test and continue such precautions during all study treatment period and for 2 months after last treatment administration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "Patients who the investigator believes can and will comply with the requirements of this protocol (e.g. return for active follow-up visits).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient is diagnosed with a concomitant malignancy and/or has a history of malignancy within the past five years or has had a malignancy that has been in complete remission for less than 5 years. Patients with effectively treated non - melanoma skin cancers or effectively treated carcinoma in situ of the cervix both of which in remission for less than 5 years will be eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient has received any anti-cancer specific treatment, including radiotherapy, immunotherapy, hormonal therapy, chemotherapy or neo-adjuvant chemotherapy, except for:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "Administration of adjuvant platinum-based doublet chemotherapy for the treatment of the current NSCLC allowed between surgery and randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "Treatment of previous malignancies as allowed by the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient has been diagnosed with a Potential Immune-Mediated Disease (pIMD). Patients with vitiligo are not excluded from the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient has a history of confirmed adrenal dysfunction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient requires concomitant treatment with any immunosuppressive agent, or with systemic corticosteroids prescribed for chronic treatment (more than 7 consecutive days).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient needs chronic long term oxygen therapy (LTOT). The patient has medically uncontrolled congestive heart failure or hypertension, unstable heart disease or uncontrolled arrhythmia at the time of randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient has an uncontrolled bleeding disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient has undergone splenectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient is known to be Human Immunodeficiency Virus (HIV)-positive.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the trial procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient has other concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient has a history of allergic disease or reactions likely to be exacerbated by any component of the study investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "The patient has received any investigational or non-registered product within the 30 days preceding randomization, or planned use during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "For female patients: the patient is pregnant or lactating or is planning to become pregnant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Participants must have histological or cytological confirmed diagnosis of the following tumor types that is advanced and/or metastatic cancer and must be, in the judgment of the investigator, an appropriate participant for experimental therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Part A: Any type of solid tumor (\"all comer\")",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Part B1: Gastric or Gastroesophageal Junction (GEJ) adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Part B2: Hepatocellular cancer (excluding fibrolamellar carcinoma)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Part B3: Renal cell carcinoma (any histology)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Part B4: Non-small cell lung cancer (squamous or non-squamous)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have at least 1 measurable lesion outside of the central nervous system (CNS) whose presence is assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Availability of a tumor sample taken after progression on the most recent line of systemic tumor therapy or willing to undergo a tumor biopsy pre-study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have a performance status of ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale in Part A and ≤ 1 on the ECOG scale in Part B.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Routine urinalysis showing ≤1+ protein or protein/creatinine ratio <0.5. For proteinuria ≥2+ or urine protein/creatinine ratio ≥0.5, 24-hour urine must be collected and the level must be <1 gram of protein in 24 hours for subject enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have discontinued all previous cancer therapies and any agents that have not received regulatory approval for any indication, for at least 21 days or 5 halflives prior to study enrollment, whichever is shorter, and recovered from the acute effects for therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have an estimated life expectancy, in the judgment of the investigator, that will permit the participant to complete 8 weeks (2 cycles) of treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Males and females with reproductive potential: Must agree to use medically approved contraceptive precautions during the study and for at least 3 months following the last dose of study drug. Females with childbearing potential must have had a negative serum pregnancy test 7 days before the first dose of study drug and must not be breast-feeding.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have serious pre-existing medical conditions (at the discretion of the investigator, such as severe acute or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have a history of hypertensive crisis or hypertensive encephalopathy or current poorly controlled hypertension despite standard medical management.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Participant has experienced any arterial thromboembolic event (ATE), including myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack, within 6 months prior to receiving study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolic event during the 3 months prior to receiving study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Are receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin, or similar agents. Participants receiving prophylactic, low-dose anticoagulation therapy are eligible provided that they are on low-molecular weight heparin or oral factor Xa inhibitors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "The participant is receiving chronic therapy with nonsteroidal anti-inflammatory drugs or other antiplatelet agents. Aspirin use at doses up to 325 mg/day is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to receiving study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have a history of GI perforation and/or fistulae within 6 months prior to receiving study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have congestive heart failure (CHF) New York Heart Association class ≥3 or symptomatic or poorly controlled cardiac arrhythmia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have undergone major surgery within 28 days prior to receiving study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to receiving study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have a known active fungal, bacterial, and/or known viral infection. Hepatocellular cancer participants with chronic viral (B or C) hepatitis are eligible if they retain adequate liver function.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have liver cirrhosis with a Child-Pugh Stage of B or C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have symptomatic CNS malignancy (with the exception of medulloblastoma) or metastasis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have corrected QT (QTc) interval of >470 milliseconds on screening electrocardiogram (ECG).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have received previous treatment with ramucirumab or Emibetuzumab, except for participants enrolled in cohort B1 (Gastric or GEJ adenocarcinoma) and B4 (non- small cell lung cancer) who may have received previous ramucirumab treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Known hypersensitivity to any of the treatment components of ramucirumab or Emibetuzumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Have a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Are pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "For Part B4 (non-small cell lung cancer) only:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "The participant has radiologically documented evidence of major blood vessel invasion or encasement by cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "Participants with a history of gross hemoptysis within 2 months prior to study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "The participant has radiographic evidence of intratumor cavitation, regardless of tumor histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Voluntarily written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Age: between 18 and 75 years (both inclusive).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1. Cohort of patients with SCLC and endometrial cáncer ECOG PS ≤ 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Life expectancy ≥ 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Patients with a histologically/cytologically confirmed diagnosis of advanced disease of any of the following tumors:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Breast cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Soft-tissue sarcoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Primary bone sarcomas.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Gynecologic tumors (endometrial adenocarcinomas, epithelial ovarian cancer...)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Hepatocellular carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Gastroenteropancreatic neuroendocrine tumors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Small cell lung cancer (SCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Gastric cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Bladder cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Adenocarcinoma of unknown primary site",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "At least three weeks since the last anticancer therapy, including radiotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Adequate bone marrow, renal, hepatic, and metabolic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan within normal range (according to institutional standards).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Women of childbearing potential must have a negative serum pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for six weeks after discontinuation of treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Concomitant diseases/conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "History or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically significant valvular heart disease within last year.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Symptomatic or any uncontrolled arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Ongoing chronic alcohol consumption, or cirrhosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Active uncontrolled infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Known human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Any other major illness that, in the Investigator's judgment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Brain metastases or leptomeningeal disease involvement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Men or women of childbearing potential who are not using an effective method of contraception",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "Patients who have had radiation therapy in more than 35% of the bone marrow. This criterion will not apply to cohort of patients with SCLC and endometrial cáncer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "History of previous bone marrow and/or stem cell transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Age ≥ 18 years, male or female;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Patients scheduled to receive carboplatin plus etoposide regimen: no prior systemic therapy (eg, chemotherapy or combined with immunotherapy);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Patients scheduled to receive topotecan regimen: previously received 1/2 lines of chemotherapy or combined immunotherapy but not topotecan.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Presence of at least one radiation-naïve measurable lesion according to RECIST 1.1 criteria;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Hemoglobin ≥ 90 g/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Neutrophil count ≥ 1.5 × 10^9/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Platelet count ≥ 100 × 10^9/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Creatinine ≤ 15 mg/L or creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault formula);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Total bilirubin ≤ 1.5 × upper limit of normal (ULN);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN or ≤ 5 × ULN (for patients with liver metastases);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Albumin ≥ 30 g/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "ECOG PS score 0 - 2;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Expected survival time ≥ 3 months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Contraception: Females: All females of childbearing potential must have a negative serum pregnancy test at screening and must use reliable contraception from signing of informed consent through 3 months after the last dose; Male: Female partners of childbearing potential must use reliable contraception from signing the informed consent until 3 months after the last dose;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Understand and sign informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Symptomatic brain metastases requiring local radiotherapy or hormonal therapy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "History of other malignancies, with the following exceptions: (1) clinically cured cutaneous basal cell or squamous cell tumors; (2) cured a) cervical cancer, b) prostate cancer, c) superficial bladder cancer; or (3) other solid tumors with a clinical cure time of more than 3 years;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Uncontrolled ischemic heart disease or clinically significant congestive heart failure (NYHA Class III or IV);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Stroke or cardiovascular or cerebrovascular event within 6 months prior to enrollment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Severe active infection;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Psychological or other social factors causing insufficient trial compliance;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Other uncontrolled serious chronic diseases or conditions that, in the opinion of the investigator, would make participation in the trial inappropriate;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Known HIV infection, active hepatitis B (defined as positive HBV DNA), and hepatitis C (positive HCV RNA);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Radiation therapy within 2 weeks prior to enrollment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Patients who have received cytotoxic drug therapy or investigational drug therapy within 4 weeks before enrollment, or non-cytotoxic anti-tumor drug therapy within 2 weeks;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Subjects in the first part of the study should not take strong or moderate inducers of CYP3A4 concomitantly within 4 weeks before taking the study drug, and strong inhibitors of CYP3A4 concomitantly within 2 weeks before taking the study drug;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Toxicity from prior anticancer therapy has not recovered to Grade 0 or 1 (except alopecia);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Hypersensitivity to the study drug (Trilaciclib, etoposide, carboplatin, topotecan) or components thereof;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Persons who are unable to act independently due to legal restriction or legal sense;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Pregnant or lactating women;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "Not suitable for participating in this study in the investigator 's opinion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Diagnosis of advanced stage NSCLC squamous histology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Platinum-based doublet chemotherapy as 1st line treatment of Stage IIIB/IV NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Eligible to receive 2nd line therapy in the opinion of the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Measurable disease according to RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Adequate Performance Status.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Availability of tumour tissue material for correlative studies. Archived tumour tissue is acceptable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Age = 18 years and above.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Written informed consent that is consistent with International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Prior treatment with Epidermal Growth Factor Receptor (EGFR) directed small molecules or antibodies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Radiotherapy within 4 weeks prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Active brain metastases .",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Any other current malignancy or malignancy diagnosed within the past three (3) years (other than basal-cell carcinoma of the skin, in situ cervical cancer, in situ prostate cancer).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Known pre-existing interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Women of child-bearing potential and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 2 months after treatment has ended.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Female patients of childbearing potential (see Section 4.2.3.3) who:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "are nursing or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "are pregnant or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "are not using an acceptable method of birth control, or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Active hepatitis B infection (defined as presence of Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Known or suspected active drug or alcohol abuse in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Any contraindications for therapy with afatinib or erlotinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Known hypersensitivity to erlotinib, afatinib or the excipients of any of the trial drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Major surgery within 4 weeks of starting study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Prior participation in an afatinib clinical study, even if not assigned to afatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Use of any investigational drug within 4 weeks of randomisation (unless a longer time period is required by local regulations or by the guidelines for the investigational product).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "Patients without Progression of their lung cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "presence of Epidermal Growth Factor Receptor (EGFR) mutations in tumor biopsy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "male or female patients age 18 years or older (For India only, male or female patients age >=18 years and <=75 years)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "adequate organ function, defined as all of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "Absolute Neutrophil Count (ANC) > 1500/mm3. (ANC >1000/mm3 may be considered in special circumstances such as benign cyclical neutropenia as judged by the investigator and in discussion with the sponsor).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "Platelet count >75,000/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "Serum creatinine < 1.5 times of the upper limit of normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "Total Bilirubin < 1.5 times upper limit of (institutional) normal (Patients with Gilbert's syndrome total bilirubin must be <4 times institutional upper limit of normal).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "Aspartate Amino Transferase (AST) and Alanine Amino Transferase (ALT) < three times the upper limit of (institutional) normal (ULN) (if related to liver metastases < five times ULN). 5) Eastern Cooperative Oncology Group (ECOG) score between 0 - 2 6) written informed consent by patient or guardian prior to admission into the trial that is consistent with International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP) guidelines and local law.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "prior treatment with an EGFR tyrosine kinase inhibitor (TKI)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "use of anti-cancer treatment within 2 weeks prior to start of trial treatment (continued use of anti-androgens and / or gonadorelin analogues for treatment of prostate cancer permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "radiotherapy within 4 weeks prior to drug administration except as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "major surgery within 4 weeks from day 1 of first dose of afatinib. At least 7 days should have elapsed since minor surgical procedure including placement of an access device or fine needle aspiration and at least 14 days for diagnostic or palliative video-assisted thoracoscopic surgery (VATS).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "known hypersensitivity to afatinib or any of its excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "history or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of >3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to starting trial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "Women of Child-Bearing Potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use medically acceptable method of contraception during the trial entry and for at least 4 weeks after treatment has ended. Adequate methods of contraception and Women of Child-Bearing Potential. Perimenopausal women must be amenorrhoeic for at least 24 months to be considered for non-childbearing potential.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "childbearing potential (see Section 4.2.3) who:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "are nursing or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "are pregnant or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "are not using an acceptable method of birth control, or do not plan to continue using this method throughout the trial and/or do not agree to submit to pregnancy testing required by this protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "history of or co-existing condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the trial or interfere with the evaluation of safety for the trial drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "previous or concomitant malignancies at other sites, except effectively treated nonmelanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "requiring treatment with any of the prohibited concomitant medications listed, that cannot be stopped for the duration of trial participation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "known pre-existing interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "presence of poorly controlled gastrointestinal disorders that could affect the absorption of the trial drug (e.g. Crohn's disease, ulcerative colitis, malabsorption, or CTC grade =2 diarrhoea of any aetiology) based on investigator assessment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "Known active hepatitis B infection (defined as presence of Hepatitis B (HepB) sAg and/or HepB DNA), active Hepatitis C (HEP C) infection (defined as presence of Hep C RNA) and/or known Human Immunodeficiency Virus (HIV) carrier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "meningeal carcinomatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "symptomatic brain metastases (patients with brain metastases, who were previously treated, are eligible provided they have asymptomatic brain metastasis for at least 4 weeks on stable doses of medication)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Phase 1 portion:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Participants with a cytologic or histologic diagnosis of nonsquamous NSCLC that is classified as Stage IV according to the 7th edition of the American Joint Committee on Cancer (AJCC) classification and for whom the combination of pemetrexed and cisplatin is deemed to be appropriate",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Participants with histologic or cytologic diagnosis of malignant mesothelioma that is unresectable",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Participants with histologic or cytologic diagnoses of advanced or metastatic solid tumors who are not candidates for any standard therapy and for whom the combination with pemetrexed and cisplatin is deemed to be appropriate",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Phase 2 portion:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Have a histological diagnosis of NSCLC other than predominantly squamous cell histology that is classified as Stage IV according to the 7th edition of the AJCC classification",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Eligible for a first line of palliative treatment with a platinum doublet",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Have archived or fresh tumor tissue (not cytology)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Phase 1 participants can have measurable or nonmeasurable disease. Phase 2 participants must have at least 1 measurable lesion according to Investigational New Drug (Response Evaluation Criteria in Solid Tumors [RECIST], v1.1) definitions. Tumor lesions located in a previously irradiated area can be considered measurable if they are new or if have shown unequivocal progression.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Have a performance status ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Have adequate hematologic, hepatic, and renal organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Prior radiation therapy for treatment of cancer is allowed to <25% of the bone marrow, and participants must have recovered from the acute toxic effects of their treatment prior to study enrollment. Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 4 weeks before study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "For women: Must be surgically sterile, postmenopausal, or compliant with a highly reliable contraceptive method (failure rate <1%) during and for 6 months after the treatment period; must have a negative serum or urine pregnancy test within 7 days before study enrollment and must not be breast-feeding. For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Have serious preexisting medical conditions or serious concomitant systemic disorders that would compromise the safety of the participant or his/her ability to complete the study, at the discretion of the investigator (for example, unstable angina pectoris or uncontrolled diabetes mellitus). Special attention should be paid to kidney and heart conditions that may be worsened with cisplatin treatment or hydration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Have central nervous system (CNS) metastases (unless the participant has completed successful local therapy for CNS metastases and has been off corticosteroids for at least 4 weeks before starting study therapy). A screening computed tomography scan or magnetic resonance imaging before enrollment in the absence of a clinical suspicion of brain metastases is not required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Have current active infection that would, in the opinion of the investigator, compromise the participant's ability to tolerate therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Have known allergy to pemetrexed, cisplatin, LY2603618, or any ingredient of pemetrexed, cisplatin, or LY2603618",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Have clinically significant (by physical exam) third-space fluid collections; for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Participants taking non-steroidal anti-inflammatory drugs who cannot interrupt the treatment appropriately according to the guidelines",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Have received a recent yellow-fever vaccination (within 28 days of enrollment) or are receiving concurrent yellow-fever vaccination",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Phase 1 portion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Have received more than 2 previous lines of chemotherapy for the advanced/metastatic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "Have received more than 6 cycles of therapy containing an alkylating agent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Subjects must have a cytological or histological confirmed diagnosis of adenocarcinoma of the lung.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Subject must be known to be RET positive (known KIF5B-RET translocation, or other confirmed RET translocations (e.g., CCDC6-RET)) or have an available tumor sample for local or central testing obtained prior to consent (Screen 1). Subjects whose samples need to be submitted for central laboratory testing must be current non-smokers and not known to have mutation in EGFR, KRAS, or ALK.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Subjects may have received up to three prior systemic anticancer treatment regimens for adenocarcinoma of the lung (including adjuvant therapies and tyrosine-kinase inhibitors [TKI]), unless discussed with the sponsor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Subjects must have a clinically indicated need for systemic chemotherapy for adenocarcinoma of the lung based on the investigator's assessment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Presence of measurable disease meeting the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "At least one lesion of at least 1.0 cm in the long-axis diameter for a non-lymph node or at least 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) using either computerized tomography (CT) or magnetic resonance imaging (MRI). If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of at least 1.5 cm.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Lesions previously treated with radiotherapy or locoregional therapy must show radiographic evidence of disease progression to be deemed a target lesion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Subjects with known brain metastases who have completed whole brain radiotherapy, stereotactic radiosurgery, or complete surgical resection will be eligible if they have remained clinically stable, asymptomatic and off of steroids for 28 days.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Adequate bone marrow function, defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L (greater than or equal to 1500/mm^3)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Hemoglobin (Hb) greater than or equal 8.5 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Platelet count greater than or equal 75 x 10^9/L (greater than or equal 75,000/mm^3)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Adequate liver function, defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Bilirubin less than or equal 1.5 x upper limit of normal (ULN) except for unconjugated hyperbilirubinemia or Gilbert's syndrome",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) less than or equal 3 x ULN (less than or equal 5 x ULN if subject has liver metastases). If alkaline phosphatase is greater than 3 x ULN (in absence of liver metastases) or greater than 5 x ULN (in presence of liver metastases) AND the subject also is known to have bone metastases, the liver-specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of total alkaline phosphatase.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Adequate renal function, defined as calculated creatinine clearance greater than 40 mL/min per the Cockcroft and Gault formula.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than 150/90 mmHg at screening and no change in antihypertensive medications within 1 week before Cycle 1/Day 1 (C1D1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS) of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Survival expectation of 12 weeks or longer after starting study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Males or females aged at least 18 years (or any age greater than 18 years as determined by country legislation) at the time of informed consent (Screen 1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Females must not be breast-feeding or pregnant at Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity of 25 IU/L or equivalent units of B-hCG). A separate baseline assessment is required if a negative Screening pregnancy test was obtained more than 72 hours before the first dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy or bilateral oophorectomy, all with surgery at least one month before dosing).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Females of childbearing potential must not have had unprotected sexual intercourse within 30 days before study entry and must agree to use a highly effective method of contraception (e.g., total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the subject must agree to use a double barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Male subjects must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must meet the criteria above (i.e., not of childbearing potential or practicing highly effective contraception throughout the study period and for 30 days after study drug discontinuation). No sperm donation is allowed during the study period and for 30 days after study drug discontinuation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Provide written informed consent (Screen 1 and Screen 2)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Willing and able to comply with all aspects of the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Subjects who have received any anticancer therapy (including surgery, locoregional, biological, immunotherapy, hormonal, or radiotherapy) within 21 days before the first dose of study drug (28 days for investigational therapies).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Leptomeningeal metastases or brain metastases except as for Inclusion Criterion #6.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Subjects who have not recovered from toxicities as a result of prior anticancer therapy to less than Grade 2 severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0, except alopecia and infertility.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Gastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Active malignancy (except for adenocarcinoma of the lung or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 24months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Major surgery within 3 weeks before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Bleeding or thrombotic disorders or use of anticoagulants such as warfarin or similar agents requiring therapeutic international normalized ratio (INR) monitoring. (Treatment with low molecular weight heparin is allowed.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Active infection (any infection requiring treatment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Symptomatic central nervous system (CNS) disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Subjects having greater than 1+ proteinuria on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Subjects with urine protein greater than or equal to 1 g/24-hour will be ineligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Any medical or other condition that in the opinion of the investigator(s) would preclude the subject's participation in a clinical study or would preclude them from completing the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "Scheduled for surgery during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Subject is ≥ 18 years of age at the time of signing the informed consent form ().",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Subject is willing and able to adhere to the study visit schedule and other protocol requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Subject must have aggressive B-cell NHL according to \"the 2016 revision of the WHO classification of lymphoid neoplasms\", histologically confirmed at last relapse by the treating institution, defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Diffuse large B-cell lymphoma (DLBCL) Not otherwise specified (NOS) including transformed indolent Non-Hodgkin lymphoma (NHL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Follicular lymphoma Grade 3B",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "T cell/histiocyte-rich large B-cell lymphoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Epstein-Barr virus (EBV) positive DLBCL, NOS",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Primary mediastinal (thymic) large B-cell lymphoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (double/triple-hit lymphoma)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Subjects disease must have relapsed or be refractory to at least 2 prior lines of therapy. Previous therapy must have included a CD20-targeted agent and an anthracycline.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Subject must have",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Positron emission tomography (PET)-positive (Deauville score 4 or 5) and computed tomography (CT) measurable disease as per Lugano Classification",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Sum of product of perpendicular diameters (SPD) of up to 6 index lesions ≥ 25 cm2 by CT scan (not applicable to Arm A or B or subjects with Richter's transformation)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Subjects must agree to not donate blood, organs, sperm or semen, and egg cells for usage in other individuals",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Participants must agree to use effective contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study based on investigator´s judgment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study based on investigator´s judgment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Subject has any condition that confounds the ability to interpret data from the study based on investigator´s judgment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Subjects with prior history of malignancies, other than aggressive R/R NHL, unless the subject has been free of the disease for ≥ 2 years with the exception of the following non-invasive malignancies:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Basal cell carcinoma of the skin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Squamous cell carcinoma of the skin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Carcinoma in situ of the cervix",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Carcinoma in situ of the breast",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) or prostate cancer that is curative.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Other completely resected stage 1 solid tumor with low risk for recurrence",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Prior treatment with any prior gene therap y product",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Prior treatment with any adoptive T cell therapy; prior hematopoietic stem cell transplant (HSCT) is allowed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Allogeneic HSCT within 90 days of leukapheresis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Prior treatment with the combination agent from the assigned arm:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Anti PD-1 or PD-L1 (Arm A and E)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "CC-122 (Arm B)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "CC-220 (Arm C)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Prior treatment with ibrutinib is not exclusionary for subjects on any study arm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Anti LAG-3 targeted agent (Arm E)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "CC-99282 (Arm F)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Presence of acute or chronic graft-versus-host disease (GVHD)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Presence of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Active hepatitis B or active hepatitis C infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "History of or active human immunodeficiency virus (HIV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Uncontrolled bacterial, viral or fungal infection at the time of leukapheresis, lymphodepleting chemotherapy or JCAR017 infusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Any history of myocarditis (Arm E); history of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease (all arms)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Subjects with active CNS or cerebrospinal fluid (CSF) involvement by malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Pregnant or nursing (lactating) women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Subjects with active auto immune disorders/processes or active neurological or inflammatory disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "For subjects to receive oral combination therapy (Arms B, C, D or F): History of a gastrointestinal (GI) condition or procedure that in the opinion of the investigator may affect oral drug absorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Progressive tumor invasion of venous or arterial vessels.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "Deep venous thrombosis (DVT)/pulmonary embolism (PE) not managed on a stable regimen of anticoagulation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Part A only",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Patients must have advanced malignant solid tumours that are metastatic or unresectable",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "At least one measurable or evaluable (non-measurable) lesion per RECIST 1.1 Part B only",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Patients must have: or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "measurable disease per RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "diagnosis of one of the following",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Advanced Non-Small Cell Lung Cancer -Squamous Histology (NSCLC-SQ) with no more than 2 lines of chemotherapy for advanced/metastatic disease ( prior EGFR directed treatment is permitted) or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (R/M SCCHN) no more than 2 lines of chemotherapy for advanced disease and no more than 1 line of prior cetuximab permitted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Other malignant solid tumours except sarcomas (for metastatic colorectal cancer, only wild type KRAS are permitted) Part A and B",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Age 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Written informed consent that is consistent with ICH-GCP guidelines and local law.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Histological/Cytological confirmed diagnosis of malignant solid tumours (exclusion of sarcomas)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Advanced disease for whom standard treatment is ineffective or no longer effective",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Recovered from previous therapy related AE to </= Grade 1 at the study entry (except, for stable sensory neuropathy </= Grade 2 and alopecia)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Adequate organ function as defined by the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "LVEF >50% or within institutional values",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Absolute neutrophil count (ANC) >1500/ mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Platelet count >75.000/ mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Estimated creatinine clearance > 45ml/ min",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Total bilirubin<1.5 times upper limit of institutional normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Aspartate amino transferase (AST) or alanine amino transferase (ALT) <3 x upper limit of institutional normal (ULN) (if related to liver metastases< 5xULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Chemotherapy, biological therapy or investigational agents within 4 weeks prior to the start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Hormonal anti-cancer treatment within 2 weeks prior to the start of study treatment (continued use of anti-androgens and/or gonadorelin analogues [LHRH] is permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Radiotherapy within 4 weeks prior to the start of study treatment, except as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to study treatment, and",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Major surgery (as judged by the investigator) within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Known hypersensitivity to afatinib or the excipients of any of the trial drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior start treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Female patients of childbearing potential who:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "are nursing or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "are pregnant or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "are not using an acceptable method of birth control or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Requiring treatment with any of the prohibited concomitant medications listed in the protocol that can not be stopped for the duration of trial participation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Known pre-existing interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Active hepatitis B infection (defined as presence of HepB sAg and/ or Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Prior participation in an afatinib clinical study, even if not assigned to afatinib treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Meningeal carcinomatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids or have been on stable dose of corticosteroids for at least 4 weeks before starting study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Any SPC listed contra-indications for cetuximab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "Use of alcohol or drugs incompatible with patient participation in the study in the investigator's opinion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "At Screening and pre-inoculation with the malaria challenge agent: normal standard mean of triplicate 12-lead electrocardiogram (ECG) parameters after 10 minutes resting in supine position in the following ranges:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Having given written informed consent prior to undertaking any study-related procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Male or female aged between 18 to 55 years inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Available for the duration of the study and for 2 weeks following the End of Study Visit (EOS).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Lives with a spouse, family member, or housemate from the time of inoculation with the malaria challenge agent through to the EOS.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Total body weight greater than or equal to 50 kg, and a body mass index (BMI) within the range of 18 to 32 kg/m2 (inclusive).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Willing to defer blood donations to a blood service for a minimum of 6 months after the EOS.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Heterosexual women of childbearing potential (WOCBP) must agree to the use of a highly effective method of birth control (see below) combined with a barrier contraceptive from the screening visit until 30 days after the last dose of the IMP (covering a full menstrual cycle of 30 days starting after 5 half-lives of last dose of IMP) and have a negative result on urine pregnancy test performed before inoculation with the malaria challenge agent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Women of non-childbearing potential (WONCBP)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Males who have, or may have female sexual partners of child bearing potential during the course of the study must agree to use a double method of contraception including condom plus diaphragm, or condom plus intrauterine device, or condom plus stable oral/transdermal/injectable/implantable hormonal contraceptive by the female partner, from the time of informed consent through to 60 days (covering a spermatogenesis cycle) after the last dose of the IMP. Abstinent males must agree to start a double method if they begin sexual relationship with a female during the study and up to 60 days after the last dose of study drug. Males with female partners of child-bearing potential that are surgically sterile, or males who have undergone sterilisation and have had testing to confirm the success of the sterilisation, may also be included and will not be required to use above described methods of contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Vital signs after 5 minutes resting in supine position:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Systolic blood pressure (SBP) - 90-140 mmHg,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Diastolic blood pressure (DBP) - 40-90 mmHg,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Heart rate (HR) 40-100 bpm.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "QT ≤ 500 msec,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "QT Interval Corrected Using Fridericia's Formula (QTcF) QTcF ≤ 450 msec, QT Interval Corrected Using Bazett's Formula (QTcB) QTcB ≤ 450 msec",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "PR interval ≤ 210 msec for both males and females, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Normal ECG tracing unless the Principal Investigator or delegate considers an ECG tracing abnormality to be not clinically relevant. 12. In the opinion of the Principal Investigator or delegate, the individual has a high probability of adherence with and completion of the study, and willing and able to withdraw and refrain from restricted medications. 13. Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination). 14. Fluent in English and able to understand and comply with written and verbal protocol-related requirements. 15. Agrees to adhere to the lifestyle considerations throughout the study (see Section 4.3.3) and is willing to consume 240 mL full-fat milk with each dose of rescue medication Riamet®. Exclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Any lifetime history of malaria or participation in a previous malaria challenge study or malaria vaccine trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Must not have had malaria exposure that is considered significant by the Principal Investigator or delegate. This includes but is not limited to:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "history of having travelled to or lived (> 2 weeks) in a malaria-endemic region during the past 12 months or planned travel to a malaria-endemic region during the course of the trial;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "history of having lived for >1 year in a malaria-endemic region in the past 10 years;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "history of having ever lived in a malaria-endemic region for more than 10 years inclusive. For endemic regions see https://malariaatlas.org/explorer/#/ Bali is not considered a malaria-endemic region.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Presence of acute infectious disease and/or abnormal body temperature (defined as an a.m. tympanic temperature >37.5 ºC or a p.m. >37.7 ºC) at pre-inoculation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Haematology, biochemistry or urinalysis results that are outside of the laboratory normal reference ranges and are either:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "considered clinically significant by the Principal Investigator or delegate; OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "considered not clinically significant by the Principal Investigator or delegate but are also outside of Sponsor-approved clinically acceptable laboratory ranges",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Breastfeeding or lactating; positive serum pregnancy test at screening, positive urine pregnancy test upon admission or at other timepoints as specified by schedule of activities tables.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Has previously received a blood transfusion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Use of antibiotics within 6 weeks of Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Use of systemic therapies with antimalarial activity within 6 weeks of Screening. This includes (but not limited to) artemisinin, amodiaquine, atovaquone, chloroquine, mefloquine, mepacrine, primaquine, proguanil, quinine, sulfadoxine-pyrimethamine, benzodiazepine, flunarizine, fluoxetine, tetracycline, azithromycin, clindamycin, doxycycline, and tafenoquine.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Prior to screening and inoculation with the malaria challenge agent:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "any systemic administration (oral, pulmonary/nasal, IV) of corticosteroids, anti-inflammatory drugs (excluding commonly used over-the-counter anti-inflammatory drugs such as ibuprofen, acetylsalicylic acid, diclofenac), immunomodulators or anticoagulants within the past three months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Ibuprofen (preferred) may be used at doses of up to 1.2 g/day, or paracetamol at doses of up to 2 g/day after discussion with the Investigator. Limited use of other non-prescription medications or dietary supplements, not believed to affect subject safety or the overall results of the study, may be permitted on a case-by-case basis following approval by the Sponsor in consultation with the Investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Any topical administration (cutaneous, eye drops) of corticosteroids within the past 2 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Any individual currently receiving or having previously received immunosuppressive therapy (including systemic steroids, adrenocorticotrophic hormone or inhaled steroids) at a dose or duration potentially associated with hypothalamic-pituitary-adrenal axis suppression within the past 12 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Any contra-indication to rescue medication according to the applicable labelling and if found to be severely glucose-6-phosphate dehydrogenase (G6PD) deficient at screening (i.e. activity of less than 10% as per World Health Organization (WHO) definition).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic/ gallbladder*/ bile duct, renal, metabolic, haematological, neurological, musculoskeletal, rheumatologic, systemic, ocular, gynaecologic (if female), infectious or autoimmune disease, or signs of acute illness. *including medical history of asymptomatic gallbladder stones.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "History of recurrent headache (eg, tension-type, cluster or migraine) with a frequency of ≥2 episodes per month on average and severe enough to require medical therapy. History of recurrent nausea and/or vomiting (for vomiting only: more than twice a month).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Asthma (excluding childhood asthma, or mild asthma with preventative asthma medication required less than monthly and no event requiring treatment in the last 2 weeks prior to screening).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Any personal history of surgical procedures that may affect IMP absorption, distribution (i.e. GI surgery) and metabolism or immune response to malaria inoculation (splenectomy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Blood donation of any volume within one month before screening, or participation in any research study involving blood sampling (more than 450 mL/unit of blood).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Any documented evidence of current or past cardiovascular disease including:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "cardiac arrhythmias or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "family history of congenital long QT syndrome, Brugada syndrome, or unexplained sudden cardiac death.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Symptomatic postural hypotension at screening irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥20 mmHg within 3 min when changing from supine to standing position.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Has evidence of increased cardiovascular risk (defined as >10%, 5-year risk for those greater than 35 years of age, as determined by the Australian Absolute Cardiovascular Disease Risk Calculator (http://www.cvdcheck.org.au). Risk factors include sex, age, systolic blood pressure (mm/Hg), smoking status, total and High-density lipoprotein (HDL) cholesterol (mmol/L) and reported diabetes status. Note: The site investigator will perform cardiovascular risk calculation once all assessments have been performed, prior to eligibility.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "History or presence of diagnosed (by an allergist/immunologist) or treated (by a physician) food or known drug allergies, or any history of anaphylaxis or other severe allergic reactions including face, mouth, or throat swelling or any difficulty breathing. Individuals with known lactose or dairy intolerance are excluded. Volunteers with seasonal allergies/hay fever or allergy to animals or house dust mite that are untreated and asymptomatic at the time of dosing can be enrolled in the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "History of convulsion (including drug or vaccine-induced episodes). A medical history of a single febrile convulsion during childhood is not an exclusion criterion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "History of substance use disorder(s) within 5 years of screening and/or history of alcohol dependancy and/or any prior intravenous use of an illicit substance.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Smoked > 1 pack of cigarettes per day for > 10 years, or who currently (within 14 days prior to screening) smokes > 5 cigarettes per day.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Any individual who, in the judgement of the Principal Investigator or delegate, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Any individual who cannot be contacted in case of emergency.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Any individual who is the Investigator, or delegates, research assistant, pharmacist, study coordinator, project manager, or other staff thereof, directly involved in conducting the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Any individual without a good peripheral venous access.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Participation in any investigational product study within the 12 weeks preceding inoculation with the malaria challenge agent or 5 times the half-life of the Investigational product, whichever is longer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Positive serology test for hepatitis B (HB) (positive Hepatitis B surface antigen (HB sAG) or anti-hepatitis B core antibody (anti-HBc Ab), hepatitis C (anti-HCV) or human immune deficiency virus (HIV) (positive for anti-HIV1 (HIV type 1) and anti-HIV2 (HIV type 2) Ab ).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Positive urine drug test at Screening, prior to inoculation with the malaria challenge agent or prior to IMP dosing. Any drug from the list of drugs tested (such as amphetamine, barbiturates, benzodiazepines, cocaine, methamphetamine, methadone, Opiates, phencyclidine, Tetrahydrocannabinol; and their metabolites) unless there is an acceptable explanation to the Principal Investigator or delegate (eg, volunteer has stated in advance that they consumed a prescription of over the counter product which contained the detected drug) and/or the volunteer has a negative urine drug screen on retest.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Positive alcohol screen at Screening, prior to inoculation with the malaria challenge agent or prior to IMP dosing.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Any consumption of citrus fruits (such as grapefruit, Seville oranges) or their juices within 7 days prior to IMP administration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "History of serious psychiatric condition that may affect participation in the study or preclude compliance with the protocol, including but not limited to: past or present psychoses, disorders requiring lithium, a history of attempted or planned suicide, more than one previous episode of major depression, any previous single episode of major depression lasting for or requiring treatment for more than 6 months, or any episode of major depression during the 5 years preceding screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer considered treated and cured), treated or untreated, within 5 years of Screening, regardless of whether there is no evidence of local recurrence or metastases.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Any vaccination within 28 days of screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05205941",
    "statement": "Any medical condition that in the opinion of the Principal Investigator or delegate would jeopardize the individual's involvement in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03462615",
    "statement": "Presence of symptoms and signs of other serious chronic disease such as severe anaemia, tuberculosis and/or central nervous system infections, as defined by WHO guidelines",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03462615",
    "statement": "All women must meet all the following inclusion criteria in order to be eligible to participate in the study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03462615",
    "statement": "Pregnant women attending first antenatal care visit at selected health facilities",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03462615",
    "statement": "Resident in the study area for at least 1 year prior to enrolment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03462615",
    "statement": "Age ≥ 16",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03462615",
    "statement": "Willing to freely participate with signed informed consent (or, if illiterate, provide a thumbprint in the presence of an independent witness)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03462615",
    "statement": "Willing to provide finger-prick blood sample",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03462615",
    "statement": "Women meeting any of the following exclusion criteria at screening will be excluded from study participation:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03462615",
    "statement": "History of malaria or antimalarial drugs used in the last three months, as recalled or documented in health record",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03462615",
    "statement": "Presence of severe malaria as defined by WHO guidelines at the moment of recruitment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has a histologically or cytologically confirmed diagnosis of metastatic squamous or nonsquamous Non-Small Cell Lung Cancer (NSCLC) -Stage IV: M1a, M1b, M1c.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has PD during/after platinum doublet chemotherapy for metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has confirmation that EGFR-, ALK-, or ROS1-directed therapy is not indicated as primary therapy (documentation of absence of tumor-activating EGFR mutations [eg, DEL19 or L858R], and absence of ALK and ROS1 gene rearrangements OR presence of a K-ras mutation).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has submitted pre-study imaging that confirmed evidence of PD following initiation of an anti-PD-1/PD-L1 inhibitor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has at least 1 measurable lesion by computerized tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, as determined by the local site assessment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has provided tumor tissue for PD-L1 biomarker analysis from an archival sample (defined as: from initial diagnosis of NSCLC and prior to receiving immunotherapy [antiPD-1/PD-L1], from the primary lesion or a metastatic lesion).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has provided prior to allocation tissue from a newly obtained formalin-fixed sample from a new biopsy (defined as: after completion of immunotherapy [anti-PD-1/PD-L1] and before receiving a randomization number), of a tumor lesion not previously irradiated.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose of study intervention but before randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has a life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Male participants receiving pembrolizumab ± lenvatinib or lenvatinib must agree to refrain from donating sperm, and either 1) be abstinent from heterosexual intercourse; or 2) follow contraceptive guidance during the treatment period or 7 days after the last dose of lenvatinib. Male participants receiving docetaxel agree to adhere to the same conditions during the treatment period and for ≥90 days after the last dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Female participants must not be pregnant, not be breastfeeding, and not be a woman of child-bearing potential (WOCBP). If a WOCBP, agrees to not donate eggs and either use contraception, or be abstinent from heterosexual intercourse during the treatment period and for ≥120 days after the last dose of pembrolizumab or 30 days after the last dose of lenvatinib, whichever occurs last. If a WOCBP receiving docetaxel, agrees to adhere to the same conditions during the treatment period and for ≥30 days after the last dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications within 1 week before randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "If participant received major surgery or radiation therapy of >30 Gy, they have recovered from the toxicity and/or complications from the intervention.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has received docetaxel as monotherapy or in combination with other therapies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has received lenvatinib as monotherapy or in combination with an anti-PD-1/PD-L1 mAb.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has received: 1) radiotherapy within 2 weeks before the first dose of study treatment; or 2) lung radiation therapy >30 Gy within 6 months before the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has received a live vaccine within 30 days before the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has clinically significant hemoptysis or tumor bleeding within 2 weeks before the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has radiographic evidence of intratumoral cavitation, encasement, or invasion of a major blood vessel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has clinically significant cardiovascular impairment within 12 months of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has a history of a gastrointestinal condition or procedure that may affect oral absorption of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has a pre-existing ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Is currently participating in a clinical trial and receiving study therapy or participated in a study of an investigational agent within 4 weeks of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of disease recurrence for 3 years since initiation of that therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has known active central nervous system metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has severe hypersensitivity to pembrolizumab and/or any of its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has a sensitivity to any of the excipients contained in lenvatinib and/or docetaxel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has an active autoimmune disease that has required systemic treatment in the past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has a history of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has an active infection requiring systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has a known history of human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has a known history of hepatitis B reactive or known active hepatitis C virus infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has active tuberculosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through at least 120 days after the last dose of pembrolizumab or lenvatinib, or 90 days (male participants) or 30 days (for female participants) after the last dose of docetaxel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "Has had an allogeneic tissue/solid organ transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Adults and children ≥ 20 kg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Symptomatic of malaria infection, i.e. history of fever within 24 hours and/or presence of fever >37.5°c.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Microscopic confirmation of asexual stages of P. falciparum (P. falciparum and mixed infection in Pailin only)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Capability of taking an oral medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Written informed consent given to participate in the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Willingness and ability to adhere to follow-up visit schedule",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Pregnancy or lactation (urine test for β HCG to be performed on any woman of child bearing age, that is 18 to 45 y/o)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Female aged 12-18y",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Parasitemia > 150 000/µL).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Signs or symptoms indicative of severe malaria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Impaired consciousness (Blantyre Coma Score <5)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Severe anaemia (Hct<15%)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria, bleeding from venepuncture sites",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Respiratory distress",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Severe jaundice",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Known hypersensitivity to artemisinins - defined as history of erythroderma/other severe cutaneous reaction, angioedema or to pyronaridine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "History of splenectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Known history or evidence of clinically significant disorders, such as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Known active Hepatitis A, e.g. by detection of anti HAV-IgM.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Known hepatitis B surface antigen (HBsAg) carrier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Known hepatitis C antibody (HCV Ab).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Liver function tests (AST/ALT levels) more than 2.5 times the upper limit of normal range.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05223933",
    "statement": "None (Non-resident present at the time of passage were tested in the study if they have suggestive signs of malaria but they were considered as visitors)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05223933",
    "statement": "Inclusion criteria in community:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05223933",
    "statement": "Fokontany in rural communes of Mananjary district (fokontany level of safety, accessibility by the study teams, and phone network availability was assessed).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05223933",
    "statement": "Agreement of the chief of Fokontany for the participation of his fokontany in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05223933",
    "statement": "Fokontany with at least 1,000 inhabitants",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05223933",
    "statement": "Individual inclusion criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05223933",
    "statement": "Resident in the relevant areas during the study period and consenting to participate",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05223933",
    "statement": "Exclusion criteria in community:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05223933",
    "statement": "Fokontany with a total population of less than 1000 inhabitants",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05223933",
    "statement": "Fokontany in an urban commune",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05223933",
    "statement": "Fokontany in an area whose access is risky and perilous",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05223933",
    "statement": "Individual exclusion criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Healthy adults (male or non-pregnant, non-lactating female) 18 to 55 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Able to provide free and willing written informed consent to participate;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "A score at least 80% correct on a 10 question Assessment of Understanding;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "No plans to travel to a malaria endemic area during the course of the study;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Duffy positive phenotype;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Normal (non-deficient) G6PD phenotype (range : 4.6 to 13.5 u/gm hemoglobin);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Free of significant health problems as established by medical history and clinical examination completed prior to the study;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Available to participate and reachable by phone for duration of study (approximately 9 months starting from screening).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Only subjects with no or low cardiac risk factors according to the Gaziano study and a normal EKG will be included in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Pregnant or nursing at screening or plans to become pregnant or nurse from the time of enrollment until 6 months after sporozoite challenge;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Duffy negative phenotype;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "G6PD deficiency or have any hemoglobinopathy by history;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Past infection with any species of malaria (as demonstrated by a positive thick smear) in the last 5 years;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "History of receipt of treatment or prophylaxis for malaria during the previous 6 months;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "History of receipt of malaria vaccine within the previous 5 years;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "History of receipt of malaria challenge (being bitten by experimentally infected mosquitoes) within the previous 5 years;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Plans to travel to malarious areas during the study period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Allergy to antimalarials or significant (e.g. systemic) hypersensitivity reactions to mosquito bites (local hypersensitivity reactions at the site of a mosquito bite are not an exclusion criterion);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "History of psoriasis (given its interaction with chloroquine);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Use of any investigational or non-registered drug or vaccine within 30 days preceding the challenge or planned use during the study period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Use or planned use of any drugs with significant anti-malarial activity, such as doxycycline, clindamycin, azithromycin, during the study period (volunteers can withhold the use of these medications during the study period, at the minimum starting from 4 weeks before the challenge until 4 weeks after becoming parasitemic);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection and history of splenectomy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying drugs within six months of challenge;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "For corticosteroids, this is defined as prednisone, or equivalent, 0.5 mg/kg/day;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Inhaled and topical steroids are allowed;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "A family history of congenital or hereditary immunodeficiency;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Chronic or active neurologic disease including seizure disorder;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by medical history, physical examination, or abnormal baseline laboratory screening tests:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "ALT above normal range (table 9);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Creatinine above normal range (table 9);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Hemoglobin below normal range (table 10);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Platelet count below normal range (table 10);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Total white cell count below normal range (table 10);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Acute disease at the time of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Acute disease is defined as the presence of a moderate or severe illness with or without fever;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Challenge can be administered to persons with a minor illness, such as diarrhea or mild upper respiratory infection without fever (i.e., oral temperature < 38°C/100.4°F);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Hepatomegaly, right upper quadrant abdominal pain or tenderness;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Seropositive for HIV, hepatitis C virus (antibodies to HIV and HCV), and/or HBsAg;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Administration of immunoglobulins and/or any blood products within the 3 months preceding challenge or planned administration during the study period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Suspected or known current alcohol abuse/drug abuse as obtained by history and physical examination;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Inability to make follow-up visits;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Exclusion criteria on day of CHMI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "The following constitute absolute contraindications to CHMI:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Healthy adult aged 18 to 45 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Red blood cells positive for the Duffy antigen/chemokine receptor (DARC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Normal serum levels of Glucose-6-phosphate dehydrogenase (G6PD).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Negative haemoglobinopathy screen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Able and willing (in the Investigator's opinion) to comply with all study requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Willing to allow the Investigators to discuss the volunteer's medical history with their General Practitioner.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Women only: Must practice continuous highly effective contraception* for the duration of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Agreement to permanently refrain from blood donation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Written informed consent to participate in the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Reachable (24/7) by mobile phone during the period between CHMI and completion of all antimalarial treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Willing to take a curative anti-malarial regimen following CHMI.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Willing to reside in Oxford for the post-challenge period, until antimalarials have been completed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Answer all questions on the informed consent quiz correctly at first or second attempt",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Female volunteers are required to use a highly effective form of contraception during the course of the study as malaria challenge could pose a serious risk to both maternal health and the unborn foetus.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "History of clinical malaria (any species).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Travel to a clearly malaria endemic locality during the study period or within the preceding six months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Use of systemic antibiotics with known antimalarial activity within 30 days of CHMI (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Use of anti-malarials within 30 days of CHMI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Weight less than 50kg, as measured at the screening visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Receipt of immunoglobulins within the three months prior to planned administration of the vaccine candidate.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Receipt of blood products (e.g., blood transfusion) at any time in the past.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Peripheral venous access unlikely to allow twice daily blood testing (as determined by the Investigator).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Receipt of any vaccine in the 30 days preceding enrolment, or planned receipt of any other vaccine within 30 days preceding or following each study vaccination, with the exception of licensed COVID-19 vaccines, which should not be received between 14 days before to 7 days after any study vaccination",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Planned receipt of a COVID-19 vaccine between 2 weeks before the day of CHMI until completion of antimalarial treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Concurrent involvement in another clinical trial or planned involvement during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data or the P. vivax parasite as assessed by the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "History of allergic disease or reactions likely to be exacerbated by any component of the vaccine e.g. egg products, Kathon",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "History of allergic disease or reactions likely to be exacerbated by malaria infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "History of clinically significant contact dermatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Any history of anaphylaxis in reaction to vaccinations",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Pregnancy, lactation or intention to become pregnant during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Use of medications known to cause prolongation of the QT interval and existing contraindication to the use of Malarone.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Use of medications known to have a potentially clinically significant interaction with Riamet and Malarone.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Any clinical condition known to prolong the QT interval.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "History of cardiac arrhythmia, including clinically relevant bradycardia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Disturbances of electrolyte balance, e.g. hypokalaemia or hypomagnesaemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Family history of congenital QT prolongation or sudden death.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Contraindications to the use of both of the proposed anti-malarial medications; Riamet Malarone.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "History of serious psychiatric condition that may affect participation in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Any other serious chronic illness requiring hospital specialist supervision.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 25 standard UK units every week.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Suspected or known injecting drug abuse in the 5 years preceding enrolment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Hepatitis B surface antigen (HBsAg) detected in serum.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Seropositive for hepatitis C virus (antibodies to HCV) at screening or (unless has taken part in a prior hepatitis C vaccine study with confirmed negative HCV antibodies prior to participation in that study, and negative HCV RNA PCR at screening for this study).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Positive family history in both 1st AND 2nd degree relatives < 50 years old for cardiac disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Volunteers unable to be closely followed for social, geographic or psychological reasons.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination. In the event of abnormal test results, confirmatory repeat tests will be requested. Procedures for identifying laboratory values meeting exclusion criteria are shown in SOP VC027.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Inability of the study team to contact the volunteer's GP to confirm medical history and safety to participate",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Acute disease, defined as moderate or severe illness with or without fever",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Current COVID-19 infection, defined as ongoing symptoms with positive COVID-19 PCR swab test taken during current illness or positive COVID-19 PCR swab test within preceding 14 days without symptoms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04201431",
    "statement": "Pregnancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "All of the following criteria must be fulfilled for a volunteer to participate in this trial:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "A volunteer will be excluded from participating in this trial if any one of the following criteria is fulfilled:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "INCLUSION CRITERIA:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Age between 18 and 50 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Good general health as a result of review of medical history and/or clinical testing at the time of screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Available for the duration of the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Willingness to participate in the study as evidenced by signing the informed consent document.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "If female: subject is willing to use reliable contraception methods for the period of at least 1month (2 months for oral contraceptive pills) prior to first vaccination to 3 months after last vaccination. Reliable methods of birth control include: pharmacologic contraceptives including oral, parenteral, and transcutaneous delivery; condoms with spermicide; diaphragm with spermicide; surgical sterilization; vaginal ring; transdermal patch; intrauterine device; abstinence; and post-menopause.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Pregnancy as determined by a positive urine or serum human choriogonadotropin (Beta-hCG) test at any point during the study (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Currently is lactating and breast-feeding (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the participant to understand and cooperate with the study protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Neutropenia as defined by an absolute neutrophil count < 1500/mm(3).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Alanine transaminase (ALT) level above the laboratory-defined upper limit of normal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Other condition that in the opinion of the investigator would jeopardize the safety or rights of a participant participating in the trial or would render the subject unable to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "History of receiving any investigational product within the past 30 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Receipt of antimalarial prophylaxis during the past 12 months, or planned travel to a destination which would require malaria prophylaxis during the period of participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Prior malaria infection by history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Participant has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "History of a severe allergic reaction or anaphylaxis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Severe asthma. This will be defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past 2 years, or that requires the use of oral or parenteral corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Clinically significant reactive airway disease that does not respond to bronchodilators.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Positive ELISA and confirmatory Western blot tests for HIV-1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Positive ELISA and confirmatory tests for hepatitis C virus (HCV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Positive hepatitis B surface antigen (HBsAg) by ELISA.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, or autoimmune thrombocytopenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Known immunodeficiency syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Use of chronic (greater than or equal to 14 days) oral or intravenous corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e. prednisone > 10 mg/ day) or immunosuppressive drugs within 30 days of starting this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Receipt of a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks prior to entry into the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "History of a surgical splenectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Receipt of blood products within the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Previous receipt of an investigational malaria vaccine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Refusal to allow storage of samples for future research.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01434381",
    "statement": "Any medical, psychiatric, social, or occupational condition or other responsibility that, in the judgment of the Principal Investigator (PI), would interfere with the evaluation of study objectives.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "In addition, the following individuals will be excluded from receiving primaquine:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "Woreda-level: Of the 19 woredas with malaria risk, the ten woredas with the highest annual parasite incidence (API) in 2018 will be eligible for the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "For Kebeles:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "Kebeles in East Hararghe Zone targeted for implementation of elimination activities by the Ethiopian Federal Ministry of Health where there is ongoing PMI-supported malaria surveillance;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "Kebeles with reported API between 1 and 50;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "Kebeles in malarious districts with comparable optimization of malaria control interventions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "For individual participants:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "All residents of the intervention study kebeles diagnosed with malaria at health facilities (index case) or reside within 100-meter radius with the index case and has NONE of the exclusion criteria listed below",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "Able to provide informed written consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "For kebeles: Kebeles planning on starting for the first time or discontinuing indoor residual spraying (IRS) campaigns in the next two years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "For individual participants:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "Children less than 6 months of age or <5 kg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "Known allergy or history of adverse reaction or chronic/congenital disease contra indicated to any of the intervention drugs: PQ, AL or CQ",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "Individuals with severe malnutrition or signs of severe disease, with evidence of any organ failure or Hgb level < 8gm/dl",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "Household members already covered by the intervention less or equal to one month before",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "Phenotypically G6PD deficient individuals",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "Pregnant women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04241705",
    "statement": "Lactating women breastfeeding infants less than 6 months of age or with unknown G6PD status",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "All of the following criteria must be fulfilled for a subject to participate in this trial:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "CATEGORY 1:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "IN ADDITION TO",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "CATEGORY 2:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "-a barrier method to be used at the time of potentially reproductive sexual activity (e.g.\n[male/female condom, 'cap,' or diaphragm] plus spermicide).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "A subject will be excluded from participating in this trial if any one of the following criteria is fulfilled:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "INCLUSION CRITERIA:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Age greater than or equal to 18 and less than or equal to 50 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "In good general health and without clinically significant medical history",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Malaria comprehension exam completed, passed (a score of greater than or equal to 80% or per investigator s discretion) and reviewed prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Reliable access to the clinical trial center and availability to participate for duration of study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Females of childbearing potential must be willing to use reliable contraception (as defined below) from 21 days prior to study day -2 to 28 days following last Sanaria .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Subject to the judgment and discretion of the PI, female participants who meet ANY ONE of the criteria listed immediately below, may not be required to take any additional measures to avoid pregnancy. Such participants will be counseled on risks at the time of consent and at appropriate points (e.g. when pregnancy testing occurs) during the study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Females who have had their uterus, and/or BOTH ovaries removed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Females who have had BOTH fallopian tubes surgically tied or removed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Females who are above the age of 45 and have spontaneously had no menses at any point during the past 12 or more consecutive months (i.e. have reached menopause)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Females who, in the conservative and reasonable judgment of the PI (e.g. due to sexual orientation or serious life choice (such as being celibate clergy or transgender), during the entire trial will NOT participate in any potentially reproductive sexual contact",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Females who, in the conservative and reasonable judgment of the PI, are in a monogamous stable relationship with a male who has undergone vasectomy at least 4 months prior or another procedure/medical condition that deems the male sterile",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Subject to the judgment and discretion of the PI, female participants who DO NOT meet ANY of the criteria listed above, will be appropriately counseled on reproductive risks and pregnancy avoidance, and will be required to adhere to the following measures and agree to 2 methods of pregnancy prevention as noted below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "a highly effective hormonal method to prevent pregnancy [e.g. CONSISTENT, CONTINUOUS use of contraceptive pill, patch, ring, implant or injection], and/or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "IUD or equivalent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Currently is breast-feeding (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Pregnancy as determined by a positive urine or serum human choriogonadotropin (beta-hCG) test at any point during the study (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Recent travel to a malaria endemic area within 5 years of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Planned travel to a malaria endemic area during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "History of confirmed malaria diagnosis on peripheral blood smear or by clinical history in the past 10 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Hemoglobin, WBC, platelets, ALT, and creatinine outside of local lab normal range (subjects may be included at the investigator s discretion for not clinically significant values outside of normal range)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Abnormal urinalysis as defined by positive urine glucose, protein, and hemoglobin. Subject can be included if investigator determine the abnormality is not clinically significant .",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Anticipated use during the study period, or use within the following periods prior to enrollment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Investigational malaria vaccine within the last five years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Malaria chemoprophylaxis within 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Chronic systemic immunosuppressive medications (>14 days) within 6 months (e.g.cytotoxic medications, oral/parental corticosteroids >0.5 mg/kg/day prednisone or equivalent). Corticosteroid nasal spray for allergic rhinitis and topical corticosteroids for mild, uncomplicated dermatitis are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Blood products or immunoglobulins within 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Systemic antibiotics with antimalarial effects within 30 days (such as clindamycin, doxycycline)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Investigational or non-registered product or vaccine within 30 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Receipt of a live vaccine within 28 days or a killed vaccine within the 14 days prior to Sanaria PfSPZ Challenge",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Medications known to interact with pyrimethamine, chloroquine, atovaquone, proguanil (during the study period only)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "History of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Sickle cell disease, sickle cell trait, or other hemoglobinopathies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Splenectomy or functional asplenia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Systemic anaphylaxis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Any allergic reactions to study drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Documented history of chronic or active neurologic disease (including seizures, uncontrolled migraine headaches)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Psoriasis or porphyria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Ocular diseases including retinopathy or visual field defects",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Clinically significant medical condition, physical examination findings, other clinically significant abnormal laboratory results, or past medical history that may have clinically significant implications for current health status and participation in the study in the opinion of the Investigator. A clinically significant condition or process includes but is not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "A process that would affect the immune response, or requires medication that affects the immune response",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Any contraindication to repeated phlebotomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "A condition or process in which signs or symptoms could be confused with reactions to malaria challenge and/or infection, including dermatologic abnormalities at the site of sporozoite inoculation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "A chronic or subclinical condition which could be exacerbated by administration of any of the PfSPZ-CVac components or malaria infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Weight > 77.2 Kg at the time of screening (this will result in a minimum dose of pyrimethamine of approximately 0.7mg/Kg for a 50mg daily dose). (Note not required for Arm 4 CHMI controls)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "History of, or known active cardiac disease including: (1) prior myocardial infarction (heart attack); (2) angina pectoris; (3) congestive heart failure; (4) valvular heart disease; (5) cardiomyopathy; (6) pericarditis; (7) stroke or transient ischemic attack; (8) exertional chest pain or shortness of breath; or ( 9) other heart conditions under the care of a doctor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Clinically significant ECG findings, as determined by the expert study cardiologist",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Moderate or high risk for coronary heart disease (CHD) based on NHANES I cardiovascular risk assessment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Acute illness at the time of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Infection with HIV, Hepatitis B, Hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Psychiatric condition that precludes compliance with the protocol including but not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Psychosis within the past 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Suspected or known current alcohol or drug abuse as defined by the American Psychiatric Association in the DSM V at the discretion of the PI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Clinical trial staff and/or Sanaria employees with direct involvement in the conduct of the trial are excluded from participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Participating in other clinical trials involving investigational interventions or off label medication use during the study period (excluding participation in the optional long term follow up visits). Participation in other trials such as observational or imaging studies will be discussed with the investigators.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Any other finding that, in the judgment of the Investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a subject s ability to give informed consent, or increase the risk of having an adverse outcome from participating in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780712",
    "statement": "Inclusion Criteria for the sepsis risk group (400 infants):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780712",
    "statement": "Inclusion Criteria for the control group (170 infants):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780712",
    "statement": "- Child born from mothers enrolled in the RECIPAL study (Pregnancy-associated malaria and Intrauterine growth restriction in Benin)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780712",
    "statement": "Exclusion Criteria for both groups:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780712",
    "statement": "Child born from mothers having one of the following criteria before delivery will be included in this study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780712",
    "statement": "Spontaneous preterm delivery (<37 weeks of gestation time)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780712",
    "statement": "Foul smelling / with meconium / colored / bloody amniotic liquid",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780712",
    "statement": "Rupture of membranes > 18 hours",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780712",
    "statement": "Maternal fever at delivery",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780712",
    "statement": "Vaginal infection",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780712",
    "statement": "Child born at the maternity of CNHU (Centre National Hospitalier et Universitaire, Cotonou, Benin) or CHUMEL (Centre Hospitalier et Universitaire de la Mère et de l'Enfant Lagune, Cotonou, Benin) or HZAC (Hopital de zone d' Abomey-Calavi, Benin).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780712",
    "statement": "Mother located near Abomey-Calavi. This criterion has been included to limit the follow-up expenses and spare the travel to the project staff in charge of the 3 month follow-up.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780712",
    "statement": "HIV + status or unknown HIV status of the mother (as the mother and child will be part of the national program to take care of mother and child HIV+ at delivery)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780712",
    "statement": "Parents do not consent to be included in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Male or female patients between the age of 3 and 60 years, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Presence of acute uncomplicated P. falciparum mono-infection confirmed by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Fever, as defined by axillary/tympanic temperature ≥ 37.5°C or oral/rectal temperature ≥ 38°C, or documented history of fever in the previous 24 hours and,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Positive microscopy of P. falciparum with parasite density between 1,000 and 100,000 asexual parasite count/μl of blood.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Written informed consent, in accordance with local practice, provided by patient and/or parent/guardian/spouse.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Ability to swallow oral medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization Criteria 2000.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Mixed Plasmodium infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Severe vomiting or severe diarrhoea.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Known history or evidence of clinically significant disorders.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Presence of significant anaemia, as defined by Hb <8 g/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Presence of febrile conditions caused by diseases other than malaria.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Known history of hypersensitivity, allergic or adverse reactions to pyronaridine, lumefantrine or artesunate or other artemisinins.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Patients with known disturbances of electrolytes balance, e.g., hypokalaemia or hypomagnesaemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Use of any other antimalarial agent within 2 weeks prior to start of the study as evidenced by a positive urine test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Patients taking any drug which is metabolised by the cytochrome enzyme CYP2D6 (flecainide, metoprol, imipramine, amitriptyline, clomipramine).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Received an investigational drug within the past 4 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen. (HBsAg) or Hepatitis C antibody (HCV Ab).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Known seropositive HIV antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Liver function tests [ASAT/ALAT levels] >2.5 times the upper limit of normal range.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00422084",
    "statement": "Known significant renal impairment as indicated by serum creatinine >1.4 mg/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Females aged ≥18 and ≤49 years and weighing ≥ 45.0 and ≤ 90.0 kg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Males aged ≥18 and ≤49 years (no weight restrictions).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "In good general health and without clinically significant medical history.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Able to provide informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Willing to have blood samples and data stored for future research.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Resides in or near Kalifabougou, Faladje, or Torodo, Mali, and available for the duration of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Females of childbearing potential must be willing to use reliable contraception from 21 days prior to study Day 0 through the final study visit as described below.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Reliable methods of birth control include 1 of the following: confirmed pharmacologic contraceptives via parenteral delivery or intrauterine or implantable device.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Pregnancy, as determined by a positive urine or serum beta-human choriogonadotropin (β hCG) test (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Currently breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the participant to understand and comply with the study protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Study comprehension examination score of <80% correct or per investigator discretion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Hemoglobin, WBC, absolute neutrophil, or platelet count outside the local laboratory-defined limits of normal. (Participants may be included at the investigator's discretion for \"not clinically significant\" values.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory-defined upper limit of normal. (Participants may be included at the investigator's discretion for \"not clinically significant\" values.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Infected with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Known or documented sickle cell disease by history. (Note: Known sickle cell trait is NOT exclusionary.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Clinically significant abnormal electrocardiogram (ECG; QTc >460 or other significant abnormal findings, including unexplained tachycardia or bradycardia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Receipt of any investigational product within the past 30 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Participation or planned participation in an interventional trial with an investigational product until the last required protocol visit. [Note: Past, current, or planned participation in observational studies is NOT exclusionary; participation in the placebo arm of the Mali adult CIS43LS MAb trial (ClinicalTrials.gov Identifier: NCT04329104) or the placebo arm of the Mali adult L9LS Mab trial (ClinicalTrials.gov Identifier: NCT05816330) is NOT exclusionary.]",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "History of a severe allergic reaction or anaphylaxis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Severe asthma (defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, or autoimmune thrombocytopenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Salivary gland disorder diagnosed by a doctor (e.g., parotitis, sialadenitis, sialolithiasis, salivary gland tumors).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Known immunodeficiency syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Known asplenia or functional asplenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Use of chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone >10 mg/day) or immunosuppressive drugs within 30 days of day 0.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Receipt of a live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks prior to study agent administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Receipt of immunoglobulins and/or blood products within the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Previous receipt of an investigational malaria vaccine or MAb in the last 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Known allergies or contraindication against artemether lumefantrine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT07060508",
    "statement": "Other condition(s) that, in the opinion of the investigator, would jeopardize the safety or rights of a participant participating in the trial, interfere with the evaluation of the study objectives, or render the participant unable to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Healthy adults (males and non-pregnant, non-lactating females) between the ages of 18 and 45 years, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Able and willing to participate for the duration of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Able and willing to provide written (not proxy) informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Provides informed consent before any study procedures, correctly answers >/= 70% of questions on the post consent quiz and is available for all study visits.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Women of childbearing potential* must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to each vaccination and on the day of malaria challenge.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Not sterilized via bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or menopausal and still menstruating or < 1 year of the last menses.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Women of childbearing potential must have used an acceptable method of contraception* in the 30 days prior to enrollment and must agree to continue use of the same method throughout the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Includes, but is not limited to, abstinence from sex with men, monogamous relationship with vasectomized partner who has been vasectomized for 6 months or more prior to enrollment, barrier methods such as condoms or diaphragms with spermicide or foam, effective intrauterine devices, NuvaRing, successful Essure placement (permanent, non-surgical, non-hormonal sterilization) with documented confirmation test at least 3 months after the procedure, and licensed hormonal methods such as implants, injectables, or oral contraceptives.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Is in good health, as judged by the investigator, and determined by vital signs (heart rate, blood pressure, and oral temperature), medical history and physical examination.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Able to understand and comply with planned study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Reachable (24/7) by mobile phone during the whole study period and willing to provide two close contacts to assist with making contact.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Lives in the greater Seattle area and within an approximately one hour commute to the study research clinic.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Willing to avoid non-study related blood donation for 3 years following P. falciparum challenge.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Agrees not to travel to a malaria endemic region during the entire course of the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Agrees not to travel away from the greater Seattle area from the day of first study immunization through 20 days after the last study immunization, and during the 29 days after CHMI.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "History of malaria infection or vaccination, residence in a malaria-endemic area for > / =5 years, travel to a malaria-endemic area in the past 6 months, or participation in a malaria research study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Is breastfeeding or plans to breastfeed at any time throughout the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Plans to become pregnant at any time throughout the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Use of any antimalarial antibiotic or drug within 28 days prior to Study Day 1 or planned use during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Any clinically significant acute or chronic medical condition* or need for chronic medications** that, in the opinion of the investigator, will interfere with immunity or affect safety.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Includes, but is not limited to, disorders of the liver, kidney, lung, heart, or nervous system, or other metabolic or autoimmune/inflammatory conditions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Receipt of systemic, prescription medications for the treatment of chronic medical conditions or variations of normal physiologic functions are permissible if, in the opinion of the investigator, they are used for conditions that are not clinically significant and would not impact the effectiveness of the vaccine or the safety of the subject or the safety and immunogenicity outcomes of the protocol. Use of systemic, over-the-counter medications and PRN systemic, prescription medications are allowed if, in the opinion of the investigator, they pose no additional risk to subject safety, vaccine efficacy or assessment of immunogenicity/reactogenicity. Topical (except corticosteroid) medications, nasal (including corticosteroid) medications, vitamins, and supplements are permissible. Any drug with antimalarial properties is not permissible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Asthma, other than mild, well-controlled asthma*.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Cold or exercise induced asthma controlled with inhaled medications other than inhaled corticosteroids is permissible. Subjects should be excluded if they require daily bronchodilator use, or have had an asthma exacerbation requiring oral/parenteral steroid use or have used theophylline or inhaled corticosteroids in the past year.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Diabetes mellitus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "History of a psychiatric condition that may make study compliance difficult, such as schizophrenia, or unstable bipolar disorder*.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Includes persons with psychoses or history of suicide attempt or gesture in the 3 years before study entry or an ongoing risk for suicide.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Any history of non-febrile seizures or complex febrile seizures*",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "History of simple febrile seizures or a family history of seizure disorder is not exclusionary",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Autoimmune disease (autoimmune thyroid disease is permissible and vitiligo or mild eczema not requiring chronic therapy is permissible).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Known or suspected congenital or acquired immunodeficiency including anatomic or functional asplenia* or immunosuppression as a result of underlying illness or treatment. *Any splenectomy is exclusionary.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Abuse of alcohol or drugs that, in the opinion of the investigator, may interfere with the subject's ability to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Body mass index (BMI) > / = 35 kg/m^2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Active neoplastic disease*.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Subjects with a history of malignancy may be included if treated by surgical excision or if treated by chemotherapy or radiation therapy and has been observed for a period that in the investigator's estimation provides a reasonable assurance of sustained cure (not less than 36 months).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Chronic topical or systemic corticosteroid use*.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Corticosteroid nasal sprays for allergic rhinitis are permissible. Persons using a topical corticosteroid for a limited duration for mild uncomplicated dermatitis such as poison ivy or contact dermatitis may be enrolled the day after their therapy is completed. Oral or parenteral (IV, SC, or IM) corticosteroids given for non-chronic conditions not expected to recur are permissible if, within the year prior to enrollment, the longest course of therapy was no more than 14 days and no oral or parenteral corticosteroids were given within 30 days prior to enrollment. Intraarticular, bursal, tendon, or epidural injections of corticosteroids are permissible if the most recent injection was at least 30 days prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Receipt or planned receipt of inactivated vaccine or allergy desensitization injection from 14 days before the first immunization through 14 days after the last immunization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Planned receipt of inactivated vaccine or allergy desensitization injection from 14 days prior to CHMI through 28 days after CHMI.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Receipt or planned receipt of live attenuated vaccine 30 days before or at any time during the study up to 28 days after CHMI.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Receipt of any experimental agent* within 30 days prior to enrollment or planned receipt prior to the end of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Vaccine, drug, biologic, device, blood product, or medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Plans to enroll in another clinical trial* that could interfere with safety assessment of the investigational product at any time during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Includes trials that have a study intervention such as a drug, biologic, or device.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Receipt of blood products or immunoglobulin within six months prior to Study Day 1 or donation of a unit of blood within two months before Study Day 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Systolic blood pressure > / = 161 mm Hg or diastolic blood pressure > / = 96 mm Hg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Resting heart rate < 55 or > 100 beats per minute.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Oral temperature > / = 38 degrees C (100.4 degrees F).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Positive serology for HIV 1/2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Positive hepatitis B surface antigen (HBsAg).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Positive antibody to hepatitis C virus (HCV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Any Grade 1 or higher screening clinical lab value* (see Toxicity Tables Section 9.2.3).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Screening clinical labs include blood tests (white blood cells [WBC], hemoglobin, platelets, creatinine, non-fasting glucose, potassium, alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, and total bilirubin) and urine dipstick tests (protein, glucose, hemoglobin). Any Grade 1 or higher value for any screening test will exclude the subject from enrollment with the exception of hematuria > / = 1 + detected during menses or other endometrial bleeding for females. In this situation, the test can be repeated if clinically warranted but is not considered an indicator of poor health status or increased risk and so is not a contraindication to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Acute febrile illness (oral temperature > / = 38 degrees C [100.4 degrees F]) or other acute illness within 3 days prior to vaccination (subject may be rescheduled).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "A screening ECG with abnormalities consistent with underlying heart disease.*",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm excluding isolated premature atrial or ventricular contractions; right or left bundle branch block; QT/QTc interval > 450 ms; or advanced (secondary or tertiary) A-V heart block.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Has a history of psoriasis or porphyria.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Has a known allergy to chloroquine, 4-aminoquinoline derivatives, atovaquone, proguanil,artemether-lumenfantrine, 8-aminoquinoline derivatives, non-steroidal anti- inflammatory drugs, or acetaminophen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Is using or intends to use a medication that is cross-reactive with CQ** or atovaquone and proguanil, such as cimetidine or metoclopramide, during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Antacids and kaolin can be administered at least 4 hours from intake of chloroquine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Does not apply to infectivity controls",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "History of retinal or visual field changes, clinically significant auditory damage, or G6PD deficiency.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Has history of or a positive test for sickle cell disease or trait or other hemoglobinopathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Plans to undergo surgery (elective or otherwise) between enrollment and the end of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Known hypersensitivity to PfSPZ or its components.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "INCLUSION CRITERIA:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "GENOTYPE ONLY COHORT",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Any age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Known resident of Bancoumana or the surrounding villages",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Acceptance and signature of the written informed consent and the assent for children aged 12-17 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Willingness to allow stored laboratory specimens to be used for future research",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "PARASITE SURVEILLANCE COHORT",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "6 months to 65 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Known resident of Bancoumana or the surrounding villages",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Willingness to allow stored laboratory specimens to be used for future research",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Acceptance and signature of the written informed consent and the assent for children aged 12-17 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "DSF COHORT",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Aged between 5 and 65 years, inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Good general health as determined by review of medical history and/or clinical testing at the time of screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Known resident of Bancoumana or the surrounding villages",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Willingness to allow stored laboratory specimens to be used for future research",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Willingness to undergo DSF",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Acceptance and signature of the written informed consent and the assent for children aged 12-17 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "GENOTYPE ONLY COHORT",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the study protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "PARASITE SURVEILLANCE CHORT",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the study protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Currently enrolled participant in protocol 17-I-N006 or another active LMIV/MRTC vaccine clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "DSF COHORT",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the study protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "Currently enrolled participant in protocol 17-I-N006 or another LMIV/MRTC vaccine clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03304704",
    "statement": "History of severe reaction to mosquito bites",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "healthy male or female (non-childbearing potential) of any race, aged 18 to 55 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "body weight at least 50kg and a body mass index 18 to 30Kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Females must be of non-childbearing potential:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Natural (spontaneous) post-menopausal defined (amenorrheic for at least 12 months without an alternative medical cause with a screening follicle stimulating hormone level >25IU/L (for post-menopause).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Premenopausal with irreversible surgical sterilization by hysterectomy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "and/or bilateral oophorectomy or salpingectomy at least 6 months before screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Males agree to use acceptable methods of contraception if the male subject's partner could become pregnant from the time of study medication until 120 days after administration of study medication. One of the following acceptable methods of contraception must be used:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Condom and occlusive cap (diaphragm or cervical/vault cap) with spermicidal foam/gel/film/cream/suppository",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Surgical sterilization (vasectomy with documentation of azoospermia) and an acceptable barrier method (condom or occlusive cap [diaphragm or cervical/vault cap] used with spermicidal foam/gel/film/cream/suppository)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "subject's female partner uses oral contraceptives (combination estrogen / progesterone pills), injectable progesterone or sub-dermal implants and an acceptable barrier method",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "subject's female partner uses medically prescribed topically applied transdermal contraceptive patch and an acceptable barrier method",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "subject's female partner has undergone documented tubal ligation (female sterilization). In addition, an acceptable barrier method must be used.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "subject's female partner has undergone documented placement of an intrauterine device or intrauterine system. In addition, an acceptable barrier method must be used.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "True abstinence: when in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Abstinent subjects have to agree to use 1 of the above-mentioned contraceptive methods, if they start sexual relationships during the study and for up to 120 days post-study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "non-smokers or ex-smokers for more than 90 days prior to screening or smoke no more than 5 cigarettes per day. If users of nicotine products (spray, patch, e-cigarette, etc.) they should use the equivalent of no more than 5 cigarettes /day",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Subjects should not donate egg or sperm from the time of administration of study medication until 120 days post-study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "capable of fully understanding and complying with the requirements of the study and must sign the informed consent form prior to undergoing any study-related procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "agree to avoid excessive UV radiation exposure (occupational exposure to the sun, sunbathing, tanning salon use, phototherapy, etc.) throughout the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Male subjects with a female partner(s) who is (are) pregnant or lactating from the time of study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Current or recurrent disease (e.g. cardiovascular, neurological, renal, gastrointestinal, oncologic or other conditions) that may affect the action, absorption or disposition of the study medication or could affect clinical assessments or clinical laboratory evaluations",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Current or relevant history of physical or psychiatric illness that may require treatment or make the subject unlikely to fully comply with the requirements or complete the study, or any condition that presents undue risk from the investigational product or study procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Any other significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of the participation in the study, may influence the result of the study, or the subject's ability to participate in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "History of photosensitivity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "History or clinical evidence of alcohol or substance abuse. Alcohol abuse is defined as regular weekly intake of more than 21 units for males and 14 units for females",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Any clinically relevant history of intolerance/allergy to milk or dairy products",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Use of an investigational product or participation in a clinical study within 90 days before study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Donation of blood products or of more than 500ml of blood in 90 days prior to study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Use of any prescription drugs within 14 days or within 5 times the elimination half-life (whichever period is longer) prior to study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Use moderate or strong inhibitors and/or inducers of CYP450/Transporters within 4 weeks prior to study drug administration (or 5 half-lives of the compound if longer)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Use of over-the-counter medications or dietary supplements, including vitamins and herbal supplements within 7 days of study drug. With the exception of paracetamol which may be used incidentally or for short-term treatment at a maximum of 2g/day",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Intake of grapefruit, grapefruit juice or other products containing grapefruit within 28 days prior to study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Excessive intake of caffeine drinks or energy drinks within 48 hours before admission (more than three 250ml cups of coffee a day, equivalent to roughly 250mg caffeine)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Any clinically significant abnormal laboratory, vital signs or other safety findings as determined by medical history, physical examination or other evaluations at screening or admission.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Any liver function tests elevated >1.5 times the upper limit of normal, considered by the investigator as clinically relevant, at screening or admission",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Abnormal serum Hemoglobin, Haptoglobin, Reticulocyte count or Lactate Dehydrogenase at screening/admission",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "abnormal ECG results at screening/admission results considered as clinically significant by the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "Confirmed positive urine drug screen (amphetamines, benzodiazepines, cocaine, cannabinoids, opiates, barbiturates or methadone) or from the alcohol breath test at screening/admission.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "positive human immunodeficiency virus, hepatitis B surface antigen, anti Hepatitis core antibody, or hepatitis C virus antibody at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02554799",
    "statement": "veins unsuitable for intravenous puncture or cannulation on either arm (e.g. veins difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture) 23. Any conditions which in the opinion of the investigator would make the subject unsuitable for enrolment or could interfere with the subjects' participation in or completion of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Adult male & non-pregnant females, 18-65 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Fever, defined as >37.5ºC, during the current illness, or history (within the last 48 hours) of fever.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Diagnosis of falciparum malaria, greater than or equal to 200 parasites/uL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Able to communicate well with the investigator and to comply with the requirements of the entire study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Willing to be admitted for the period of drug administration and/or to follow up (return to hospital)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Provision of the written informed consent to participate as shown by a signature on the informed consent form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Administration of any investigational drug in the period 0 to 16 weeks before entry to the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "The use of any medication during the period 0 to 14 days (prescribed drugs) or 0 to 5 days (OTC) before entry to the study (including herbal or dietary supplements), except those deemed by the principal investigator / clinical investigator not to interfere with the outcome of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Existence of any surgical or medical condition that, in the judgment of the clinical investigator, might interfere with the distribution, metabolism or excretion of the drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "History of serious adverse reaction or hypersensitivity to study drug or follow on treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Mixed malaria infection (malaria other than falciparum malaria mono-infection as detected by screening blood smear)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Severe falciparum malaria (as defined by the WHO; Attachment 1).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Donation or loss of greater than 400 ml of blood in the period 0 to 12 weeks before entry to the study,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Transfusion of blood within past 30 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Refusal to prevent pregnancy during the 14 days of the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Pregnancy as defined clinically or by a positive urine BHCG at the time of screening, or nursing mothers.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Laboratory evidence or history of significant cardiovascular, liver or renal functional abnormality, which in the opinion of the investigator would place them at increased risk. Specifically, the following will serve as exclusionary lab values:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Creatinine >1.4 x ULN (>2.0 mg/dL)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "Glucose <LLN (65mg/dL)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00298610",
    "statement": "AST, ALT >3x ULN (120 U/L)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "INCLUSION CRITERIA:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Males or females between 18 and 45 years, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Good general health as determined by means of the screening procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Available for the duration of the trial (48 weeks).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Willingness to participate in the study as evidenced by signing the informed consent document.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "For female subjects: Negative pregnancy tests at Screening and Day 0, in conjunction with a history indicating a low probability of pregnancy in the opinion of the physician. Sexually active females of childbearing potential will be required to be correctly using an efficacious method of contraception for at least 1 month before randomization and during the on-study phase to Month 7. Female subjects unable to become pregnant must have this documented (e.g. tubal ligation, hysterectomy, or postmenopausal [at least one year since last menstrual period]).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "History of malaria, residence for more than 1 month in a malaria endemic area (as determined by interview), or plans to visit a malaria endemic area during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "For female subjects: Positive pregnancy test at screening or Day 0, as well as those currently lactating and breast feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, chronic infectious or renal disease by history, physical examination, and/or laboratory studies including urinalysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the volunteer to understand and cooperate with the study protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25 times the upper limit of normal of the testing laboratory).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Laboratory evidence of renal disease (serum creatinine greater than the upper limit of normal of the testing laboratory, or more than trace protein or blood on urine dipstick testing confirmed by repeat testing of clean-catch, midstream sample). (More than trace blood on urine dipstick will not exclude a female who is actively menstruating).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Laboratory evidence of hematologic disease (absolute leukocyte count less than 3000/mm(3) or greater than 11,500/mm(3); hemoglobin less than 0.9 times the lower limit of normal of the testing laboratory, by gender; absolute granulocyte count less than 1300/mm(3); absolute lymphocyte count less than 1000/mm(3); or platelet count less than 11,000/mm(3)).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Participation in another investigational vaccine or drug trial within 30 days of starting this study, or while this study is ongoing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "History of a severe allergic reaction or anaphylaxis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Severe asthma. This will be defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or parenteral corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Clinically significant reactive airway disease that does not respond to bronchodilators.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Positive ELISA for anti-HCV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Positive hepatitis B surface antigen (HBsAg) by ELISA.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Positive ELISA for anti-HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Use of systemic corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 30 days of starting this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Receipt of a live vaccine within past 4 weeks or non-live vaccine within past 2 weeks prior to entry into the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "History of a surgical splenectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Receipt of blood products within the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "Previous receipt of an investigational malaria vaccine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00487916",
    "statement": "History of a known allergy to nickel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the time of screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Free of significant health problems as established by medical history and clinical examination before entering into the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Available to participate for duration of study (approximately seven months)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "If the subject is female, she must be of non-childbearing potential (either surgically sterilized or one year post-menopausal) or, if of childbearing potential, she must be capable of preventing pregnancy, have a negative pregnancy test at the time of each vaccination, and must agree to continue such precautions for two months after completion of the vaccination series.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "If the volunteer indicates he/she is active duty military (on the DCT sign-in page and intake form), approval from their supervisor through the Division Director using the Statement of Supervisor's Approval Form must be signed and on file prior to receipt of any test product",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Written informed consent must be obtained from the subject before screening procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Test of Understanding",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Prior to entry into this study, subjects must score at least 80% correct on a 10- question multiple-choice quiz that assesses their understanding of this study. If they do not score 80% on the initial quiz, the protocol information will be reviewed with them to ensure comprehension, and they will have the opportunity to retest. If a volunteer fails to correctly answer 8 of 10 questions after two attempts they will be excluded from the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Prior receipt of any investigational malaria vaccine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Prior receipt of a vaccine containing either QS-21, MPL or AS02 or AS01",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying drugs within six months of vaccination. For corticosteroids, this is defined as prednisone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Planned administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of the study vaccine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Any past history of malaria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Planned travel to malarious areas during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "A family history of congenital or hereditary immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Chronic or active neurologic disease including seizure disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "History of splenectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or abnormal baseline laboratory screening tests",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "ALT above normal range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Creatinine above normal range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Hemoglobin below normal range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Platelet count below normal range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Total white cell count below normal range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Acute disease at the time of enrollment (acute disease is defined as the presence of a moderate or severe illness with or without fever). All vaccines can be administered to persons with a minor illness, such as diarrhea or mild upper respiratory infection without fever, i.e., Oral temperature < 37.5°C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Hepatomegaly, right upper quadrant abdominal pain or tenderness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Seropositive for HIV, Hepatitis C virus (antibodies to HCV) and/or HBsAg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Pregnant or lactating female",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Suspected or known current alcohol abuse/drug abuse as obtained by history and physical examination",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Female who is willing or intends to become pregnant during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Any history of allergic reaction or anaphylaxis to previous vaccination",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Inability to make follow-up visits or complete diary cards",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Allergy to kanamycin, nickel, or imidazole",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00666380",
    "statement": "Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Male or female patient age >6 months <70 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Body weight >5 kg <90 kg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Presence of mono-infection of P. falciparum with:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Microscopically confirmed parasite infection, in range 1,000 to 100,000 asexual parasites /µL of blood.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Written informed consent provided by the adult patient, or parent or legally acceptable representative (LAR) of the minor patient or by an impartial witness (if the patient or patient's LAR is illiterate), and by the medically qualified Investigator. Children will be asked to provide assent where appropriate. The age from which this will be sought will be defined by local legislation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Presence of severe malaria (according to World Health Organization (WHO) definition - WHO 2013)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Anti-malarial treatment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "With piperaquine -based compound, mefloquine, naphthoquine or sulphadoxine/pyrimethamine (SP) within the previous 6 weeks (after their inhibition of new infections has fallen below 50%).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "With amodiaquine or chloroquine within the previous 4 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "With quinine, halofantrine, lumefantrine-based compounds and any other anti-malarial treatment or antibiotics with anti-malarial activity (including cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin) within the past 14 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "With any herbal products or traditional medicines, within the past 7 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Known history or evidence of clinically significant disorders such as, respiratory (including active tuberculosis), hepatic, renal, gastrointestinal, immunological, neurological (including auditory), endocrine, infectious, malignancy, psychiatric, history of convulsions or other abnormality (including head trauma).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Family history of sudden death or of congenital or clinical conditions known to prolong QTcB or QTcF interval or e.g. patients with a history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Any predisposing cardiac conditions for arrhythmia such as severe hypertension, left ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac failure accompanied by reduced left ventricle ejection fraction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Any treatment which can induce a lengthening of QT interval, such as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol),",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine),",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Anti-depressive agents, certain antimicrobial agents, including agents of the following classes macrolides (e.g. erythromycin, clarithromycin), fluoroquinolones (e.g. moxifloxacin, sparfloxacin), imidazole and triazole antifungal agents, and also pentamidine and saquinavir,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Certain non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine), cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl, methadone, vinca alkaloids, arsenic trioxide.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Anti-emetics with known QT prolongation potential such as domperidone",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Mixed Plasmodium infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Severe vomiting, defined as more than three times in the 24 hours prior to enrolment in the study or inability to tolerate oral treatment, or severe diarrhoea defined as 3 or more watery stools per day",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Severe malnutrition (defined for subjects aged ten years or less as the weight-for-height being below -3 standard deviation or less than 70% of median of the National Centre for Health Statistics (NCHS)/WHO normalised reference values, and for subjects aged greater than ten years, a body mass index (BMI) of less than 16 (WFP Manual, Chapter 1)).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Known history of hypersensitivity, allergic or adverse reactions to piperaquine or other aminoquinolones or to OZ439 or OZ277",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "If Total Bilirubin is normal, exclude the patient if liver function tests Aspartate transaminase (AST)/ Alanine transaminase (ALT) ≥ 2x Upper limit of normal (ULN).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "If Total Bilirubin is > 1 and ≤ 1.5xULN, exclude the patient if AST/ALT >1.5xULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Total Bilirubin > 1.5XULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Haemoglobin level below 8 g/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Serum creatinine levels ≥2 x ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Female patients of child bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures not to become pregnant during the study period and safety follow-up period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Have received an investigational drug within the past 4 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083380",
    "statement": "Previous participation in any malaria vaccine study or received malaria vaccine in any other circumstance.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "All of the following criteria must be fulfilled for a participant to participate in this trial:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "A participant will be excluded from participating in this trial if any one of the following criteria is fulfilled:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "INCLUSION CRITERIA:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Age >=18 and <=50 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "In good general health and without clinically significant medical history.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Does not live alone from study Day 0 until the end of the antimalarial drug treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Malaria comprehension exam completed, passed (a score of >=80% or per investigator s discretion) and reviewed prior to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Reliable access to the NIH CC and availability to participate for duration of study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Females of childbearing potential must be willing to use reliable contraception (as defined below) from 21 days prior to study Day 0 to 28 days following IBSM.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Sign written informed consent prior to undertaking any study-related procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Currently breastfeeding (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Pregnant as determined by a positive urine or serum human choriogonadotropin (Beta-hCG) test (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Planned travel to a malaria-endemic area during the study period and up to 2 weeks following the EOS visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "History of recent travel to or residence in a P. vivax malaria-endemic region for more than 2 weeks during the past 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Planned travel to a malaria-endemic region during the course of the study (for endemic regions, see www.cdc.gov/malaria/travelers/country_table).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Any history of confirmed malaria diagnosis on peripheral blood smear or by clinical history",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Participation in a previous malaria challenge study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Screening laboratory parameters outside of local lab normal range, to include serum-corrected calcium, creatinine, hepatic transaminase enzymes (ALT, AST), total bilirubin (unless the participant has documented Gilbert syndrome), and hemoglobin. Participants may be included at the investigator s discretion for not clinically significant values outside of normal range.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Abnormal urinalysis as defined by positive urine glucose, protein, and hemoglobin. Participant can be included if investigator determine the abnormality is not clinically significant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Duffy blood group negative (male or female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "ABO blood type other than O (male or female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Rh blood group negative (females of childbearing potential).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Anticipated use during the study period, or use within the following periods prior to enrollment of any of the following: Investigational malaria vaccine within the last 2 years; Malaria chemoprophylaxis within the past 6 months; Chronic systemic immunosuppressive medications (>14 days) within 6 months; Blood products or immunoglobulins within the previous 6 months; Systemic antibiotics or medications with potential antimalarial effects within the past 6 weeks; Investigational or non-registered product or vaccine within 30 days; Receipt of any vaccination within 28 days prior to P. vivax IBSM; Medications known to interact with artemether/lumefantrine; Anticoagulants within the past 28 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "History of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Sickle cell disease, sickle cell trait, or other hemoglobinopathies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Splenectomy or functional asplenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Systemic anaphylaxis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Any allergic reactions to artemether/lumefantrine, chloroquine (or any 4-aminoquinolines), artemether or other artemisinin derivatives, or their excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within 5 years of screening, regardless of whether there is evidence of local recurrence or metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Blood transfusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Clinically significant medical condition, physical examination findings, other clinically significant abnormal laboratory results, or past medical history that may have clinically significant implications for current health status and participation in the study in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Vital signs taken after 5 minutes of resting in seated or supine position that fall outside the following ranges:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Systolic blood pressure <=90 mm Hg or >=140 mm Hg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Diastolic blood pressure <=50 mm Hg or >=90 mm Hg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Heart rate <=40 bpm or >=100 bpm.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Body mass index less than 17.0 or greater than 35.0 kg/m2 at the time of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "History of, or known active cardiac disease including: (1) prior myocardial infarction (heart attack); (2) angina pectoris; (3) congestive heart failure; (4) valvular heart disease; (5) cardiomyopathy; (6) pericarditis; (7) stroke or transient ischemic attack; (8) exertional chest pain or shortness of breath; (9) symptomatic cardiac arrhythmias; (10) clinically relevant bradycardia; or (11) other heart conditions under the care of a doctor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Clinically significant electrocardiogram (ECG) findings as determined by the expert study cardiologist, or QTcF >=450 ms, or presence of second- or third-degree atrioventricular block or abnormal T wave morphology.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Moderate or high risk for coronary heart disease based on National Health and Nutrition Examination Survey (NHANES) I cardiovascular risk assessment (Appendix A).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Family history of sudden death or of congenital prolongation of the QTc interval or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "History of electrolyte disturbances, particularly hypokalemia, hypocalcemia, or hypomagnesemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Acute infectious disease or fever (e.g., temperature >=38.5 degrees C) within the 5 days prior to inoculation with malaria parasites.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Evidence of acute illness within the 4 weeks prior to screening that the investigator deems may compromise participant safety.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Positive result on any of the following tests: hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV) antibodies, and anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Positive urine drug test for any drug unless there is an explanation acceptable to the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Elevated serum ethanol level.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Psychiatric condition that precludes compliance with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Suspected or known current alcohol or drug abuse as defined by the American Psychiatric Association in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, at the discretion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Smoking more than 5 cigarettes or equivalent per day and unable to stop smoking for the duration of admission. Participants may smoke up to 5 cigarettes or equivalent per day for the rest of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "History or presence of alcohol abuse (alcohol consumption of more than 4 standard drinks per day), drug habituation, or any prior intravenous usage of an illicit substance.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Excessive consumption of beverages or food containing xanthine bases (such as Red Bull, chocolate, etc.), or more than 400 mg of caffeine per day (equivalent to more than 4 cups of coffee per day).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Ingestion of any poppy seeds within the 24 hours prior to the screening blood test (participants will be advised by phone not to consume any poppy seeds in this time period).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Use of prescription drugs or non-prescription drugs and herbal supplements (such as St John's Wort) within 14 days or 5 half-lives (whichever is longer) prior to the inoculation administration. (Note: diazepam interferes with the analysis of blood levels of chloroquine and thus should not have been used for at least 8 weeks prior to administration of the study drug). If needed (i.e., an incidental and limited need), ibuprofen up to 1.2 g/day or acetaminophen up to 4 g/day is acceptable. The participant must inform the investigator of any ibuprofen or acetaminophen use at the next convenient time. Limited use of other non-prescription medications or dietary supplements not believed to affect participant safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor in consultation with the investigator. Participants are requested to refrain from taking non-approved concomitant medications from recruitment until the conclusion of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Clinical trial staff with direct involvement in the conduct of the trial are excluded from participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Participating in other clinical trials involving investigational interventions or off-label medication use during the study period or within the 12 weeks preceding study day 0. Participation in other trials such as observational or imaging studies will be discussed with the investigators.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Blood donation of any volume within 4 weeks prior to study day 0, or participation in any research study involving blood sampling (more than 450 mL/unit of blood), or blood donation to Red Cross (or other) blood bank within 8 weeks prior to study day 0.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Unwillingness to defer blood donations for at least 3 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Unwillingness to abstain from consumption of quinine-containing foods/beverages, such as tonic water or lemon bitter, from inoculation (study day 0) to the end of antimalarial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Unwillingness to abstain from consumption of grapefruit or Seville oranges from inoculation (study day 0) to the end of antimalarial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Any participant without a good peripheral venous access.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Participant who, in the judgment of the investigator, is likely to be noncompliant during the study, or is unable to cooperate because of a language or mental deficit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05095272",
    "statement": "Any other finding that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a participant s ability to give informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Capable of giving signed informed consent as described in Appendix 2, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, prior to any study-specific procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Men and women aged 18 to 55 years (inclusive), with suitable veins for cannulation or repeated venipuncture.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Total body weight ≥50 kg, and a body mass index between 18 to 32 kg/m2, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Female subjects are eligible to participate if they have a negative pregnancy test at the Screening Visit and on admission to the study center, not lactating",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Male subjects with female partners of childbearing potential must agree to use contraception as detailed in Appendix 7 of this protocol from the time of informed consent until at least 3 months after dosing with the investigational product. Male subjects with female partners that are surgically sterile, or male subjects who have undergone sterilization and have had testing to confirm the success of the sterilization, may also be included.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Male subjects must not donate sperm from the day of dosing until at least 3 months after dosing with the investigational product.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Medically healthy with clinically insignificant screening results based on a comprehensive medical history and physical examination as judged by the Principal Investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Has to agree to abstain from alcohol intake 48 hours before administration of the study treatment and inoculation with P. falciparum, and during the confinement period of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Able to be compliant with the protocol and attend all scheduled visits.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Previously treated with study treatment in the present study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "History of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Any known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "History of splenectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Subjects with history of schizophrenia, bi-polar disease, psychoses, disorders requiring lithium, attempted or planned suicide, or any other severe (disabling) chronic psychiatric diagnosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Subjects who have been hospitalized within 5 years prior to enrollment for either a psychiatric illness or due to danger to self or others.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "History of an episode of minor depression that required at least 6 months of pharmacological therapy and/or psychotherapy within the last 5 years; or any episode of major depression.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Presence of clinically significant infectious disease or fever (eg, sublingual temperature ≥38.5°C) within 5 days prior to study treatment administration (Parts A and C) or inoculation with the malaria challenge agent (Part B).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Hematology, biochemistry, or urinalysis results at Screening or at Day -1 (Parts A and C) or between Day -11 to -9 (Part B) that are outside of Sponsor-approved clinically acceptable laboratory ranges (Appendix 4), or are considered clinically significant by the Investigator. One repeat is permitted at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Any positive result at Screening for hepatitis B surface antigen, anti-hepatitis B core antibodies, rapid plasma reagin, anti-hepatitis C virus antibody, and anti-human immunodeficiency virus 1 and 2 antibodies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Symptomatic postural hypotension at Screening (confirmed on 2 consecutive readings), irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥20 mmHg within 2 to 3 minutes when changing from supine to standing position.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Abnormal vital signs at Screening (supine and standing) and on Day 1 (Parts A and C) or pre-inoculation on Day 8 (Part B) (supine), defined as any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Systolic blood pressure <90 or >140 mmHg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Diastolic blood pressure <40 or >90 mmHg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Pulse rate <40 or >100 bpm.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Family history of sudden death or of congenital prolongation of the QTc interval or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Any clinically important abnormalities in rhythm, conduction or morphology of the resting ECG, and any clinically important abnormalities in the 12 lead ECG as considered by the Investigator that may interfere with the interpretation of QTc interval changes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Prolonged Fridericia QT correction formula (QTcF) (>450 msec for males and >470 msec for females), prolonged Bazett's QT correction formula (QTcB) (>450 msec for males and >470 msec for females), or PR interval >210 msec (both males and females), or shortened QTcF <340 msec or family history of long QT syndrome at the Screening Visit and on Day 1 (Parts A and C) or pre-inoculation on Day -8 (Part B).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Plasma donation within 1 month of the Screening Visit or any blood donation/blood loss >500 mL or blood transfusion during the 3 months prior to the Screening Visit. For Parts B and C, subjects who have ever received a blood transfusion will be excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Current smokers (tobacco use of >5 cigarettes or equivalent per day), or those unable to stop smoking during confinement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "History of alcohol abuse or excessive intake of alcohol defined as an average weekly intake of >14 drinks/week for men or >7 drinks/week for women. One drink is equivalent to 12 g alcohol = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of 80-proof distilled spirits.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "History of drug habituation, or any prior intravenous usage of an illicit substance.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Positive urine drug and alcohol breath test at Screening or on admission to the study center prior to the administration of investigational product (Day -1 for Parts A and C and Day 1 for Part B)/inoculation with malaria challenge agent (Day -8 for Part B and Day 3 for Part C). Positive for any drug listed in Appendix 4 in the urine drug screen, unless there is an explanation acceptable to an Investigator (eg, the subject has stated in advance that they consumed a prescription or over-the-counter product which contained the detected drug) and/or the subject has a negative urine drug screen on retest by the pathology laboratory. Any subject testing positive for acetaminophen (paracetamol) at Screening and/or inoculation day may still be eligible for study participation, at the Investigator's discretion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Excessive intake of caffeine-containing drinks or food, eg, coffee, tea, chocolate, Red Bull, or cola (more than 400 mg of caffeine per day, equivalent to >4 cups of coffee per day) for 48 hours before the start of dosing or inoculation with malaria challenge agent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Ingestion of any poppy seeds within 24 hours prior to each Drug Abuse Screening (Screening Visit [all Parts], Day 1 [Part A and Part C], Day -8 and Day 1 [Part B], and Day 3 [Part C]). Subjects will be advised by phone not to consume any poppy seeds in this time period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Any history or presence of diagnosed (by an allergist/immunologist) or treated (by a physician) food or known drug allergies, or history of anaphylaxis or other severe allergic reactions including face, mouth, or throat swelling or any difficulty breathing. Subjects with seasonal allergies/hay fever or allergy to animals or house dust mite that are untreated and asymptomatic at the time of dosing can be enrolled in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Use of any prescribed or nonprescribed medication including antacids, analgesics, herbal preparations, or vitamins (other than paracetamol/acetaminophen [<4 g per day], ibuprofen [<1.2 g per day], or routine vitamins [megadose intake of 20 to 600 times the recommended daily dose is prohibited]) within 2 weeks prior to the first administration of investigational product or 5 times the medication's half life, whichever is longer. Limited use of other non prescription medications or dietary supplements, not believed to affect subject safety or the overall results of the study, may be permitted a case-by-case basis following discussion with the Investigator and approval of the Sponsor. Hormone replacement therapy is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Any vaccination within the last 28 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Any recent (<6 weeks) or current systemic therapy with an antibiotic or drug with potential antimalarial activity (eg, chloroquine, piperaquine phosphate, benzodiazepine, flunarizine, fluoxetine, tetracycline, azithromycin, clindamycin, doxycycline etc.).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 3 months of the administration of investigational product in this study. The period of exclusion begins 3 months after dosing (or greater than 5 times half life) or 1 month after the last visit, whichever is the longest. Note: Subjects consented and screened, but not dosed in this study or a previous Phase I study, are not excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Involvement in the planning and/or conduct of the study (applies to the Sponsor, contract research organizations, and study center staff, etc.).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Subjects who are unlikely to co operate with the requirements of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04327310",
    "statement": "Judgment by the Investigator that the subject should not participate in the study if they have any ongoing or recent (ie, during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "If the subject is female, she must be of non-childbearing potential (either surgically sterilized or one year post-menopausal) or, if of childbearing potential, she must have a negative pregnancy test at the time of vaccination, be capable of preventing pregnancy for at least one month prior to determination of eligibility (to include abstinence or contraceptives (for example intrauterine contraceptive device; oral contraceptives; Norplant® or Depo-Provera® ), and must agree to continue such precautions for two months after completion of the vaccination series.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Written informed consent must be obtained from the subject before screening procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "• A male or non-lactating female 18 to 50 years of age (inclusive) at the time of screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Free of significant health problems as established by medical history and clinical examination before entering into the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Available to participate for duration of study (approximately seven months)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "• Prior receipt of any investigational malaria vaccine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Prior receipt of a vaccine containing either QS-21, MPL or AS02A or AS01B",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Administration of chronic (defined as more than 14 days) immunosuppressants or other immune modifying drugs within six months of vaccination. For corticosteroids, this is defined as prednisone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Planned administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of the study vaccine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "A family history of congenital or hereditary immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Chronic or active neurologic disease including seizure disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "History of splenectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or abnormal baseline laboratory screening tests",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "ALT above normal range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Creatinine above normal range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Hemoglobin below normal range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Platelet count below normal range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Total white cell count below normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Acute disease at the time of enrollment (acute disease is defined as the presence of a moderate or severe illness with or without fever). All vaccines can be administered to persons with a minor illness, such as diarrhea or mild upper respiratory infection without fever, i.e. Oral temperature < 37.5°C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Hepatomegaly, right upper quadrant abdominal pain or tenderness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Pregnant or lactating female",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Suspected or known current alcohol abuse/drug abuse as obtained by history and physical examination",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Female who is willing or intends to become pregnant during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Any history of allergic reaction or anaphylaxis to previous vaccination",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Unwilling to allow blood samples to be stored for future use",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Inability to make follow up visits",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Allergy to kanamycin, nickel, or imidazole",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Previous allergy to Rabies Vaccine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02458092",
    "statement": "Allergy to chicken and chicken products",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "INCLUSION CRITERIA:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Males or females between 18 and 45 years, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Known residents of the village of Don gu bougou, Mali.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Good general health as determined by means of the screening procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Available for the duration of the trial (30 weeks).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Willingness to participate in the study as evidenced by signing the informed consent document.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Pregnancy as determined by a positive urine beta-hCG at any point during the study (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "If female, participant and her spouse have not used or are unwilling to use reliable contraceptive methods such as: abstinence, birth control pills or birth control patches or vaginal ring, diaphragm with spermicide, IUD (intrauterine device), condom with spermicide, progestin implant or injection, or surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation) prior to enrollment to 3 months after the second vaccination. (At the time of vaccination a female participant must have a negative urine pregnancy test on two occasions at least two weeks apart, and must have used a reliable contraceptive method in the interim).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Currently lactating and breast-feeding (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, chronic infectious or renal disease by history, physical examination, and/or laboratory studies including urinalysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the volunteer to understand and cooperate with the study protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Pre-existing known autoimmune diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Laboratory evidence of possible autoimmune disease determined by anti-dsDNA titer that equals or exceeds 25 IU.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25 times the upper limit of normal of the testing laboratory).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Laboratory evidence of renal disease (serum creatinine greater than the upper limit of normal of the testing laboratory, or more than trace protein or blood on urine dipstick testing confirmed by repeat testing of clean-catch, midstream sample). (More than trace blood on urine dipstick will not exclude a female who is actively menstruating.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Laboratory evidence of hematologic disease (absolute leukocyte count less than 3000/mm(3) or greater than 11,500/mm(3); hemoglobin less than 0.9 times the lower limit of normal of the testing laboratory, by gender; absolute granulocyte count less than 1300/ mm(3); absolute lymphocyte count less than 1000/mm(3); or platelet count less than 110,000/mm(3)).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Participation in another investigational vaccine or drug trial within 30 days of starting this study, or while this study is ongoing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "History of a severe allergic reaction or anaphylaxis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Severe asthma. This will be defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or parenteral corticosteroids;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Clinically significant reactive airway disease that does not respond to bronchodilators.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Positive rapid diagnostic test for anti-Hepatitis C virus (HCV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Positive rapid diagnostic test for Hepatitis B surface antigen (HBsAg).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Known immunodeficiency syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Use of systemic corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 30 days of starting this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Receipt of a live vaccine within past 4 weeks or a non-live vaccine within past 2 weeks prior to entry into the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "History of a surgical splenectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Receipt of blood products within the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "Previous receipt of an investigational malaria vaccine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "History of a known allergy to nickel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "History of known allergy to yeast.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00414336",
    "statement": "History of use of chloroquine or related compounds (amodiaquine or primaquine) within 8 weeks of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Have given informed consent by signing and dating the informed consent form (ICF) before initiation of any trial-specific procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Are willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions and other requirements of the trial. This includes that they are able to understand and follow trial-related instructions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Are aged 18 to 55 years, have a body mass index over 18.5 kg/m^2 and under 35 kg/m^2 and weigh at least 45 kg at Visit 0.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Are healthy, in the clinical judgment of the investigator based on volunteer-reported medical history data, and physical examination, 12-lead electrocardiogram (ECG), vital signs, and clinical laboratory test outcomes at Visit 0.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Note: Healthy volunteers with pre-existing stable disease (e.g., obesity, hypertension), defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 90 days before Visit 0, can be included.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Agree not to enroll in another trial with an IMP starting from Visit 0 and until 12 weeks after receiving Dose 3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Have not traveled and agree not to travel to a malaria-endemic region, as defined per Centers for Disease Control and Prevention (CDC) (https://www.cdc.gov/malaria/travelers/country_table/a.html) starting 6 months before Visit 0 and continuously until 28 days after receiving Dose 3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Negative human immunodeficiency virus -1 and -2 blood test result at Visit 0.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Negative Hepatitis B surface antigen test result at Visit 0 and negative anti-Hepatitis C virus (anti-HCV) antibodies, or negative HCV polymerase chain reaction test result if the anti-HCV is positive at Visit 0.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Volunteers of childbearing potential (VOCBP) that have a negative serum beta-human chorionic gonadotropin pregnancy test result at Visit 0 and negative urine pregnancy test results before each IMP administration. Volunteers born female who are postmenopausal or permanently sterilized will not be considered VOCBP.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "VOCBP who agree to practice a highly effective form of contraception starting at Visit 0 and continuously until 90 days after receiving Dose 3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "VOCBP who agree not to donate or cryopreserve eggs (ova, oocytes) for the purposes of assisted reproduction during trial, starting at Visit 0 and continuously until 90 days after receiving Dose 3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Men who have not had a vasectomy and are sexually active with partners of childbearing potential and who agree to use condoms and to practice a highly effective form of contraception with their sexual partners of childbearing potential during the trial, starting at Visit 0 and continuously until 90 days after receiving Dose 3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Men who are willing to refrain from sperm donation, starting at Visit 0 and continuously until 90 days after receiving Dose 3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "History of Plasmodium parasitemia (any species) based on volunteer-reported medical history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Prior residence for ≥6 months continuously in a malaria-endemic region as defined per CDC (https://www.cdc.gov/malaria/travelers/country_table/a.html) at any point during their lifetime.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Breastfeeding or intending to become pregnant or to father children starting with Visit 0 and continuously until 90 days after receiving Dose 3.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "History of any serious adverse reactions to vaccines or to vaccine components such as lipids, and including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain. (Not excluded from participation: a volunteer who had an anaphylactic adverse reaction to pertussis vaccine as a child).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Current or history of the following medical conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Uncontrolled or moderate or severe respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease); symptoms of asthma severity as defined in the US National Asthma Education and Prevention Program Expert Panel report, 2020 - e.g., exclude a volunteer who:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Uses a short-acting rescue inhaler (typically a beta 2 agonist) daily, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Uses high dose inhaled corticosteroids (per American Academy of Allergy Asthma and Immunology), or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "In the past year has either of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Greater than one exacerbation of symptoms treated with oral/parenteral corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Needed hospitalization, or intubation for asthma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "History of Diabetes mellitus type 1 or type 2, including cases controlled with diet alone or elevated hemoglobin A1C ≥6.5% at screening (not excluded: history of isolated gestational diabetes).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Hypertension:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "If a person has a history of hypertension, or elevated blood pressure detected during screening, exclude for blood pressure that is not well controlled. Well controlled blood pressure is defined as consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must be ≤150 mm Hg systolic and ≤100 mm Hg diastolic at screening and enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Malignancy within 5 years of screening, excluding localized basal or squamous cell skin cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Any current or history of cardiovascular diseases, (e.g., myocarditis, pericarditis, myocardial infarction, congestive heart failure, cardiomyopathy or clinically significant arrhythmias), unless such disease is not considered relevant for participation in this trial in the investigator's judgment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "An abnormal screening ECG (i.e., showing the corrected QT interval by Fridericia [QTcF] greater than 450 ms; significant ST-T wave changes suggestive of myocardial ischemia or of an acute or indeterminate-age myocardial infarction; left ventricular hypertrophy; any non-sinus rhythm including isolated premature ventricular contractions; complete right or left bundle branch block [QRS greater than 120 ms]; second-or third-degree atrioventricular block); or other clinically significant abnormalities on the ECG at the investigator's discretion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Seizure disorder: History of seizure(s) within the past 3 years or has used medications in order to prevent or treat seizure(s) at any time within the past 3 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Documented major psychiatric illness, including bipolar disorder, major depressive disorder, schizophrenia, autism, and attention deficit-hyperactivity disorder that at the discretion of the investigator could interfere with participation and follow-up as outlined by the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "The following diseases associated with immune dysregulation:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Primary immunodeficiencies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "History of solid organ or bone marrow transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Asplenia: any condition resulting in the absence of a functional spleen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Previous vaccination with an approved or investigational malaria vaccine at any time or having taken part in a human malaria challenge study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Receipt of any investigational product within 28 days before Visit 0.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Any planned non-trial vaccinations starting at Visit 0 and continuously until 28 days after Dose 3.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Note: Seasonal influenza and Coronavirus Disease 2019 (COVID-19) vaccines are allowed; however, they should be administered at least 14 days before or 28 days after any IMP administration. Emergency vaccinations, such as tetanus, are allowed to be administered when medically indicated.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Received blood/plasma products, monoclonal antibodies or immunoglobulin within 120 days before Visit 1 or planned administration starting at Visit 0 and continuously until the last trial visit (365 days after Dose 3).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Received allergy treatment with antigen injections within 28 days before and after each IMP administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Current or planned treatment with immunosuppressive therapy, including systemic corticosteroids (if systemic corticosteroids are administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent) starting at Visit 0 and continuously until 28 days after Dose 3. Intraarticular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Have a history of alcohol abuse or drug addiction within 1 year before Visit 0 or have a history (within the past 5 years) of substance abuse, which in the opinion of the investigator, could compromise their wellbeing if they participate as participants in the trial, or that could prevent, limit, or confound the protocol specified assessments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Any existing condition which may affect vaccine injection and/or assessment of local reactions at the injection site, e.g., tattoos, severe scars, etc.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Are vulnerable individuals as per International Council for Harmonisation (ICH) E6 definition, i.e., are individuals whose willingness to volunteer in a clinical trial may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06069544",
    "statement": "Any screening hematology and/or blood chemistry laboratory value (per the US FDA 2007) that meets the definition of a Grade ≥2 abnormality or a Grade 1 abnormality at the investigator's discretion at Visit 0 or a Visit 0 troponin above the reference range. Individuals with abnormal but not clinically significant parameters not included in the toxicity guidance may be considered eligible at discretion of investigator, with the exception of abnormal troponin values.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Male or female patients between the age of 18 and 60 years, inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Body weight between 45 kg and 90 kg inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Presence of mono-infection of P. falciparum confirmed by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Microscopically confirmed parasite infection: 1,000 to 75,000 asexual parasite count/µL blood.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Written informed consent, in accordance with local practice, provided by patient. If the patient is unable to write, witnessed consent is permitted according to local ethical considerations",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Ability to swallow oral medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Ability and willingness to participate and access the health facility",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Agree to hospitalization for at least 72h until parasites have fallen below the level of polymerase chain reaction (PCR) detection and have no signs or symptoms of malaria; and then to return once daily to the study centre for blood sampling for quantitative polymerase chain reaction (qPCR), and rehospitalisation when qPCR levels are detectable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization Criteria 2010",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Mixed Plasmodium infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Severe vomiting, defined as more than three times in the 24 hours prior to inclusion in the study or inability to tolerate oral treatment, or severe diarrhoea defined as 3 or more watery stools per day",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Presence of other serious or chronic clinical condition requiring hospitalization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Severe malnutrition (defined as the weight-for-height being below -3 standard deviation or less than 70% of median of the NCHS/WHO normalized reference values)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Known history or evidence of clinically significant disorders such as cardiovascular (including arrhythmia, QTc interval greater than or equal to 450 msec), respiratory (including active tuberculosis), history of jaundice, hepatic, renal, gastrointestinal, immunological (including active HIV-AIDS), neurological (including auditory), endocrine, infectious, malignancy, psychiatric, history of convulsions or other abnormality (including head trauma)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Known history of hypersensitivity, allergic or adverse reactions to artemisinin containing compounds or mefloquine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Known active Hepatitis A Immunoglobulin M (IgM) (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Have received any antimalarial treatment in the preceding 14 days, as determined by history and screening test",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Have received antibacterial with known antimalarial activity in the preceding 14 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Have received an investigational drug within the past 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Liver function tests (Aspartate Aminotransferase(ASAT)/Alanine Aminotransferase (ALAT) levels) > 2x upper limit of normal (ULN) if Total Bilirubin normal or >1.5xULN if Total bilirubin between >1 and >1.5xULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Hemoglobin (Hb) level =< 8g/dl",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Total Bilirubin > 1.5XULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Serum creatinine levels more than 2 times the upper limit of normal range (>2xULN).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01713621",
    "statement": "Female patients must be neither pregnant as demonstrated by a negative serum pregnancy test at screening and urinary pregnancy test pre-dose (the result of the pre-dose assessment must be confirmed negative prior to dosing) nor lactating, and must be willing to take measures not to become pregnant during the study period and safety follow-up period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "All of the following criteria must be fulfilled for a volunteer to participate in this trial:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "EXCLUSION CRITERIA (US):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "A volunteer will be excluded from participating in this trial if any one of the following criteria is fulfilled:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "EXCLUSION CRITERIA (MALI):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "A volunteer will be excluded from participating in this trial if any one of the following criteria is fulfilled:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "INCLUSION CRITERIA:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Age between 18 and 50 years (US) or 18 and 45 years (Mali), inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Good general health as a result of review of medical history and/or clinical testing at the time of screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Available for the duration of the trial (52 weeks in the U.S. and 104 weeks in Mali)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Willingness to participate in the study as evidenced by signing the informed consent document, or by fingerprinting the consent document with the signature of a witness (Mali)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Known resident of the village of Bancoumana (Mali)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Pregnancy as determined by a positive urine or serum test at any point during the study for human choriogonadotropin (Beta-hCG) (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Subject is unwilling to use reliable contraception methods for the period of at least 2 months prior to first vaccination to 3 months after last vaccination (if female). Reliable methods of birth control include: pharmacologic contraceptives including oral, parenteral, and transcutaneous delivery; condoms with spermicide; diaphragm with spermicide; surgical sterilization; vaginal ring; intrauterine device; abstinence; and post-menopause (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Currently is lactating and breast-feeding (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the participant to understand and cooperate with the study protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Neutropenia as defined by an absolute neutrophil count less than 1500/mm(3).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Alanine transaminase (ALT) level above the laboratory-defined upper limit of normal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Other condition that in the opinion of the investigator would jeopardize the safety or rights of a participant participating in the trial or would render the subject unable to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "History of receiving any investigational product within the past 30 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Participant has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "History of a severe allergic reaction or anaphylaxis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Severe asthma. This will be defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past 2 years, or that requires the use of oral or parenteral corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Clinically significant reactive airway disease that does not respond to bronchodilators",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Positive ELISA and confirmatory Western blot tests for HIV-1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Positive ELISA and confirmatory tests for hepatitis C virus (HCV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Positive hepatitis B surface antigen (HBsAg) by ELISA.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren s syndrome, or autoimmune thrombocytopenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Known immunodeficiency syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Positive serum anti-dsDNA titer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 30 days of starting this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Receipt of a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks prior to entry into the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "History of a surgical splenectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Receipt of blood products within the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Previous receipt of an investigational malaria vaccine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Receipt of antimalarial prophylaxis during the past 12 months, or receipt of chloroquine or related compounds (hydroxychloroquine, amodiaquine, or primaquine) in the 8 weeks prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Prior malaria infection by history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Any medical, psychiatric, social, or occupational condition or other responsibility that, in the judgment of the Principal Investigator (PI), would interfere with the evaluation of study objectives.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Pregnancy as determined by a positive urine (Beta-hCG test at any point during the study (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "If female, subject and her spouse have not used or are unwilling to use reliable contraceptive methods such as: abstinence, birth control pills or birth control patches or vaginal ring, diaphragm with spermicide, IUD (intrauterine device), condom with spermicide, progestin implant or injection, or surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation) prior to enrollment to 3 months after the final vaccination. (At the time of vaccination, a female subject must have had a negative urine pregnancy test on 2 occasions at least 2 weeks apart, and must have used a reliable contraceptive method in the interim.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Currently is lactating and breast-feeding (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, chronic infectious or renal disease by history, physical examination, and/or laboratory studies including urinalysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the study protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Pre-existing known autoimmune diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren s syndrome, autoimmune thrombocytopenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Laboratory evidence of possible autoimmune disease determined by anti-dsDNA titer that equals or exceeds 25 IU.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25 times the upper limit of normal of the testing laboratory).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Laboratory evidence of renal disease (serum creatinine greater than the upper limit of normal of the testing laboratory, or more than trace protein or blood on urine dipstick testing confirmed by repeat testing of clean-catch, midstream sample). (More than trace blood on urine dipstick will not exclude a female who is actively menstruating.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Laboratory evidence of hematologic disease (absolute leukocyte count less than 3000/mm(3) or greater than 11,500/mm(3); hemoglobin less than 0.9 times the lower limit of normal of the testing laboratory, by gender; absolute granulocyte count less than 1300/mm(3); absolute lymphocyte count less than 1000/mm(3); or platelet count less than 110,000/mm(3).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Participation in another investigational vaccine or drug trial within 30 days of starting this study, or while this study is ongoing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "History of a severe allergic reaction or anaphylaxis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Severe asthma. This will be defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past 2 years, or that requires the use of oral or parenteral corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Clinically significant reactive airway disease that does not respond to bronchodilators",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Positive hepatitis B surface antigen (HBsAg). Hepatitis C antibody by rapid diagnostic test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Known immunodeficiency syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Use of systemic corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 30 days of starting this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Receipt of a live vaccine within past 4 weeks or a non-live vaccine within past 2 weeks prior to entry into the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "History of a surgical splenectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Receipt of blood products within the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "Previous receipt of an investigational malaria vaccine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00889616",
    "statement": "History of use of chloroquine or related compounds (hydroxychloroquine, amodiaquine, or primaquine) within 8 weeks of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Had given informed consent by signing and dating the informed consent form (ICF) before initiation of any trial-specific procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Were willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions (e.g., to follow good practices to reduce their chances of being infected or spreading Coronavirus Disease 2019 [COVID-19]), and other requirements of the trial. This includes that they were able to understand and follow trial-related instructions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Were aged 18 to 55 years, had a body mass index over 18.5 kg/m^2 and under 35 kg/m^2 and weighed at least 45 kg at Visit 0",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Were healthy, in the clinical judgment of the investigator based on volunteer-reported medical history data, and physical examination, 12-lead electrocardiogram (ECG), vital signs, and clinical laboratory test outcomes at Visit 0",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Note: Healthy volunteers with pre-existing stable disease (e.g., obesity, hypertension), defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 90 days before Visit 0, were included",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Agreed not to enroll in another trial with an investigational medicinal product (IMP) starting from Visit 0 and until 12 weeks after receiving Dose 3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Agreed not to travel to a malaria endemic region starting from Visit 0 and until 28 days after Dose 3, as defined per CDC (Centers for Disease Control and Prevention)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Negative human immunodeficiency virus (HIV) -1 and -2 blood test result at Visit 0",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Negative severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) antigen test result at Visit 0",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Negative hepatitis B surface antigen (HBsAg) test result at Visit 0 and negative anti Hepatitis C virus (anti-HCV) antibodies, or negative HCV polymerase chain reaction test result if the anti-HCV was positive at Visit 0",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Volunteers of childbearing potential (VOCBP) who had a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test result at Visit 0 and negative urine pregnancy test results before each IMP administration. Volunteers born female who were postmenopausal or permanently sterilized were not considered VOBCP",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "VOCBP who agreed to practice a highly effective form of contraception and required their male sexual partners to use condoms with a spermicidal agent, starting at Visit 0 and continuously until 90 days after receiving Dose 3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "VOCBP who agreed not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during trial, starting at Visit 0 and continuously until 90 days after receiving Dose 3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Men who were sexually active with partners of childbearing potential and who did not have a vasectomy that agreed to use condoms with a spermicidal agent and to practice a highly effective form of contraception with their sexual partners born female during the trial, starting at Visit 0 and continuously until 90 days after receiving Dose 3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Men who were willing to refrain from sperm donation, starting at Visit 0 and continuously until 90 days after receiving Dose 3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "History of malaria infection (any species) based on volunteer-reported medical history",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Travel to a malaria endemic region starting 6 months before Visit 0 and continuously until 28 days after receiving Dose 3, as defined per CDC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Prior residence for greater than or equal to (>=) 6 months in a malaria endemic region",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Were breastfeeding or had intended to become pregnant starting with Visit 0 and continuously until 90 days after receiving Dose 3 or fathered children starting with Visit 0 and continuously until 90 days after receiving Dose 3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "History of any serious adverse reactions to vaccines or to vaccine components such as lipids and including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain. (Not excluded from participation: a volunteer who had an anaphylactic adverse reaction to pertussis vaccine as a child).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Current or history of the following medical conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Uncontrolled or moderate or severe respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease); symptoms of asthma severity as defined in the US National Asthma Education and Prevention Program Expert Panel report, 2020 - e.g., exclude a volunteer who:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Used a short-acting rescue inhaler (typically a beta 2 agonist) daily, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Used high dose inhaled corticosteroids (per American Academy of Allergy Asthma & Immunology), or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "In the past year has had either of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Greater than one exacerbation of symptoms treated with oral/parenteral corticosteroids;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Needed hospitalization, or intubation for asthma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Diabetes mellitus type 1 or type 2, including cases controlled with diet alone (Not excluded: history of isolated gestational diabetes).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Hypertension:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "If a person had been found to have elevated blood pressure or hypertension during screening or previously, they were excluded for blood pressure that is not well controlled. Well controlled blood pressure was defined as consistently less than or equal to (<=)140 mm Hg systolic and <= 90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must be <= 150 mm Hg systolic and <=100 mm Hg diastolic at enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "If a person did not have a history of elevated blood pressure or hypertension previously or during screening, also excluded for systolic blood pressure greater than (>)150 mm Hg at enrollment or diastolic blood pressure ≥100 mm Hg at enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Malignancy within 5 years of screening, excluding localized basal or squamous cell cancer;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Any current or history of cardiovascular diseases, (e.g., myocarditis, pericarditis, myocardial infarction, congestive heart failure, cardiomyopathy or clinically significant arrhythmias), unless such disease was not considered relevant for participation in this trial in the investigator's judgment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Seizure disorder: History of seizure(s) within past 3 years. Also excluded if volunteer had used medications in order to prevent or treat seizure(s) at any time within the past 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Documented major psychiatric illness, including bipolar disorder, major depressive disorder, schizophrenia, autism, and attention deficit-hyperactivity disorder that at the discretion of the investigator could interfere with participation and follow-up as outlined by the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "The following diseases associated with immune dysregulation:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Primary immunodeficiencies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "History of solid organ or bone marrow transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Asplenia: any condition resulting in the absence of a functional spleen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Previous vaccination with an approved or investigational malaria vaccine at any time or having taken part in a human malaria challenge study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Receipt of any investigational product within 28 days before Visit 0",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Any planned non-trial vaccinations starting at Visit 0 and continuously until Visit 11 (28 days after Dose 3)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Note: Seasonal influenza and COVID-19 vaccines were allowed; however, they should have been administered at least 14 days before or after any IMP injection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Received blood/plasma products or immunoglobulin within 120 days before Visit 1 or planned administration starting at Visit 0 and continuously until Visit 12",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Received allergy treatment with antigen injections within 28 days before first IMP administration or that were scheduled within 14 days after Visits 1, 5 and 9",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Current or planned treatment with immunosuppressive therapy, including systemic corticosteroids (if systemic corticosteroids are administered for >=14 days at a dose of >= 20 mg/day of prednisone or equivalent) starting at Visit 0 and continuously until Visit 11 (28 days after Dose 3). Intraarticular, intrabursal, or topical (skin or eyes) corticosteroids were permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Had a history of alcohol abuse or drug addiction within 1 year before Visit 0 or had a history (within the past 5 years) of substance abuse which in the opinion of the investigator, could compromise their wellbeing if they participate as participants in the trial, or that could prevent, limit, or confound the protocol-specified assessments",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Any existing condition which may have affected vaccine injection and/or assessment of local reactions assessment at the injection site, e.g., tattoos, severe scars, etc.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Were vulnerable individuals as per International Council for Harmonization (ICH) E6 definition, i.e., were individuals whose willingness to volunteer in a clinical trial may have been unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Any screening hematology and/or blood chemistry laboratory value that met the definition of a Grade >= 2 abnormality or of Grade 1 at the investigator's discretion at Visit 0. Individuals with abnormal but not clinically significant parameters were not included in the toxicity guidance may have been considered eligible at the discretion of the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05581641",
    "statement": "Had current febrile illness (body temperature >=38.0°C/ >=100.4°F) or febrile illness within 48 hours of Visit 0",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Male or female patients ≤12 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Body weight ≥ 5 kg and < 25 kg with no clinical evidence of severe malnutrition (defined as a child whose weight-for-height is below -3 standard deviations or <70% of the median of the NCHS/WHO normalised reference values).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Presence of acute uncomplicated P. falciparum mono-infection confirmed by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Fever, as defined by axillary temperature ≥37.5°C or oral/tympanic/rectal temperature ≥38°C, or documented history of fever in the previous 24 hours and,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Positive microscopy of P. falciparum with parasite density between 1,000 and 200,000 asexual parasite count/µl of blood.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Written informed consent, in accordance with local practice, provided by parent/guardian. If the parent/guardian is unable to write, witnessed consent is permitted according to local ethical considerations. Where possible, patient assent will be sought.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Ability to swallow whole volume of liquid in which medication is suspended.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the study period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Ability and willingness to participate based on information given to parent or guardian and access to health facility. The patient is to comply with all scheduled follow up visits until D42.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization Criteria 2000 [Attachment 3].",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Mixed Plasmodium infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Severe vomiting, defined as >3 times in the 24 hours prior to inclusion in the study or inability to tolerate oral treatment, or severe diarrhoea defined as ≥3 watery stools per day.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Known history or evidence of clinically significant disorders such as cardiovascular (including arrhythmia, QTc interval ≥450 milliseconds), respiratory (including active tuberculosis), history of jaundice, hepatic, renal, gastrointestinal, immunological (including active HIV-AIDS), neurological (including auditory), endocrine, infectious, malignancy, psychiatric, history of convulsions or other abnormality (including recent head trauma).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Presence of significant anaemia, as defined by Hb <8 g/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Presence of febrile conditions caused by diseases other than malaria.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Known history of hypersensitivity, allergic or adverse reactions to pyronaridine, lumefantrine or artesunate or other artemisinins.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Patients with known disturbances of electrolytes balance, e.g. hypokalaemia or hypomagnesaemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Use of any other antimalarial agent within 2 weeks prior to start of the study as evidenced by reported patient history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Patients taking any drug which is metabolised by the cytochrome enzyme CYP2D6 (flecainide, metoprol, imipramine, amitriptyline, clomipramine).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Received an investigational drug within the past 4 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Known positive for HIV antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Liver function tests [ASAT/ALAT levels] >2.5 times upper limit of normal range.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Known significant renal impairment as indicated by serum creatinine of >1.4 mg/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00541385",
    "statement": "Previous participation in any clinical study with pyronaridine artesunate.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "5xSST at Screening and Baseline should be ≥ 11 seconds and participant must demonstrate the ability to complete the test at baseline (i.e., complete the test within 30 seconds).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "6. Other Inclusion criteria per protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Signed Informed Consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Males and females aged ≥18 years with a multi-system primary mitochondrial disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "A confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation (m.3243A>G PMD) plus an age adjusted heteroplasmy percentage ≥ 20% in white blood cells [=blood heteroplasmy/0.977(age+12)]. Or in urine (urinary epithelial cells), or buccal smear or skeletal muscle (results (obtained per local guidance) ≥ 20% must be available prior to the subject being randomized).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Presence of chronic fatigue (not attributable to other etiologies than PMD):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Patient self-reported chronic fatigue for at least 3 months prior to the Screening Visit and recorded in the clinical patient files; AND",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Presence of fatigue (raw total score >22), assessed by Neuro-QoL SFv1-F at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Presence of mitochondrial myopathy defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Treatment with any IMP within 3 months (or 5 times the half-life of the IMP, whichever is longer) prior to screening or plans to use an IMP (other than the study intervention) during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Bone deformities, motor abnormalities or chronic ulcers that in the opinion of the PI may interfere with and/or confound the interpretation of the subject's performance during the 5 times sit to stand test (5XSST).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Surgery of gastrointestinal tract that might interfere with drug absorption. Or severe GI dysmotility, chronic vomiting, diarrhea, bouts of pseudo-obstruction which will impair appropriate IMP absorption in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Clinically significant respiratory disease and/or cardiac disease (medical history or current clinical findings) in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Prior interventional cardiac procedure (e.g., cardiac catheterization, angioplasty/percutaneous coronary intervention, balloon valvuloplasty, etc.) within 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "QTcF > 450 msec (men) or QTcF > 470 msec (women).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Structural heart disease based on cardiac MRI or Echocardiography (e.g., clinically significant valve disease; i.e., aortic or mitral valve stenosis or regurgitation) and/or abnormal conduction (QRS >120 msec, PR > 120 msec), and/or repolarization (QTcF > 450 msec (men) or QTcF > 470 msec (women)). Myocardial function (LVEF <52% in men and < 54% in women), symptomatic ischemic heart disease (inducible ischemia or coronary obstruction), and/or pathologic hypertrophy (e.g. > 15mm septal or posterior wall thickness), that is not well controlled under current specialized care. Subjects with congestive heart failure class II and above should also be excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Family history of unexplained/uninvestigated syncope or congenital long and short QT syndrome or sudden death (under the age of 60). ECG evidence of acute or recent ischemia, acute or Recent Myocardial Infraction, atrial fibrillation, high grade AV Blocks (Second Degree AV Block Type II or Third-degree AV Block), complete Heart Block or active conduction system abnormalities with the exception of any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "First degree atrioventricular (AV)-block",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Second degree AV-block Type 1 (Mobitz Type 1/Wenckebach type)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Right bundle branch block.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "History of acute heart failure (within the last 3 months).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Higher degree of AV-blocks (AVB II° or III°).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06451757",
    "statement": "Other exclusion criteria per protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "18-75 years old.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Established type 2 diabetes as assessed by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Fasting blood glucose (>126 mg/dL/7 mmol/L), or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "2 hr oral glucose tolerance test (>200 mg/dL/11.1 mmol/L), or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "HbA1c is ≥7.0% within 3 months of enrollment and on a stable dose of metformin and/or sulfonylureas for at least 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Body Mass Index (BMI) >23 kg/m2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Treated with metformin and/or sulfonylureas (monotherapy or combination therapy) stable and maximally tolerated for at least three months prior to study participation. Subjects should be on stable and maximally tolerated doses throughout the study unless sulfonylureas require adjustment to reduce the risk of hypoglycemia during the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Subjects who are otherwise in generally satisfactory health.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Likely to follow study requirements, in particular, to adhere to maintaining a suitable diet and keeping an online diary of their food intake and weight measured once weekly via EDC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Female subjects have negative urine pregnancy test at the Screening visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Provides signed informed consent to participate in the study. Informed consent must be given by the subject prior to inclusion in the study, and before performing any study procedures, including the screening visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Have type 1 diabetes (insulin-dependent diabetes mellitus [IDDM]).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Treated with long-acting glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, alpha-glucosidase inhibitor, regular insulin, rapid-acting insulin analog, or sodium-glucose cotransport-2 inhibitors (SGLT-2). Treatment with any of these drugs should have been stopped at least 3 months before inclusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Current or recent (within past 30 days) participation in another investigational drug or device study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Have participated in a previous study of BTI320.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Have any uncontrolled cardiovascular risk factors (hypertension, hyperlipidemia), past clinical manifestation of coronary artery disease, blood dyscrasias, or significant cerebrovascular disease in the previous year. Any concomitant drug treatment for a condition not related to diabetes should be discussed and approved with the study Medical Monitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Pregnant or breastfeeding, or plan to become pregnant within one year after randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Food allergy or severe food intolerance assessed by the Principal Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "History of allergy or intolerance to BTI320 (PAZ320 or SugarDown) or equivalent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Have known condition(s) influencing their glycemic levels (e.g. Cushing syndrome, pancreatic diseases, acromegaly).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Have human immunodeficiency virus (HIV) infection, hepatitis, tuberculosis, or other serious infectious disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "History of alcohol addiction or drug abuse (illegal or controlled pharmaceutical substances) within past year prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Have planned major surgery within 6 months after randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Have a terminal illness.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Serum creatinine of >1.4 mg/dL (>124 μmol/L) in women or >1.5 mg/dL (>133 μmol/L) in men or subjects with end-stage renal disease (Estimated Glomerular Filtration Rate calculated by CKD-EPI [eGFR] <10 mL/min/1.73 m2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Have serum Alanine Aminotransferase (SGPT) >3 times upper limit of normal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "History of cancer, other than non-melanoma skin cancer, that requires treatment during the previous five years prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "History of hemolytic anemia, repeated blood transfusions, or other conditions making HbA1c results unreliable as an indicator of chronic glucose level; hematocrit (Hct) <35% for men and <33% for women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "History of solid organ transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Treatment with systemic glucocorticoids (except for short-term therapy [5 days or less]).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Treatment with atypical anti-psychotics.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "In the opinion of the principal investigator, the subject is unlikely to follow the study protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03655535",
    "statement": "Employment/lifestyle that requires nocturnal hours.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "Provision of informed consent prior to any study specific procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "Female or male aged ≥18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "History of type 2 diabetes mellitus for more than 12 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "HbA1c≥7.0% and ≤11.0%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "Stable antidiabetic treatment during the last 12 weeks up to randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "eGFR 25-75 mL/minute/1.73m2, inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "Micro or macroalbuminuria (UACR 30 - 3500 mg/g)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "Treatment with ACE inhibitor or an ARB for at least 3 months prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "Body mass index between 20 and 45 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "Any of the following CV/Vascular Diseases within 3 month prior to signing the consent at Visit 1:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "Myocardial infarction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "cardiac surgery or revascularization (CABG/PTCA)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "unstable angina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "unstable HF",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "New York Heart Association (NYHA) Class III-IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "transient ischemic attack (TIA) or significant cerebrovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "unstable or previously undiagnosed arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) > 3X ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "Total Bilirubin (TB) >2 mg/dL (34.2 μmol/L)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "History of acute kidney injury requiring renal replacement therapy (dialysis or ultrafiltration) or any biopsy or imaging verifying intercurrent kidney disease other than diabetic nephropathy or diabetic nephropathy with nephrosclerosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "Ongoing treatment with a SGLT2 inhibitor, GLP-1 agonist or DPP4 inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02547935",
    "statement": "Any condition which, in the judgment of the Investigator, may render the patient unable to complete the study or which may pose a significant risk to the patient or patient suspected or with confirmed poor protocol or medication compliance",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Males and females aged at least 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "At least a 3-month history of chronic stable angina triggered by physical effort and relieved by rest and/or sublingual nitroglycerin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "CAD documented by one or more of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Angiographic evidence of ≥ 50% stenosis of one or more major coronary arteries",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "History of myocardial infarction (MI) documented by positive myocardial muscle creatine kinase (CK-MB) enzymes, troponins, or electrocardiogram (ECG) changes",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Cardiac imaging study or exercise test diagnostic for CAD",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Treatment with up to 2 antianginal therapies at a stable dose for at least 2 weeks prior to the Qualifying Period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Documented history of T2DM",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Willing to maintain stable tobacco usage habits throughout the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Willing to maintain stable activity levels throughout the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Females of childbearing potential must agree to utilize highly effective contraception methods from Screening throughout the duration of study treatment and for 14 days following the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "New York Heart Association (NYHA) Class III and IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Acute coronary syndrome in the prior 2 months or planned coronary revascularization during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Stroke or transient ischemic attack within 6 months prior to Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "QTc > 500 milliseconds",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Uncontrolled hypertension (seated systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Systolic blood pressure < 100 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Clinically significant hepatic impairment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Prior treatment with ranolazine, or known hypersensitivity or intolerance to ranolazine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Females who are breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Positive serum pregnancy test",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Participation in another investigational drug or device study within 1 month prior to Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Current treatment with trimetazidine, ivabradine, or nicorandil. Subjects will need to discontinue these medications 2 weeks prior to the Qualifying Period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Current treatment with potent inhibitors of cytochrome (CYP)3A (eg, ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Current treatment with CYP3A and P glycoprotein (Pgp) inducers (eg, rifampicin/rifampin, carbamazepine, and St. John's wort [Hypericum perforatum])",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Current treatment with CYP3A4 substrates with a narrow therapeutic range (eg, cyclosporine, tacrolimus, and sirolimus)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Subjects taking simvastatin who cannot reduce the dose to 20 mg once daily or who cannot switch to another statin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Current treatment with Class I or III antiarrhythmic medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "History of illicit drug use or alcohol abuse within 1 year of Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01425359",
    "statement": "Any other conditions that, in the opinion of the investigator, are likely to prevent compliance with the study protocol or pose a safety concern if the subject participates in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "Patients aged >= 6 months to 12 years presenting to Ndirande Health Centre with signs or symptoms consistent with malaria including but not limited to one or more of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "fever at the time of evaluation (axillary temperature 37.5° C by digital thermometer)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "report of fever within the last two days",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "profound anemia (conjunctival or palmar pallor)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "headache",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "body aches",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "abdominal pain",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "decreased intake of food or fluids",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "weakness",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "Positive malaria smear for P. falciparum mono-infection",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "Parasite density of 2,000-200,000/microliter or < 10%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "Willingness to remain at the Health Centre under continuous observation until the resolution of the infection",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "Parental consent for each participant, and child assent for children older than 5 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "Signs of severe malaria: One or more of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "hemoglobin < 5 g/dl",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "parasitemia > 10%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "prostration * as indicated by inability to drink or breastfeed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "respiratory distress (deep Kussmaul respirations)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "bleeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "recent seizures*, coma* or mental obtundation* (Blantyre coma score less than 5)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "persistent vomiting*",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "Presence of a severe disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "Presence of a febrile condition caused by diseases other than malaria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "Known allergy or history of adverse reaction to sulfadoxine/pyrimethamine (SP), sulfa drugs or chloroquine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "Chronic medication with an antifolate drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00125489",
    "statement": "Enrollment in this clinical study in the past 28 days *Each of these symptoms or signs is considered a \"danger sign.\"",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Male and non-pregnant females age 18 to 50 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Good general health status as demonstrated by medical history, physical exam, and screening laboratory test performed within 90 days of enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Ability and willingness to provide informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "No laboratory evidence of hematologic, hepatic, or renal disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Assessment of Understanding questionnaire completed and passed prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Reliable access to the clinical trials centers and availability to participate for duration of study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "If the subject is biologically female and of reproductive potential she must agree to consistent pregnancy prevention",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Recent travel to a malaria endemic area within 6 months of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Planned travel to a malaria endemic area during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "History of confirmed malaria diagnosis on peripheral blood smear",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Anticipated use during the study period, or use within the following periods prior to enrollment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Investigational malaria vaccine at any time",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Malaria chemoprophylaxis within 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Chronic systemic immunosuppressive medications within 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Blood products or immunoglobulins within 120 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Investigational product or vaccine within 30 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Systemic antibiotics with antimalarial effects within 30 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Receipt of a live vaccine within 28 days or a killed vaccine within the 14 days prior to each ITV infection and challenge",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Medications known to interact with primaquine, chloroquine or atovaquone/proguanil (only during the study period)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "History of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Sickle cell disease, sickle cell trait, or other hemoglobinopathies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Splenectomy or functional asplenia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Systemic anaphylaxis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Gelatin allergy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Severe allergic reactions to mosquito bites of study drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Documented history of chronic or active neurologic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Psoriasis or porphyria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Ocular diseases including retinopathy or visual field defects",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Glucose 6 phosphate dehydrogenase (G6PD) deficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Clinically significant medical condition, physical examination findings, other clinically significant abnormal laboratory results, or past medical history that may have clinically significant implications for current health status in the opinion of the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Weight <55 kg or >90 kg; body mass index (BMI) <18.5% or >31%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "History of known active cardiac disease or stroke",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Clinically significant abnormal screening electrocardiogram (ECG)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Moderate or high risk for coronary heart disease (CHD) based on NHANES I cardiovascular risk assessment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Acute illness at the time of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Pregnant or nursing female",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Infection with HIV, Hepatitis B, Hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Psychiatric condition that precludes compliance with the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Suspected or known current alcohol or drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Any other finding that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a subject's ability to give informed consent, or increase the risk of having an adverse outcome from participating in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500980",
    "statement": "Clinical trial staff with direct involvement in the conduct of the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Unstable angina, myocardial infarction, valvular heart disease, encephalopathy, ischemic attacks, hemorrhagic or ischemic cerebrovascular accident (CVA) or ongoing pulmonary embolism within last year, arrhythmia, hepatopathy, uncontrolled infection, hemoptysis or oxygen requiring dyspnea, known HIV infection, bleeding risk, muscular problems, peripheral neuropathy, Symptomatic or progressive brain metastases or leptomeningeal disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Voluntarily signed and dated written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Age between 18 and 75 years old (both inclusive)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Life expectancy ≥ 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Patients with a histologically/cytologically confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Breast cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Epithelial ovarian cancer or gynecological cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Head and neck squamous cell carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Platinum-refractory germ-cell tumors.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Adenocarcinoma or carcinoma of unknown primary site",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Adequate bone marrow, renal, hepatic, and metabolic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Recovery to grade ≤ 1 or to baseline from any Adverse Event (AE) derived from previous treatment (excluding alopecia of any grade).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Pre-menopausal women must have a negative pregnancy test before study entry and agree to use a medically acceptable method of contraception throughout the treatment period and for at least six weeks after treatment discontinuation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Prior treatment with PM01183 or weekly paclitaxel or nanoalbumin-paclitaxel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Patients who have previously discontinued paclitaxel-based regimes due to drug related toxicity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Known hypersensitivity to bevacizumab or any component of its formulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Patients who have previously discontinued bevacizumab-containing regimes due to drug-related toxicity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "More than three prior lines of chemotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Less than three months since last taxane-containing therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Wash-out period:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Less than three weeks since the last chemotherapy-containing regimen",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Less than three weeks since the last radiotherapy dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Less than four weeks since last monoclonal antibody-containing therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Concomitant diseases/conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Men or pre-menopausal women who are not using an effective method of contraception as previously described; actively breast feeding women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Patients who have pelvic irradiation with doses ≥ 45 Grays (Gy).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "History of previous bone marrow and/or stem cell transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Confirmed bone marrow involvement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Histologically or cytologically confirmed carcinoma of the breast",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Locally advanced breast cancer that is not amenable to curative radiation or surgical cure and/or metastatic disease appropriate for systemic single cytotoxic chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA1 or BRCA2 mutation from Myriad Genetics or other laboratory approved by the Sponsor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "No more than 3 prior chemotherapy-inclusive regimens for locally advanced and/or metastatic disease (no limit on prior hormonal therapies or targeted anticancer therapies such as mechanistic target of rapamycin (mTOR) or CDK4/6 inhibitors, immune-oncology agents, tyrosine kinase inhibitors, or monoclonal antibodies against CTL4 or VEGF)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Prior treatment with a taxane and/or anthracycline in the neoadjuvant, adjuvant, locally advanced, or metastatic setting unless medically contraindicated",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Have measurable or non-measurable, evaluable disease by the revised response evaluation criteria in solid tumors (RECIST) v.1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "First-line locally advanced and/or metastatic breast cancer with no prior adjuvant chemotherapy unless the Investigator determines that one of the 4 cytotoxic chemotherapy agents in the control arm would otherwise be offered to the subject",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Prior treatment with a PARP inhibitor (not including iniparib)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Not a candidate for treatment with at least 1 of the treatments of protocol-specific physician's choice (ie, capecitabine, eribulin, gemcitabine, vinorelbine)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Subjects who had objective disease progression while receiving platinum chemotherapy administered for locally advanced or metastatic disease; subjects who received low-dose platinum therapy administered in combination with radiation therapy are not excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Subjects who have received platinum in the adjuvant or neoadjuvant setting are eligible; however, subjects may not have relapsed within 6 months of the last dose of prior platinum therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Cytotoxic chemotherapy within 14 days before randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Radiation or anti-hormonal therapy or other targeted anticancer therapy within 14 days before randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "HER2 positive breast cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Active inflammatory breast cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "CNS metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Exception: Adequately treated brain metastases documented by baseline CT or MRI scan that has not progressed since previous scans and that does not require corticosteroids (except prednisone ≤ 5 mg/day or equivalent) for management of CNS symptoms. A repeat CT or MRI following the identification of CNS metastases (obtained at least 2 weeks after definitive therapy) must document adequately treated brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Subjects with leptomeningeal carcinomatosis are not permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Prior malignancy except for any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Prior BRCA-associated cancer as long as there is no current evidence of the cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Carcinoma in situ or non-melanoma skin cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "A cancer diagnosed and definitively treated ≥ 5 years before randomization with no subsequent evidence of recurrence",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Known to be human immunodeficiency virus positive",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Known active hepatitis C virus, or known active hepatitis B virus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "Known hypersensitivity to any of the components of talazoparib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Male or female patients between the ages of 3 and 60 years, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Presence of acute uncomplicated P. falciparum mono-infection confirmed by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Fever, as defined by axillary/tympanic temperature ≥37.5°C or oral/rectal temperature ≥38°C, or documented history of fever in the previous 24 hours and,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Positive microscopy of P. falciparum with parasite density between 1,000 and 100,000 asexual parasite count/µl of blood",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Written informed consent provided by patient and/or parent/guardian/spouse.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Ability to swallow oral medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization Criteria 2000.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Mixed Plasmodium infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Severe vomiting or severe diarrhoea.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Known history or evidence of clinically significant disorders.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Presence of significant anaemia, as defined by Hb <8 g/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Presence of febrile conditions caused by diseases other than malaria.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Known history of hypersensitivity, allergic or adverse reactions to pyronaridine, mefloquine or artesunate or other artemisinins.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Use of any other antimalarial agent within 2 weeks prior to start of the study as evidenced by positive urine test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Presence of significant renal or hepatic impairment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Receipt of an investigational drug within the past 4 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Known active Hepatitis A IgM, Hepatitis B surface antigen or Hepatitis C antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Known seropositive HIV antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403260",
    "statement": "Previous participation in any clinical study with PA.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05936151",
    "statement": "Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05936151",
    "statement": "Have either",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05936151",
    "statement": "no T2D with an HbA1c < 6.5% or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05936151",
    "statement": "have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05936151",
    "statement": "Have been diagnosed with chronic kidney disease (CKD).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05936151",
    "statement": "Have a self-reported change in body weight >5 kilogram (kg) (11 pounds) within 90 days before screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05936151",
    "statement": "Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05936151",
    "statement": "Have a prior or planned surgical treatment for obesity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05936151",
    "statement": "Have Type 1 Diabetes (T1D)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05936151",
    "statement": "Have acute or chronic hepatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05936151",
    "statement": "Have a history of malignant disease within 5 years before screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320021",
    "statement": "Males and Females (non-pregnant and non-lactating) between 18 and 70 years of age with type 1 or type 2 diabetes",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320021",
    "statement": "Sitting blood pressure of <=170/100 mm Hg at weeks -2 and -1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320021",
    "statement": "Hemoglobin A1C <=12% at week -2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320021",
    "statement": "Patients with diagnosis of diabetic nephropathy as defined by",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320021",
    "statement": "Serum Creatinine <=2.0 mg/dL at weeks -2 and -1 (PYR-205) Serum Creatinine >2.0 mg/dL but <=3.5 mg/dL at weeks -2 and -1 (PYR-207)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320021",
    "statement": "Urinary albumin excretion >=300 mg/24 hours at week -2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320021",
    "statement": "No other known or suspected etiology for nephropathy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320021",
    "statement": "Voluntary written consent to participate in this study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320021",
    "statement": "History of allergic or adverse response to any B vitamin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320021",
    "statement": "History of major cardiovascular or cerebrovascular events",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320021",
    "statement": "History of cancer except adequately treated basal or squamous cell carcinoma of the skin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320021",
    "statement": "History of diabetic ketoacidosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320021",
    "statement": "Autoimmune diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320021",
    "statement": "History of significant peripheral neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Body mass index (BMI) ≥ 27 and ≤ 40 kg/m2 (inclusive) at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Glycated haemoglobin (HbA1c) ≤ 8.0% at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Diagnosed with T2DM with glucose control managed with metformin monotherapy where no significant dose change (increase or decrease ≥ 500 mg/day) has occurred in the 3 months prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Any subject who has received another investigational product as part of a clinical study or a GLP-1 analogue-containing preparation within the last 30 days or 5 half-lives of the drug (whichever is longer) at the time of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Any subject who has received any of the following medications prior to the start of the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Herbal preparations or drugs licensed for control of body weight or appetite (eg, orlistat, bupropion naltrexone, phentermine-topiramate, phentermine, lorcaserin)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Opiates, domperidone, metoclopramide or other drugs known to alter gastric emptying",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Glucagon",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Warfarin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Any contraindication to magnetic resonance imaging/MRS scanning including claustrophobia or dislike of confined spaces",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight loss), a history of type 1 diabetes mellitus (T1DM) or diabetic ketoacidosis, or if the subject has been treated with daily SC insulin within 90 days prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Recurrent unexplained hypoglycaemic episodes (defined as glucose < 3.0 mmol/L or < 54 mg/dL on more than 2 occasions in 6 months prior to screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Significant inflammatory bowel disease, gastroparesis, or other severe disease or surgery affecting the upper GI tract (including weightreducing surgery and procedures) which may affect gastric emptying or could affect the interpretation of safety and tolerability data",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Acute or chronic pancreatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Significant hepatic disease (except for NASH or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or subjects with any of the following results at screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Alanine transaminase (ALT) ≥ 3 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Total bilirubin ≥ 2 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Impaired renal function defined as estimated glomerular filtration rate (eGFR) < 30 mL/minute/1.73m2 at screening (glomerular filtration rate estimated according to Modification of Diet in Renal Disease (MDRD) using MDRD Study Equation IDMS-traceable (International System of Units [SI] units)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Poorly controlled hypertension defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Systolic blood pressure (BP) > 180 mm Hg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Diastolic BP > 105 mm Hg After 10 minutes of supine rest and confirmed by repeated measurement at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Unstable angina pectoris, myocardial infarction, transient ischemic attack or stroke within 3 months prior to screening, or subjects who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Severe congestive heart failure (New York Heart Association Class III or IV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Basal calcitonin level > 50 ng/L at screening or history/family history of medullary thyroid carcinoma or multiple endocrine neoplasia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell, squamous cell skin cancer, or in situ cervical cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Any positive results for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Substance dependence or history of alcohol abuse and/or excess alcohol intake (defined as > 21 units per week for a male subject, and >14 units per week for a female subject). Subjects must have a negative alcohol test result at screening and prior to randomisation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Male and female subjects, aged 18 to 60 years, who are English or Spanish speakers.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "BMI 25 to 34.9 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject has type 2 diabetes with HgbA1c < 8.0%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject's glucose is controlled with either diet alone or oral agents that do not cause hypoglycemia (e.g. Metformin, DPP-4 inhibitors, Thiazolidinediones, Alpha-Glucosidase Inhibitors and GLP-1 agonists).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject is motivated to increase their activity and make other lifestyle changes.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject has:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "A compatible Apple mobile device with the iOS 7 operating system installed:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "iPhone 4 or newer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "iPad 2 or newer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "iPad Mini",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "iPod touch 5th gen (2012 model) or newer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "500MB of free space on the iPhone, iPad, or iPod touch",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "A valid mobile phone number to receive daily updates via SMS text messaging",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "An active iTunes account/password to install study-related software (\"apps\")",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Access to Wi-Fi or a mobile data plan to send study data",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Female subject is surgically sterile, post-menopausal or agrees to use an acceptable method of birth control as defined in section 2.7.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject agrees to not use any new vitamin and/or mineral supplement until after study completion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject agrees to not take any dietary or herbal supplements or products until after study completion. Seven-day washout period prior to study inclusion allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject is willing and able to comply with the protocol including:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Attending 3 visits, approximately 2 hours each",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Wearing and inputting required information into the Fitbit Flex activity tracker",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Receiving alerts from the Medidata Patient Cloud",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Working on making nutrition and exercise changes over the 8-week study period",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Using and updating his/her iPhone, iPad, iPad Mini or iTouch as per study requirements (e.g. downloading the iOS7 operating system, downloading the Medidata Patient Cloud and Fitbit Flex apps, and receiving daily text messages).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject is able to understand and sign the informed consent to participate in the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject has any of the following medical conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "active heart disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "uncontrolled high blood pressure (≥ 140/90 mmHg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "renal or hepatic impairment/disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Type I diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "bipolar disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "active psychiatric disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Parkinson's disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "unstable thyroid disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "immune disorder (such as HIV/AIDS)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "any medical condition deemed exclusionary by the Principal Investigator (PI)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject has a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within five years prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject is taking oral agents that can cause hypoglycemia (e.g. sulfonylureas, meglitinides and insulin).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject is taking or has taken in the past 28 days any supplement or medication (prescription or over the counter) for weight loss (see section 2.6.2); 28-day washout required for study inclusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject is on an unstable dose of medication (defined as fewer than 90 days at the same dose).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject is currently taking any medication deemed exclusionary by PI.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject exhibits evidence of hepatic or renal dysfunction as evidenced by ALT, AST, AP being ≥ 2 times the upper limit of normal or serum creatinine value ≥ 2.0 mg/dl or other clinically significant abnormal clinical laboratory value per PI discretion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject has a clinically relevant abnormality as defined by the PI or interpreting physician with respect to the electrocardiogram (ECG).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject has a QTc interval > 450 msec for males and > 470 msec for females.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject has a history of drug or alcohol abuse in the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject has begun/stopped smoking ≤ 6 months ago OR has plans to begin/quit smoking.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject has experienced a weight loss or gain greater than 4.5 kg (approximately 10 lbs) in the past 3 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject is pregnant, lactating, or planning to become pregnant during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject has any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the study data.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02227303",
    "statement": "Subject has taken an investigational product within 30 days of study enrollment (visit 2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Females of non childbearing potential;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Patients with T2DM, inadequately controlled with metformin;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "HbA1c ≥7.0% to ≤10.5% (for T2DM); HbA1c <6.5% (for non-diabetic obese, if enrolled)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Total body weight >50 kg (110 lbs)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "BMI ≥24.5 to ≤45.5 kg/m2 (T2DM), BMI >30.5 to ≤45.5 kg/m2 (for non-diabetic obese)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, hepatic, psychiatric, neurological, dermatological, or allergic disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Medical history of T2DM (for non-diabetic obese participants, if enrolled);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Evidence or history of clinically significant cardiovascular disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Any malignancy not considered cured;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Acute pancreatitis or history of chronic pancreatitis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Acute gallbladder disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Any condition possibly affecting drug absorption;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Personal or family history of MTC or MEN2;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Medical or psychiatric condition that may increase the risk of study participation;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Any vaccination within the 1 week prior to admission to the CRU;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Previous administration with an investigational drug within 30 days or 5 half-lives preceding first dose;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Known prior participation in a trial involving PF-07081532;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "A positive urine drug screen at screening or admission;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Positive testing at screening for HIV, HBsAg, HBcAb, HBsAb or HCVAb;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Positive COVID-19 test at screening or admission;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Supine BP ≥160 mm Hg (systolic) or ≥100 mm Hg (diastolic);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "12-lead ECG clinically relevant abnormalities that may affect participant safety or interpretation of study results;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Participants with ANY of the following abnormalities in clinical laboratory tests: *AST or ALT level ≥1.5x ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Total bilirubin level ≥1.5x ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "TSH> ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Fasting C-peptide <0.8 ng/mL;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Serum calcitonin > ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Amylase > ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Lipase > ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "eGFR <60 mL/min/1.73m2 (per MDRD equation);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "FPG >270 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "History of alcohol abuse, binge drinking and/or any illicit drug use or dependence within 6 months of Screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "History of sensitivity to heparin or heparin induced thrombocytopenia;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05158244",
    "statement": "Known intolerance to any GLP-1R agonist.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Key Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Key Exclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient is an ambulatory male or female from 25 to 75 years old at the Screening Visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient has type 2 diabetes diagnosed by a physician or nurse practitioner ≥6 months before the Screening Visit, has been on ≥1 antihyperglycemic medication for ≥12 weeks preceding the Randomization Visit, and has been on a stable regimen (ie, same drug and same dose) of ≥1 antihyperglycemic medication for ≥28 days preceding the Randomization Visit. (Modification of short-acting insulin throughout the Screening Period will not affect eligibility.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient has been on a stable regimen (ie, same drug and dose) of antihypertensive medications, which must include an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB), for ≥28 days preceding the Randomization Visit and is expected to remain on their regimen through the Follow-up Visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient has the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Estimated glomerular filtration rate (eGFR) 30 to 75 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation (1) at the Screening and Baseline Visits",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Urine albumin-to-creatinine ratio (UACR) >200 mg/g at the Screening and Baseline Visits and <5000 mg/g at Screening and Baseline Visits",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Serum albumin >3.0 g/dL at the Screening and Baseline Visits",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Hemoglobin A1c (HbA1c) ≤11% at the Screening and Baseline Visits",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Systolic blood pressure (BP) of 110 to 160 mm Hg at the Screening and Baseline Visits",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Women of childbearing potential must have a negative pregnancy test prior to randomization and must agree to use protocol-specified contraception from the Screening Visit through 60 days after the final dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Male patients must be surgically sterile by vasectomy (conducted ≥60 days before the Screening Visit or confirmed via sperm analysis) or must agree to use protocol-specified contraception from the Screening Visit through 60 days after the final dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Other inclusion criteria per protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient has a history of secondary hypertension (ie, renal artery stenosis, primary aldosteronism, or pheochromocytoma).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient has a body mass index (BMI) <20 or >45 kg/m2 at the Screening Visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient has a history of platelet dysfunction, hemophilia, von Willebrand disease, coagulation disorder, other bleeding diathesis, or significant, nontraumatic bleeding episode(s), such as from a gastrointestinal source.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient has hepatic impairment defined as Child-Pugh A, B, C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient has significant comorbidities (eg, malignancy, advanced liver disease, pulmonary hypertension, pulmonary fibrosis, lung disease requiring supplemental oxygen) or other significant conditions that, in the Investigator's opinion, would limit the patient's ability to complete or participate in this clinical study; has been hospitalized for cardiovascular, renal, or metabolic cause in the 3 months before the Screening Visit; or has a life expectancy of less than 1 year.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient has had prior dialysis, renal transplant, or planned renal transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient has clinically active, symptomatic, or unstable coronary artery or heart disease within the 3 months before the Screening Visit, defined as 1 of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Hospitalization for myocardial infarction (MI), unstable angina, or heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "New-onset angina with positive functional study or coronary angiogram revealing stenosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Coronary revascularization procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient has a history of clinically significant hypersensitivity or allergies to any of the inactive ingredients contained in the active or placebo drug products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient has previously received IW-1973 in a study, or received an investigational drug during the 30 days or 5 half-lives of that investigational drug (whichever is longer) before the Screening Visit, or is planning to receive another investigational drug at any time during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient is taking specific inhibitors of phosphodiesterase 5 (PDE5), nonspecific inhibitors of PDE5 (including dipyridamole and theophylline), any supplements for the treatment of erectile dysfunction, riociguat, or nitrates or nitric oxide (NO) donors in any form. These medications and supplements are prohibited from 7 days before Randomization through the duration of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Patient is taking strong cytochrome P450 3A (CYP3A) inhibitors (eg, ketoconazole, indinavir, nelfinavir, ritonavir, saquinavir, clarithromycin, telithromycin, itraconazole, and nefazodone). These medications are prohibited 14 days before Randomization through the duration of the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03217591",
    "statement": "Other exclusion criteria per protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients with type 2 diabetes",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Adults who are at least 19 years old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients who have taken Glimepiride at a stable dose (≥4mg/day) for 8 weeks or more before Visit 1 (screening) as monotherapy or Patients who have taken Glimepiride at a stable dose (≥4mg/day) and Metformin for 8 weeks or more before Visit 1 (screening) as combination therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients who satisfy the following HbA1c (%) criteria: 7 ≤ HbA1c ≤ 11",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients who have been provided an explanation about the objective, method, effects, etc. of the clinical trial and whose informed consent form has been signed by himself/herself or his/her representative",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients who fall under one of the following 3 cases",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients who are surgically sterile",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Post-menopausal females who are above 45 years of age and 2 years after the last menstruation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Fertile premenopausal female patients or male patients without having a surgical sterilization, who have agreed to use at least two contraception methods (one of the barrier methods must be included) for up to 14 days after the administration of the last investigational product to avoid pregnancy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients with type 1 diabetes, diabetic ketoacidosis, diabetic coma and pre-coma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients with gestational diabetes or secondary diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients with NYHA Class III, IV congestive heart failure or arrhythmias requiring treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients with thyroid gland dysfunction and TSH that is out of normal range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients with pituitary insufficiency or adrenal insufficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients with hereditary problems, such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Female patients who are pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients whose BMI exceeds 40 kg/m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients whose creatinine clearance is below 30mL/min/1.73m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients whose bilirubin level exceeds 1.5 times the upper limit of the normal range and whose ALT/AST level exceeds 2.5 times the upper limit of the normal range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients who are continuously taking the following drugs for 2 weeks or more at Visit 1 (screening), or need to take them continuously and repeatedly",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "cyclosporin, sirolimus, tacrolimus, nicotinic acid (≥1500mg/day), isotretinoin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Strong CYP3A4 inducers: rifampicin (rifampin), phenytoin, carbamazepine, rifabutin, phenobarbital",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "warfarin, dicoumarin, digoxin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "systemic glucocorticoids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients who have taken anti-obesity drugs or had a surgery related to obesity within 12 weeks before Visit 1 (screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients who have received insulin and GLP-1 analogue treatment within 8 weeks prior to Visit 1 (screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients who have received a treatment due to malignant tumor within 5years before Visit 1 (screening) However, patients whose basal cell or squamous cell skin cancer or in situ cervical cancer has been treated can be enrolled.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients with a history of myocardial infarction, unstable angina and coronary artery bypass surgery within 6 months prior to Visit 1 (screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients with a history of alcohol or drug addiction within 1 year prior to Visit 1 (screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients who have a medical history of hypersensitivity to the same class as Gemigliptin or dipeptidyl peptidase 4 (DPP 4) inhibitor drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients with a history of hypersensitivity to the drugs belonging to the same class as Glimepiride or sulfonylureas and sulfonamide",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients who have participated in another clinical trial within 3 months prior to Visit 1 (screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02089126",
    "statement": "Patients deemed unsuitable for this trial based on the judgment of the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with metformin alone, or with metformin and not more than one other oral antidiabetic drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Diagnosis of type 2 diabetes prior to informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Glycosylated haemoglobin A1 (HbA1c)at screening: For patients undergoing wash out of previous medication: HbA1c 6.5 - 9.0% For patients not undergoing wash-out of previous medication: HbA1c 7.0 - 10.0%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Glycosylated haemoglobin A1 (HbA1c) 7.0 - 10.0% at the beginning of Placebo Run-in",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Age 18 -80 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "BMI (Body Mass Index) less than 40 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Signed and dated written informed consent by date of Visit 1a in accordance with GCP and local legislation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months prior to informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Impaired hepatic function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Known hypersensitivity or allergy to the investigational product or its excipients or metformin or placebo",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Treatment with rosiglitazone or pioglitazone within 3 months prior to informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Treatment with an injectable GLP-1 analogue (e.g. exenatide) within 3 months prior to informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Treatment with insulin within 3 months prior to informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Treatment with anti-obesity drugs (e.g. sibutramine, orlistat, rimonabant) within 3 months prior to informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation or drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Participation in another trial with an investigational drug within 2 months prior to informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Pre-menopausal women who:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "are nursing or pregnant,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Renal failure or renal impairment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Unstable or acute congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Acute or chronic metabolic acidosis (present in patient history)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00601250",
    "statement": "Hereditary galactose intolerance",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Drugs and Alcohol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Healthy male subjects aged 18 to 55 years inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Body Mass Index (BMI) is between 19-35kg/m2 (inclusive), with a minimum body weight of 45kg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject must read and write at a comprehension level that is sufficient to provide written informed consent, and be able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has provided informed consent to participate in the study as indicated by providing a signed and dated written informed consent form prior to the initiation of any study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "General",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Presence of any clinically relevant abnormality identified on the screening medical assessment, laboratory examination or 12-lead ECG, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study. These include any unstable medical disorder; disorders that would interfere with the action, absorption, distribution, metabolism, or excretion of bupropion or GSK189075; disorders which may pose a safety concern or interfere with the accurate assessment of safety or efficacy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Laboratory",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Clinically significant abnormalities at Screening including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Systolic blood pressure outside the range of 90 - 140 mmHg, diastolic blood pressure outside the range of 50 - 90 mmHg, and pulse rate at rest > 100 and < 45 bpm.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Positive tests for hepatitis B surface antigen, hepatitis C antibodies, and HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Positive cotinine, drug and/or alcohol test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Significant ECG abnormalities are defined as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Parameter Range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Heart Rate < 40 and >100 bpm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "PR Interval <120 and > 220 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "QRS duration < 70 and >120 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "QTC Interval (Bazett) > 450 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "ALT, alkaline phosphatase, or total bilirubin ³ 1.5 times the upper limits of normal (Note: Subjects with an increased total bilirubin may enter the study only if direct bilirubin is within normal limits).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Fasting triglycerides >400 mg/dL (>11.3 mmol/L).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Clinically significant abnormalities of T3 and TSH.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Serum creatinine clearance <60ml/min (estimated from serum creatinine (SCr) and demographic data using the MDRD calculation):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "A validated web-based calculator is found at:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "http://nephron.com/cgi-bin/MDRDSIdefault.cgi",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "To calculate estimated GFR (mL/min/1.73m2) manually:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "= 186 x (SCr in mg/dL)-1.154 x (age)-0.203 x (0.742 if female) x (1.210 if African-American)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "= exp(5.228-1.154 x ln (SCr)-0.203x ln(age)-(0.299 if female) + (0.192 if African American))",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Any other clinically significant laboratory abnormality as determined by the Principal Investigator in consultation with the GSK Medical Monitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Central Nervous System",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Current diagnosis or a previous history of mania, psychosis, major depression, or other major psychiatric disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Current or past history of seizure disorder or brain injury (traumatic or disease-related); or any condition which, in the opinion of the investigator, predisposes to seizure; those treated with other medications or treatment regimes that lower seizure threshold; those undergoing abrupt discontinuation of alcohol or sedatives (including benzodiazepines or benzodiazepine-like agents).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Note: A single childhood febrile seizure is not exclusionary.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "History or current diagnosis of anorexia nervosa or bulimia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subjects who, in the investigator's judgement, pose a homicidal or suicidal risk, have ever made a suicide attempt, or have ever been homicidal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Hepatic and Gastrointestinal systems",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "History of hepatic disease or known hepatic or biliary abnormalities, (with the exception of previously documented diagnosis of Gilbert's syndrome) and/or a history of biliary or gastrointestinal disorder, which might affect absorption, distribution, metabolism, or excretion of drugs (except appendectomy or cholecystectomy more than 12 weeks prior to the study).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Endocrine system",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Untreated or unstable thyroid disease. Subjects taking thyroid medications must be on a stable dosing regimen for at least 4 weeks prior to the first dose of study drug until completion of the Follow-up visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Cardiac system",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has a history of clinically significant cardiac rhythm disorder or QTc interval ³450 milliseconds at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has history of ischemic heart disease, including stable/unstable angina or acute myocardial infarction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Uncontrolled hypertension with systolic blood pressure >140mm Hg and diastolic blood pressure >90mm Hg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has a history of alcohol abuse or an average weekly intake of greater than 21 units per week (one unit = 1 glass of wine = 1 measure of spirits = ½ pint of beer).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Unwilling or unable to abstain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of tobacco in any form (smoking cigarettes, cigars, and/or pipes, or chewing tobacco-containing products), for 4 weeks prior to Screening until completion of the Follow-up visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Unwilling or unable to abstain from the use of prescription or non-prescription drugs, vitamins, or dietary/herbal supplements within 1 week prior to the first dose of study drug until completion of the Follow-up visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject is currently using medications that may alter gastric/small bowel motility, result in diarrhea, or bind concomitant medications. For example, but not limited to: erythromycin, antacids, prokinetic agents and cholestyramine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has a history of drug or other allergy that, in the opinion of the Principal Investigator, contraindicates their participation in this study. • Concomitant medications usage that includes:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of agents that are known to inhibit or induce cytochrome P450 enzymes within 14 days prior to the first dose of study medication , including grapefruit-containing products and St. John's Wort.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of bupropion hydrochloride or GSK189075 within the last 6 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of anti-depressant medication for clinically significant depression.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days prior to the first dose in Treatment Period 1, unless in the opinion of the Investigator and Sponsor the medication will not interfere with the study procedures or compromise subject safety.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Note: Occasional use of acetaminophen and ibuprofen according to directions provided in the product label may be acceptable during the study, at the discretion of the Principal Investigator. Acetaminophen will be limited to doses up to 2 grams/day and ibuprofen at doses up to 1.2 grams/day.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Drug hypersensitivity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "History of hypersensitivity to WELLBUTRIN SR, ZYBAN, GSK189075 or any of their constituents or closely related compounds.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "History of sensitivity to heparin or heparin-induced thrombocytopenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Other",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Past treatment with a new molecular entity (investigational drug) or any other trial during the previous 30 days, or 5 half-lives, whichever is longer. A new molecular entity is defined as any compound not in Phase 3. (The washout period of 30 days is counted from the last dose of study drug in the previous study until the first dose of study drug).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Participation in the study would result in subject's donation of blood in excess of 500mL within a 56-day period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Is 19 to 70 (inclusive) years old at Visit 1 (Screening).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Is diagnosed with Type 2 Diabetes Mellitus with",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "HbA1c between 6.0 to 9.5% (inclusive) for subjects managing their diabetes with: i. Diet and exercise alone, or ii. A stable regimen (minimum of 2 months at Visit 1) of metformin alone, or iii. A stable regimen (minimum of 2 months at Visit 1) of DPP-4 inhibitor alone, OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "HbA1c between 6.0 to 8.5% (inclusive) for subjects managing their diabetes with a stable (minimum of 2 months at Visit 1) combination regimen of metformin and DPP-4 inhibitors.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has serum creatinine below the upper limit of normal at Visit 1 and an estimated creatinine clearance above 80 using the Crockroft and Gault equation (CrCl = [(140 - age) x body weight in kg] / (serum creatinine x 72) x (0.85 for females) [ref. 3].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has a body mass index (BMI) of 25.0 to 40.0 kg/m^2 (inclusive) at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Is male, or is female and meets all of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Not breastfeeding",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Negative pregnancy test result (human chorionic gonadotropin, beta subunit) at Visit 1 (Screening) (not applicable to hysterectomized females)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Surgically sterile, postmenopausal, or if of childbearing potential, must practice and be willing to continue to practice appropriate birth control during the entire duration of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has a physical examination with no clinically significant abnormalities as judged by the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Ability to understand and willingness to adhere to protocol requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "If on chronic thyroid pharmacologic therapy, the dose must be stable for at least 3 months prior to Visit 1 (Screening), and must have thyroid-stimulating hormone (TSH) test result in normal range at Visit 1 (Screening).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Hepatic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Renal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Gastrointestinal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Endocrine disorder except diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Seizure disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Organ transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Chronic infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has any chronic disease requiring medication that has been adjusted in the past 90 days (subjects may take acute intermittent over-the-counter medications such as Tylenol, if needed).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has any drug treatment that affects gastric pH (prescription or over-the-counter), including any antacids or medications such as Rolaids or Pepcid within 2 days of Visit 1 (Screening).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has had major surgery of any kind within 6 months of Visit 1 (Screening).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has received a blood transfusion within 6 months of Visit 1 (Screening).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has a history of >5 kg weight change within 3 months of Visit 1 (Screening).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormalities other than those expected in subjects with diabetes and judged by the investigator to be clinically significant at Visit 1 (Screening).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has donated blood within 2 months of Visit 1 (Screening) or is planning to donate blood during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has used insulin within 3 months of Visit 1 (Screening).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has received GLP-1 receptor agonists and/or thiazolidinedione treatment within 6 months of Visit 1 (Screening).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has known intolerance to metformin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has received any investigational drug within 1 month (or five half-lives of the investigational drug, whichever is greater) of Visit 1 (Screening).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Has known allergies or hypersensitivity to any component of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Is employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract worker, or designee of the company).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01677299",
    "statement": "Smokes more than 10 cigarettes per day, 2 cigars per day, or uses more than 1 can of smokeless tobacco per week.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients who have given voluntary written consent to participate in this study prior to conducting Screening Visit procedures;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Male and female patients 25 years of age or older with a diagnosis of type 2 diabetes; • If a woman is of childbearing potential (WOCBP) she must agree to use appropriate birth control (double barrier methods, hormonal contraceptives, or intrauterine device)for the duration of the study (WOCBP is defined as all women who are not surgically sterile or are not at least 1 year post-menopausal). All WOCBP must have a negative serum pregnancy test at the Screening Visit;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "At the Screening Visit, ALL patients must have a history of overt diabetic nephropathy, as defined by the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "A SCr measurement of 1.3 mg/dL to 3.3 mg/dL (women) or 1.5 mg/dL to 3.5 mg/dL (men) inclusive, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "A 24-hour urine collection PCR ≥1200 mg/g;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients must be receiving an ACE-I or an ARB, for at least 3 months prior to the Qualifying Visit (Screening Visit for those patients not entering into the Optional Run-in Period), where the dose of the ACE-I or the ARB is considered appropriate for that patient and has been stable for at least 2 months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients must be on stable blood pressure medications for 2 months prior to the Qualifying Visit (Screening Visit for those patients not entering into the Optional Run-in Period), with a seated blood pressure at the Qualifying Visit of ≤160/90 mmHg;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "At the Qualifying Visit (only applies to those patients who enter into the Optional Run-in Period), the following eligibility parameters must be met in order to be randomized:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "A SCr measurement within 25% of the SCr measurement at the Screening Visit; and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "A 24-hour urine collection PCR ≥600 mg/g.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients with type 1 diabetes;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients with a diagnosis of chronic renal disease other than diabetic renal disease with or without hypertensive renal disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients receiving a renin inhibitor or an aldosterone antagonist or a combination of an ACE-I and an ARB within 2 months of the Qualifying Visit (Screening Visit for those patients not entering into the Optional Run-in Period);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients with a history of solid organ transplantation;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients with a history of myocardial infarction, coronary re-vascularization procedures (including percutaneous transluminal coronary angioplasty), cerebrovascular accident ortransient ischemic attack within 1 month prior to the Screening Visit;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients with a diagnosis of Class III or IV congestive heart failure at any time (as defined by the New York Heart Association);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients with a history of neoplastic disease (except basal or squamous cell carcinoma of the skin) within 5 years prior to the Screening Visit;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients with any history of dialysis within 2 years prior to the Screening Visit;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients in whom dialysis or renal transplantation is anticipated by their physician within 1 year after the Screening Visit;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients who used SCr altering drugs within 1 month prior to the Screening Visit;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients who require systemic immunosuppression therapy for >2 weeks (except for inhalant steroids);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients with clinically significant liver disease or transaminase (alanine aminotransferase and aspartate aminotransferase) levels >2.5 x upper limit of normal measured at the Screening Visit;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients with bilirubin levels >1.5 x upper limit of normal measured at the Screening Visit;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients with a history of allergic or other adverse response to vitamin B preparations;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients who require >50 mg of vitamin B6 daily;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients who have a history of dysphasia and swallowing disorders;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients with a history of hypersensitivity to Pyridorin or any of the excipients in the Pyridorin formulation;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients who have taken pyridoxamine or any other investigational drug within 30 days prior to the Screening Visit, or have participated in a previous Pyridorin trial or another clinical trial within 30 days prior to the Screening Visit;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients with a current history of drug or alcohol abuse;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients unlikely to comply with the study protocol (e.g., an inability and unwillingness to participate in adequate training, an uncooperative attitude, inability to return for follow-up visits, or unlikelihood of completing the study);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Women who are lactating, pregnant or intend to become pregnant during the course of the study; and",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00734253",
    "statement": "Patients who are employees of NephroGenex or its representatives.",
    "type": "Exclusion",
    "tags": {}
  }
]